<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001058.pub3" GROUP_ID="PREG" ID="398199081020073188" MERGED_FROM="" MODIFIED="2013-12-19 10:27:55 +0000" MODIFIED_BY="Leanne Jones" NOTES="&lt;p&gt;&lt;span modified=&quot;2009-07-02 12:54:00 +0200&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;Do not understand this part&lt;/span&gt;&lt;span modified=&quot;2009-07-02 12:54:00 +0200&quot; modified_by=&quot;[Empty name]&quot; class=&quot;deleted&quot;&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.1&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.6&lt;br&gt;Exported from Review Manager 4.2.1&lt;br&gt;Short title (no longer in use): Antibiotics for preterm rupture of membranes. In the abstract in order to stay within the word limit I have not written each result with its confidence intervals.&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-12-18 12:03:24 +0000" NOTES_MODIFIED_BY="Leanne Jones" REVIEW_NO="0081" REVMAN_SUB_VERSION="5.2.7 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="12.0">
<COVER_SHEET MODIFIED="2013-12-19 10:27:55 +0000" MODIFIED_BY="Leanne Jones">
<TITLE>Antibiotics for preterm rupture of membranes</TITLE>
<CONTACT MODIFIED="2013-12-19 10:27:55 +0000" MODIFIED_BY="Leanne Jones"><PERSON ID="7735" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Sara</FIRST_NAME><LAST_NAME>Kenyon</LAST_NAME><POSITION>Senior Lecturer</POSITION><EMAIL_1>s.kenyon@bham.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>School of Health and Population Sciences</DEPARTMENT><ORGANISATION>University of Birmingham</ORGANISATION><ADDRESS_1>Public Health Building</ADDRESS_1><CITY>Edgbaston</CITY><ZIP>B15 2TT</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 121 4149063</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-12-19 10:27:55 +0000" MODIFIED_BY="Leanne Jones"><PERSON ID="7735" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Sara</FIRST_NAME><LAST_NAME>Kenyon</LAST_NAME><POSITION>Senior Lecturer</POSITION><EMAIL_1>s.kenyon@bham.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>School of Health and Population Sciences</DEPARTMENT><ORGANISATION>University of Birmingham</ORGANISATION><ADDRESS_1>Public Health Building</ADDRESS_1><CITY>Edgbaston</CITY><ZIP>B15 2TT</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 121 4149063</PHONE_1></ADDRESS></PERSON><PERSON ID="5699" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Michel</FIRST_NAME><LAST_NAME>Boulvain</LAST_NAME><POSITION>Médecin adjoint agrégé</POSITION><EMAIL_1>michel.boulvain@hcuge.ch</EMAIL_1><ADDRESS><DEPARTMENT>Département de Gynécologie et d'Obstétrique, Unité de Développement en Obstétrique</DEPARTMENT><ORGANISATION>Maternité Hôpitaux Universitaires de Genève</ORGANISATION><ADDRESS_1>Boulevard de la Cluse, 32</ADDRESS_1><CITY>Genève 14</CITY><ZIP>CH-1211</ZIP><COUNTRY CODE="CH">Switzerland</COUNTRY><PHONE_1>+ 41 22 3824317</PHONE_1><FAX_1>+41 22 3824424</FAX_1><FAX_2>+41 22 3824165</FAX_2></ADDRESS></PERSON><PERSON ID="7935" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>James P</FIRST_NAME><LAST_NAME>Neilson</LAST_NAME><POSITION>Professor of Obstetrics and Gynaecology</POSITION><EMAIL_1>jneilson@liverpool.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Women's and Children's Health</DEPARTMENT><ORGANISATION>The University of Liverpool</ORGANISATION><ADDRESS_1>First Floor, Liverpool Women's NHS Foundation Trust</ADDRESS_1><ADDRESS_2>Crown Street</ADDRESS_2><CITY>Liverpool</CITY><ZIP>L8 7SS</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 151 7959551</PHONE_1><FAX_1>+44 151 7024024</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-12-05 10:08:07 +0000" MODIFIED_BY="Therese Dowswell">
<UP_TO_DATE>
<DATE DAY="26" MONTH="11" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="30" MONTH="9" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="4" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="1998"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="1998"/>
<LAST_CITATION_ISSUE ISSUE="12" YEAR="2013"/>
</DATES>
<WHATS_NEW MODIFIED="2013-12-17 11:53:29 +0000" MODIFIED_BY="Sonja L  Henderson" NOTES="&lt;p&gt;September 2004&lt;br&gt;This update includes comparisons between different treatment durations (Lewis 2003; Segal 2003) and adds data to the outcome of 'death alone' from a non-placebo controlled trial (Camli 1997).&lt;br&gt;&lt;br&gt;January 2003&lt;br&gt;The revised title clarifies the inclusion of women who had evidence of uterine activity at randomisation to a trial.  The text has been extensively revised. No new data from placebo-controlled, randomised trials have been included since the previous update, but further analysis has been undertaken in an attempt to assess the effectiveness and safety of individual antibiotic agents. New data have been included on the single outcome of perinatal death from non-placebo (but randomised) controlled trials.&lt;/p&gt;" NOTES_MODIFIED="2013-12-17 11:53:29 +0000" NOTES_MODIFIED_BY="Sonja L  Henderson">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-12-17 11:53:29 +0000" MODIFIED_BY="Sonja L Henderson">
<DATE DAY="17" MONTH="12" YEAR="2013"/>
<DESCRIPTION>
<P>We have added graph labels for all comparisons. There are no implications for the text of the review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-12-17 10:48:49 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-12-17 10:48:49 +0000" MODIFIED_BY="Sonja L Henderson">
<DATE DAY="9" MONTH="10" YEAR="2013"/>
<DESCRIPTION>
<P>Search updated 30 September 2013. Four new trial reports identified; none eligible for inclusion. Recommendation to give antibiotics routinely in these circumstances made clearer in conclusions.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2013-12-17 10:48:43 +0000" MODIFIED_BY="Sonja L Henderson">
<DATE DAY="9" MONTH="10" YEAR="2013"/>
<DESCRIPTION>
<P>Review updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2013-10-17 14:10:39 +0100" MODIFIED_BY="Sonja L Henderson">
<DATE DAY="7" MONTH="7" YEAR="2010"/>
<DESCRIPTION>
<P>The decision to prescribe antibiotics for women with PROM is now not clearcut, and if antibiotics are prescribed it is unclear which would be the antibiotic of choice.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-10-17 14:10:44 +0100" MODIFIED_BY="Sonja L Henderson">
<DATE DAY="29" MONTH="4" YEAR="2010"/>
<DESCRIPTION>
<P>Search updated. 23 new trial reports identified.</P>
<P>Fourteen new reports of trials already included have been added, including follow-up data at seven years from the largest included trial (<LINK REF="STD-Kenyon-2001" TYPE="STUDY">Kenyon 2001</LINK>). One new trial has been added (<LINK REF="STD-Fuhr-2006" TYPE="STUDY">Fuhr 2006</LINK>).</P>
<P>Nine new trials have been excluded and a trial that was previously included has now been excluded (<LINK REF="STD-Almeida-1996" TYPE="STUDY">Almeida 1996</LINK>).</P>
<P>Outcomes were divided into primary and secondary and subgroup comparisons undertaken to look at the effect of different antibiotics for primary outcomes only.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-04-29 11:49:06 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="29" MONTH="1" YEAR="2009"/>
<DESCRIPTION>
<P>Author contact details edited.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2009-01-29 10:06:03 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="20" MONTH="2" YEAR="2008"/>
<DESCRIPTION>
<P>Feedback from William Stones added along with reply from the author.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-05-14 13:38:00 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="20" MONTH="2" YEAR="2008"/>
<DESCRIPTION>
<P>Corrected error in dose of amoxycillin given in 'Characteristics of included studies' table for Almeida 1996a.</P>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="24" MONTH="1" YEAR="2003"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2013-10-17 15:08:13 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2010-06-10 08:09:41 +0100" MODIFIED_BY="[Empty name]">
<SOURCE>
<NAME>University of Liverpool</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>University of Geneva</NAME>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Leicester Royal Infirmary</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2010-06-10 08:09:41 +0100" MODIFIED_BY="[Empty name]">
<NAME>University of Birmingham</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2013-10-17 15:08:13 +0100" MODIFIED_BY="Sonja L Henderson">
<SOURCE MODIFIED="2013-10-17 15:08:13 +0100" MODIFIED_BY="Sonja L Henderson">
<NAME>UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), Department of Reproductive Health and Research (RHR), World Health Organization</NAME>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-11-26 10:55:17 +0000" MODIFIED_BY="Sonja L  Henderson">
<SUMMARY MODIFIED="2013-11-26 10:54:10 +0000" MODIFIED_BY="Sonja L  Henderson">
<TITLE MODIFIED="2009-09-24 14:27:21 +0100" MODIFIED_BY="Sonja L  Henderson">Antibiotics for preterm rupture of membranes</TITLE>
<SUMMARY_BODY MODIFIED="2013-11-26 10:54:10 +0000" MODIFIED_BY="Sonja L  Henderson" NOTES="&lt;p&gt;&lt;span modified=&quot;2009-06-15 12:20:00 +0200&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;seems confusing given the long term results (MB)&lt;/span&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-11-26 10:54:10 +0000" NOTES_MODIFIED_BY="Sonja L  Henderson">
<P>Certain antibiotics given to women whose waters have broken early will improve babies' health. Babies born too soon are more likely to suffer ill health in the early days and sometimes throughout life. Early labour and birth (before 37 weeks) may be due to undetected infection as well as the waters breaking early. The review of 22 trials, involving 6872 women and their babies, found that, in the short term, certain antibiotics given to women, when their waters break early, increase the time babies stay in the womb. They reduced infection, but did not save more babies. One antibiotic (co-amoxiclav) increased the number of babies with a rare condition of inflammation of the bowel (necrotising enterocolitis). Although, in the longer term (at seven years of age) antibiotics seem to have little effect on the health of children, the short-term advantages are such that we recommend antibiotics should be given routinely.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-11-26 10:54:02 +0000" MODIFIED_BY="Lynn Hampson">
<ABS_BACKGROUND MODIFIED="2009-10-29 14:32:40 +0000" MODIFIED_BY="[Empty name]">
<P>Premature birth carries substantial neonatal morbidity and mortality. Subclinical infection is associated with preterm rupture of membranes (PROM). Prophylactic maternal antibiotic therapy might lessen infectious morbidity and delay labour, but could suppress labour without treating underlying infection.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-10-29 14:32:47 +0000" MODIFIED_BY="[Empty name]">
<P>To evaluate the immediate and long-term effects of administering antibiotics to women with PROM before 37 weeks, on maternal infectious morbidity, neonatal morbidity and mortality, and longer-term childhood development.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-10-18 11:37:12 +0100" MODIFIED_BY="Lynn Hampson">
<P>We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (30 September 2013).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-09-15 16:15:47 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials comparing antibiotic administration with placebo that reported clinically relevant outcomes were included as were trials of different antibiotics. Trials in which no placebo was used were included for the outcome of perinatal death alone.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>We extracted data from each report without blinding of either the results or the treatments that women received. We sought unpublished data from a number of authors.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-11-26 10:54:02 +0000" MODIFIED_BY="Denise Atherton">
<P>We included 22 trials, involving 6872 women and babies.</P>
<P>The use of antibiotics following PROM is associated with statistically significant reductions in chorioamnionitis (average risk ratio (RR) 0.66, 95% confidence interval (CI) 0.46 to 0.96, and a reduction in the numbers of babies born within 48 hours (average RR 0.71, 95% CI 0.58 to 0.87) and seven days of randomisation (average RR 0.79, 95% CI 0.71 to 0.89). The following markers of neonatal morbidity were reduced: neonatal infection (RR 0.67, 95% CI 0.52 to 0.85), use of surfactant (RR 0.83, 95% CI 0.72 to 0.96), oxygen therapy (RR 0.88, 95% CI 0.81 to 0.96), and abnormal cerebral ultrasound scan prior to discharge from hospital (RR 0.81, 95% CI 0.68 to 0.98). Co-amoxiclav was associated with an increased risk of neonatal necrotising enterocolitis (RR 4.72, 95% CI 1.57 to 14.23).</P>
<P>One study evaluated the children's health at seven years of age (ORACLE Children Study) and found antibiotics seemed to have little effect on the health of children.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-11-26 09:22:35 +0000" MODIFIED_BY="Denise Atherton">
<P>Routine prescription of antibiotics for women with preterm rupture of the membranes is associated with prolongation of pregnancy and improvements in a number of short-term neonatal morbidities, but no significant reduction in perinatal mortality. Despite lack of evidence of longer-term benefit in childhood, the advantages on short-term morbidities are such that we would recommend antibiotics are routinely prescribed. The antibiotic of choice is not clear but co-amoxiclav should be avoided in women due to increased risk of neonatal necrotising enterocolitis.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-11-26 10:55:17 +0000" MODIFIED_BY="Lynn Hampson">
<BACKGROUND MODIFIED="2013-11-23 17:05:50 +0000" MODIFIED_BY="[Empty name]">
<P>The rate of preterm birth is 5% to 9% of all births in Europe, and 12% to 13% in the USA; the rates in both continents are increasing, partly due to the higher number of multiple births associated with assisted conceptions (<LINK REF="REF-Goldenberg-2008" TYPE="REFERENCE">Goldenberg 2008</LINK>). About 30% to 35% of preterm births are the result of maternal or fetal disease, but 40% to 45% of premature births result from spontaneous preterm labour (SPL) and 25% to 30% from preterm rupture of the membranes (PROM). Once the membranes have ruptured prematurely, 50% of women will go into labour within 24 to 48 hours and 70% to 90% within seven days (<LINK REF="REF-Dale-1989" TYPE="REFERENCE">Dale 1989</LINK>). For families struggling to cope with having a baby in special care, this will be one of the most difficult, emotional and stressful times of their lives (<LINK REF="REF-Taylor-2001" TYPE="REFERENCE">Taylor 2001</LINK>), whatever the longer-term outcome. The sequelae of preterm birth also pose significant challenges. Children born preterm are at increased risk of major disabilities, such as cerebral palsy, with the risk increasing with decreasing gestation at birth (<LINK REF="REF-Costeloe-2012" TYPE="REFERENCE">Costeloe 2012</LINK>; <LINK REF="REF-Marlow-2005" TYPE="REFERENCE">Marlow 2005</LINK>). Many preterm children without disability develop important behavioural and educational difficulties (<LINK REF="REF-Saigal-2008" TYPE="REFERENCE">Saigal 2008</LINK>).The prevention of preterm birth and reduction of associated disability are therefore important health priorities.</P>
<P>The causes of PROM are multifactorial. Infection appears to have an important role, either as a cause or as a consequence of PROM. Some organisms may produce collagenases, mucinases and proteases, which weaken the amnion and chorion and may lead to PROM. On the other hand, infection may occur secondary to membrane rupture. Ascending infection may lead to occult deciduitis, intra-amniotic infection or fetal infection.</P>
<P>A possible mechanism for the link between infection and preterm delivery is bacterial stimulation of the biosynthesis of prostaglandins, either directly via phospholipase A2 and C (<LINK REF="REF-Bejar-1981" TYPE="REFERENCE">Bejar 1981</LINK>), or indirectly via substances such as interleukin-1, tumour necrosis factor and platelet activating factor, all of which may be found in infected amniotic fluid (<LINK REF="REF-Yoon-2000" TYPE="REFERENCE">Yoon 2000</LINK>).</P>
<P>There is increasing evidence that, in addition to preterm birth, perinatal infection is an independent antecedent of other disability, particularly cerebral palsy and chronic lung disease (<LINK REF="REF-Dammann-2005" TYPE="REFERENCE">Dammann 2005</LINK>; <LINK REF="REF-Romero-2007" TYPE="REFERENCE">Romero 2007</LINK>). One theory was that perinatal prescription of antibiotics could prevent neurological and respiratory disability by two mechanisms, either by prolonging pregnancy, or by preventing or eliminating infection, or both. In contrast, it was also thought possible that prolongation of pregnancy might increase rather than decrease disability by continuing fetal exposure to inflammatory cytokines, which have already been implicated in the genesis of neurological damage (<LINK REF="REF-Dammann-1997" TYPE="REFERENCE">Dammann 1997</LINK>; <LINK REF="REF-Wu-2002" TYPE="REFERENCE">Wu 2002</LINK>) and chronic lung disease (<LINK REF="REF-Kotecha-1996" TYPE="REFERENCE">Kotecha 1996</LINK>; <LINK REF="REF-Speer-2003" TYPE="REFERENCE">Speer 2003</LINK>). </P>
<P>In addition to a generic effect of antibiotics, there may, in theory, be differences in the effects of different antibiotics. For example, macrolide antibiotics such as clindamycin and erythromycin, which reduce bacterial virulence, may have advantages over the beta lactam antibiotics (co-amoxiclav, cephalosporins) which, by destroying bacteria, release endotoxins and prostaglandins and may worsen outcomes (<LINK REF="REF-McGregor-1997" TYPE="REFERENCE">McGregor 1997</LINK>). Thus, separate comparisons of these antibiotics are included in the review.</P>
<P>The use of antibiotics for women with preterm labour with intact membranes is addressed by another review (<LINK REF="REF-King-2002" TYPE="REFERENCE">King 2002</LINK>).</P>
</BACKGROUND>
<OBJECTIVES>
<P>To assess the effects of administering antibiotics to women with preterm rupture of membranes on fetal and neonatal morbidity and mortality, maternal infectious morbidity and mortality, and long-term childhood development.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-11-25 10:08:13 +0000" MODIFIED_BY="Lynn Hampson">
<SELECTION_CRITERIA MODIFIED="2013-11-23 17:06:17 +0000" MODIFIED_BY="Lynn Hampson">
<CRIT_STUDIES MODIFIED="2013-11-23 17:05:58 +0000" MODIFIED_BY="Denise Atherton">
<P>We considered all randomised controlled comparisons of antibiotic administration versus placebo, given to women with preterm rupture of membranes, for inclusion in this review. We also included comparisons of different antibiotics. For the unambiguous and important outcome of perinatal death alone, we included trials in the review that were randomised but not placebo-controlled. We excluded trials that used inappropriate methods of randomisation. We included trials where the method of randomisation was not specified in detail in the expectation that their inclusion in this review would encourage the authors to make available further information on the method of randomisation. We excluded trials where non-randomised cohorts were amalgamated with randomised participants if the results of the randomised participants were not reported separately. We included trials in which post-randomisation exclusions occurred, provided there was no evidence that these occurred preferentially in one or other arm of the trials. We excluded studies where outcomes for over 20% of participants were not reported.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Women with preterm (less than 37 weeks) rupture of the membranes.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-11-23 17:06:04 +0000" MODIFIED_BY="Lynn Hampson">
<P>Comparison of:</P>
<UL>
<LI>any antibiotic versus placebo.</LI>
</UL>
<P>We planned to undertake subgroup comparisons for the primary outcome as follows:</P>
<UL>
<LI>all penicillins (excluding co-amoxiclav) versus placebo;</LI>
<LI>beta lactam (including co-amoxiclav) antibiotics versus placebo;</LI>
<LI>macrolide (including erythromycin) antibiotics versus placebo.</LI>
</UL>
<P>Additional comparisons:</P>
<UL>
<LI>beta lactam (including co-amoxiclav) antibiotics versus macrolide antibiotics (including erythromycin);</LI>
<LI>all penicillins (except co-amoxiclav) versus macrolide antibiotics (including erythromycin).</LI>
</UL>
<UL>
<LI>Antibiotic versus no antibiotic (including non-placebo controlled trials) - perinatal death only:</LI>
<UL>
<LI>Subgroup comparison of non-placebo controlled trials only.</LI>
</UL>
<LI>Different treatment regimens of same antibiotic.</LI>
</UL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-11-23 17:06:17 +0000" MODIFIED_BY="Denise Atherton">
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<UL>
<LI>Maternal death.</LI>
<LI>Serious maternal morbidity:</LI>
<UL>
<LI>septicaemia;</LI>
<LI>need for intensive care;</LI>
<LI>organ failure, need for ventilation;</LI>
<LI>need for hysterectomy.</LI>
</UL>
<LI>Perinatal death or death before discharge from hospital.</LI>
<LI>Perinatal morbidity:</LI>
<UL>
<LI>neonatal infection including pneumonia;</LI>
<LI>necrotising enterocolitis;</LI>
<LI>oxygen treatment greater than 36 weeks' postconceptual age;</LI>
<LI>major cerebral abnormality on ultrasound prior to discharge.</LI>
</UL>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<UL>
<LI>Major maternal adverse drug reaction.</LI>
<LI>Maternal infection after delivery prior to discharge.</LI>
<LI>Chorioamnionitis (infection of the womb).</LI>
<LI>Caesarean section.</LI>
<LI>Days from randomisation to birth.</LI>
<LI>Days from birth to discharge from hospital.</LI>
<LI>Birth within 48 hours.</LI>
<LI>Birth within seven days.</LI>
<LI>Birth before 37 weeks.</LI>
<LI>Birthweight.</LI>
<LI>Birthweight less than 2500 g.</LI>
<LI>Need for intensive care.</LI>
<LI>Days in neonatal intensive care unit.</LI>
<LI>Positive neonatal blood culture.</LI>
<LI>Respiratory distress syndrome.</LI>
<LI>Treatment with surfactant.</LI>
<LI>Days of ventilation.</LI>
<LI>Days of oxygen therapy.</LI>
<LI>Oxygen treatment greater than 28 days.</LI>
<LI>Neonatal encephalopathy.</LI>
<LI>Long-term health outcomes (as defined by trial authors) after at least two years.</LI>
</UL>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-10-18 11:37:30 +0100" MODIFIED_BY="Lynn Hampson">
<ELECTRONIC_SEARCHES MODIFIED="2013-10-18 11:37:30 +0100" MODIFIED_BY="Lynn Hampson">
<P>We searched the Cochrane Pregnancy and Childbirth Group&#8217;s Trials Register by contacting the Trials Search Co-ordinator (30 September 2013).</P>
<P>The Cochrane Pregnancy and Childbirth Group&#8217;s Trials Register is maintained by the Trials Search Co-ordinator and contains trials identified from:</P>
<OL>
<LI>monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);</LI>
<LI>weekly searches of MEDLINE;</LI>
<LI>weekly searches of Embase;</LI>
<LI>handsearches of 30 journals and the proceedings of major conferences;</LI>
<LI>weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts.</LI>
</OL>
<P>Details of the search strategies for CENTRAL, MEDLINE and Embase, the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service can be found in the &#8216;Specialized Register&#8217; section within the editorial information about the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PREG/frame.html">Cochrane Pregnancy and Childbirth Group</A>.</P>
<P>Trials identified through the searching activities described above are each assigned to a review topic (or topics). The Trials Search Co-ordinator searches the register for each review using the topic list rather than keywords.</P>
<P>We did not apply any language restrictions.</P>
</ELECTRONIC_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-11-25 10:08:13 +0000" MODIFIED_BY="Lynn Hampson">
<P>For the methods used when assessing the trials identified in a previous version of this review (<LINK REF="REF-Kenyon-2003" TYPE="REFERENCE">Kenyon 2003</LINK>),<I> </I>see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
<P>For the previous update (<LINK REF="REF-Kenyon-2010" TYPE="REFERENCE">Kenyon 2010</LINK>), we used the following methods when assessing the reports identified by the updated search (<LINK REF="REF-Amon-1988b" TYPE="REFERENCE">Amon 1988b</LINK>; <LINK REF="REF-Beazley-1998" TYPE="REFERENCE">Beazley 1998</LINK>; <LINK REF="STD-Bergstrom-1991" TYPE="STUDY">Bergstrom 1991</LINK>; <LINK REF="STD-Cardamakis-1990" TYPE="STUDY">Cardamakis 1990</LINK>; <LINK REF="REF-Christmas-1990" TYPE="REFERENCE">Christmas 1990</LINK>; <LINK REF="STD-Fuhr-2006" TYPE="STUDY">Fuhr 2006</LINK>; <LINK REF="REF-Gilbert-2005" TYPE="REFERENCE">Gilbert 2005</LINK>; <LINK REF="STD-Gordon-1974" TYPE="STUDY">Gordon 1974</LINK>; <LINK REF="STD-Halis-2001" TYPE="STUDY">Halis 2001</LINK>; <LINK REF="REF-Hauth-1997" TYPE="REFERENCE">Hauth 1997</LINK>; <LINK REF="REF-Hnat-2005" TYPE="REFERENCE">Hnat 2005</LINK>; <LINK REF="REF-Kenyon-2008a" TYPE="REFERENCE">Kenyon 2008a</LINK>; <LINK REF="REF-Kenyon-2008c" TYPE="REFERENCE">Kenyon 2008c</LINK>; <LINK REF="STD-Kim-2008" TYPE="STUDY">Kim 2008</LINK>; <LINK REF="REF-Lockwood-1993b" TYPE="REFERENCE">Lockwood 1993b</LINK>; <LINK REF="REF-Morales-1988" TYPE="REFERENCE">Morales 1988</LINK>; <LINK REF="STD-Ogasawara-1996" TYPE="STUDY">Ogasawara 1996</LINK>; <LINK REF="STD-Ogasawara-1997" TYPE="STUDY">Ogasawara 1997</LINK>; <LINK REF="STD-Ogasawara-1999" TYPE="STUDY">Ogasawara 1999</LINK>; <LINK REF="REF-Owen-1993b" TYPE="REFERENCE">Owen 1993b</LINK>; <LINK REF="REF-Sanchez_x002d_Ramos-1990" TYPE="REFERENCE">Sanchez-Ramos 1990</LINK>; <LINK REF="REF-Svare-1997b" TYPE="REFERENCE">Svare 1997b</LINK>; <LINK REF="REF-Thurnau-1997" TYPE="REFERENCE">Thurnau 1997</LINK>). For this update, we would have used the following methods if we had identified new studies for inclusion.</P>
<STUDY_SELECTION MODIFIED="2009-10-29 13:51:28 +0000" MODIFIED_BY="[Empty name]">
<P>Two review authors (S Kenyon (SK) and M Boulvain (MB)) independently assessed for inclusion all the potential studies we identified as a result of the search strategy. We resolved any disagreement through discussion or, if required, we consulted the third review author (JP Neilson (JPN)).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-11-23 17:06:39 +0000" MODIFIED_BY="Denise Atherton">
<P>We designed a form to extract data. For eligible studies, review authors SK and MB extracted the data using the agreed form. We resolved discrepancies through discussion or, if required, we consulted the third review author (JPN). We entered data into Review Manager software (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>) and checked for accuracy.</P>
<P>When information regarding any of the above was unclear, we attempted to contact authors of the original reports asking them to provide further details.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-11-23 17:07:05 +0000" MODIFIED_BY="Lynn Hampson">
<P>Two<I> </I>review authors (SK and MB) independently assessed risk of bias for each study using the criteria outlined in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We resolved any disagreement by discussion or by involving the third review author (JPN).</P>
<SUBSECTION>
<HEADING LEVEL="4">(1) Sequence generation (checking for possible selection bias)</HEADING>
<P>We describe for each included study the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups.</P>
<P>We assessed the method as:</P>
<UL>
<LI>low risk of bias (any truly random process, e.g. random number table; computer random number generator);</LI>
<LI>high risk of bias (any non-random process, e.g. odd or even date of birth; hospital or clinic record number);</LI>
<LI>unclear risk of bias.   </LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4"> (2) Allocation concealment (checking for possible selection bias)</HEADING>
<P>We describe for each included study the method used to conceal the allocation sequence in sufficient detail and determine whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes);</LI>
<LI>high risk of bias (open random allocation; unsealed or non-opaque envelopes, alternation; date of birth);</LI>
<LI>unclear risk of bias.   </LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(3) Blinding (checking for possible performance bias)</HEADING>
<P>We describe for each included study the methods used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. We judged studies at low risk of bias if they were blinded, or if we judge that the lack of blinding could not have affected the results. We assessed blinding separately for different outcomes or classes of outcomes.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>low, high or unclear risk of bias for participants;</LI>
<LI>low, high or unclear risk of bias for personnel;</LI>
<LI>low, high or unclear risk of bias for outcome assessors.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(4) Incomplete outcome data (checking for possible attrition bias through withdrawals, dropouts, protocol deviations)</HEADING>
<P>We describe for each included study, and for each outcome or class of outcomes, the completeness of data including attrition and exclusions from the analysis. We have stated whether attrition and exclusions were reported, the numbers included in the analysis at each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes. We decided a cut-off for exclusion of a study for the level of missing data at 20%. Where sufficient information has been reported, or can be supplied by the trial authors, we planned to re-include missing data in the analyses which we undertake. We assessed methods as:</P>
<UL>
<LI>low risk of bias;</LI>
<LI>high risk of bias:</LI>
<LI>unclear risk of bias. </LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(5) Selective reporting bias</HEADING>
<P>We describe for each included study how we investigated the possibility of selective outcome reporting bias and what we found.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>low risk of bias (where it is clear that all of the study&#8217;s pre-specified outcomes and all expected outcomes of interest to the review have been reported);</LI>
<LI>high risk of bias (where not all the study&#8217;s pre-specified outcomes have been reported; one or more reported primary outcomes were not pre-specified; outcomes of interest are reported incompletely and so cannot be used; study fails to include results of a key outcome that would have been expected to have been reported);</LI>
<LI>unclear risk of bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(6) Other sources of bias</HEADING>
<P>We describe for each included study any important concerns we have about other possible sources of bias.</P>
<P>We assessed whether each study was free of other problems that could put it at risk of bias:</P>
<UL>
<LI>yes;</LI>
<LI>no;</LI>
<LI>unclear.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(7) Overall risk of bias</HEADING>
<P>We made explicit judgements about whether studies are at high risk of bias, according to the criteria given in the <I>Cochrane Handbook</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). With reference to (1) to (6) above, we assessed the likely magnitude and direction of the bias and whether we considered it is likely to impact on the findings (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). We considered this to be unlikely and, therefore, have not undertaken sensitivity analyses. </P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2009-10-29 13:53:09 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Dichotomous data</HEADING>
<P>For dichotomous data, we present results as summary risk ratio with 95% confidence intervals.<I> </I>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Continuous data</HEADING>
<P>For continuous data, we use the mean difference if outcomes are measured in the same way between trials. We use the standardised mean difference to combine trials that measure the same outcome, but use different methods. <B> </B>
</P>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2013-11-23 17:07:20 +0000" MODIFIED_BY="Lynn Hampson">
<SUBSECTION>
<HEADING LEVEL="4">Cluster-randomised trials</HEADING>
<P>We would have included cluster-randomised trials in the analyses along with individually-randomised trials. Their sample sizes would have been adjusted using the methods described in the <I>Cochrane</I> <I>Handbook</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) using an estimate of the intracluster correlation co-efficient (ICC) derived from the trial (if possible), or from another source. If ICCs from other sources had been used, we would have reported this and conducted sensitivity analyses to investigate the effect of variation in the ICC. If we had identified both cluster-randomised trials and individually-randomised trials, we would have synthesised the relevant information. We would have considered it reasonable to combine the results from both if there was little heterogeneity among the study designs and the interaction between the effect of intervention and the choice of randomisation unit was considered to be unlikely.</P>
<P>We would have also acknowledged heterogeneity in the randomisation unit and performed a separate meta-analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Cross-over trials</HEADING>
<P>If we had identified any cross-over trials on this topic, and deemed such trials eligible for inclusion, we would have included them in the analyses with parallel group trials, using methods described by<B> </B>
<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Multi-arm studies</HEADING>
<P>For the subgroup comparisons undertaken, to avoid double counting, we divided out data from the shared group approximately evenly among the comparisons as described in the<I> Cochrane</I> <I>Handbook </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</SUBSECTION>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2013-10-17 14:19:24 +0100" MODIFIED_BY="Denise Atherton">
<P>For included studies, we noted levels of attrition. We planned to explore the impact of including studies with high levels of missing data in the overall assessment of treatment effect by using sensitivity analysis.</P>
<P>For all outcomes we have carried out analyses, as far as possible, on an intention-to-treat basis, i.e. we attempted to include all participants randomised to each group in the analyses. The denominator for each outcome in each trial was the number randomised minus any participants whose outcomes are known to be missing.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2010-07-07 08:59:18 +0100" MODIFIED_BY="Denise Atherton">
<P>We used the I² and Tau² statistic to measure heterogeneity among the trials in each analysis. We performed subgroup analysis to obtain meta-analysis results for more clinically comparable studies, to reduce heterogeneity where it existed.<B> </B>
</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2010-07-07 08:34:12 +0100" MODIFIED_BY="Denise Atherton">
<P>Where we suspected reporting bias (<I>see</I> &#8216;Selective reporting bias&#8217; above), we attempted to contact study authors asking them to provide missing outcome data. Where this was not possible, and we thought the missing data likely to introduce serious bias, we planned to explore the impact of including such studies in the overall assessment of results by a sensitivity analysis.<B> </B>Funnel plots for primary outcomes only show no evidence of publication bias: <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>,<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>; <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-11-23 15:32:56 +0000" MODIFIED_BY="Denise Atherton">
<P>We carried out statistical analysis using the Review Manager software (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>). As we suspected clinical or methodological heterogeneity between studies sufficient to suggest that treatment effects may differ between trials, we used random-effects meta-analysis.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2013-10-03 09:11:17 +0100" MODIFIED_BY="Denise Atherton">
<P>We conducted planned subgroup analyses classifying whole trials by interaction tests available in <LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2013-11-23 17:07:26 +0000" MODIFIED_BY="Lynn Hampson">
<P>We made explicit judgements about whether studies were at high risk of bias, according to the criteria given in the <I>Cochrane Handbook</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). With reference to (1) to (6) above, we assessed the likely magnitude and direction of the bias and whether we considered it was likely to impact on the findings (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). We considered this to be unlikely and therefore, have not undertaken sensitivity analyses. </P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-11-26 10:55:17 +0000" MODIFIED_BY="Denise Atherton">
<STUDY_DESCRIPTION MODIFIED="2013-11-26 10:55:05 +0000" MODIFIED_BY="Denise Atherton">
<P>The search identified 51 trials. We included 22 trials in the review, involving 6872 women and their babies, and excluded 29. Of the trials included, the majority were small with the exception of <LINK REF="STD-Kenyon-2001" TYPE="STUDY">Kenyon 2001</LINK>, which randomised 4826 women, and <LINK REF="STD-Mercer-1997" TYPE="STUDY">Mercer 1997</LINK>, which randomised 614 women. Women were recruited between 20 and 37 weeks of gestation and inclusion criteria varied from clinicians definition of PROM to amniocentesis being carried out as part of an infection screen (<LINK REF="STD-Mercer-1992" TYPE="STUDY">Mercer 1992</LINK>). The majority of women were not in active labour. Ten trials tested broad spectrum penicillins either alone or in combination (<LINK REF="STD-Cox-1995" TYPE="STUDY">Cox 1995</LINK>; <LINK REF="STD-Ernest-1994" TYPE="STUDY">Ernest 1994</LINK>; <LINK REF="STD-Fuhr-2006" TYPE="STUDY">Fuhr 2006</LINK>; <LINK REF="STD-Grable-1996" TYPE="STUDY">Grable 1996</LINK>; <LINK REF="STD-Johnston-1990" TYPE="STUDY">Johnston 1990</LINK>; <LINK REF="STD-Kenyon-2001" TYPE="STUDY">Kenyon 2001</LINK>; <LINK REF="STD-Kurki--1992" TYPE="STUDY">Kurki 1992</LINK>; <LINK REF="STD-Lockwood-1993a" TYPE="STUDY">Lockwood 1993a</LINK>; <LINK REF="STD-Mercer-1997" TYPE="STUDY">Mercer 1997</LINK>; <LINK REF="STD-Svare-1997a" TYPE="STUDY">Svare 1997a</LINK>). Five trials tested macrolide antibiotics (erythromycin) either alone or in combination (<LINK REF="STD-Garcia_x002d_Burguillo-1995" TYPE="STUDY">Garcia-Burguillo 1995</LINK>; <LINK REF="STD-Kenyon-2001" TYPE="STUDY">Kenyon 2001</LINK>; <LINK REF="STD-McGregor-1991" TYPE="STUDY">McGregor 1991</LINK>; <LINK REF="STD-Mercer-1992" TYPE="STUDY">Mercer 1992</LINK>; <LINK REF="STD-Mercer-1997" TYPE="STUDY">Mercer 1997</LINK>) and one tested clindamycin and gentamycin (<LINK REF="STD-Ovalle_x002d_Salas-1997" TYPE="STUDY">Ovalle-Salas 1997</LINK>). The duration of treatment varied between two doses (<LINK REF="STD-Kurki--1992" TYPE="STUDY">Kurki 1992</LINK>) and 10 days (<LINK REF="STD-Kenyon-2001" TYPE="STUDY">Kenyon 2001</LINK>) with five trials opting for a maximum of seven days of treatment (<LINK REF="STD-Fuhr-2006" TYPE="STUDY">Fuhr 2006</LINK>; <LINK REF="STD-McGregor-1991" TYPE="STUDY">McGregor 1991</LINK>; <LINK REF="STD-Mercer-1997" TYPE="STUDY">Mercer 1997</LINK>; <LINK REF="STD-Ovalle_x002d_Salas-1997" TYPE="STUDY">Ovalle-Salas 1997</LINK>; <LINK REF="STD-Svare-1997a" TYPE="STUDY">Svare 1997a</LINK>). Four trials treated women until delivery (<LINK REF="STD-Ernest-1994" TYPE="STUDY">Ernest 1994</LINK>; <LINK REF="STD-Garcia_x002d_Burguillo-1995" TYPE="STUDY">Garcia-Burguillo 1995</LINK>; <LINK REF="STD-Johnston-1990" TYPE="STUDY">Johnston 1990</LINK>; <LINK REF="STD-Mercer-1992" TYPE="STUDY">Mercer 1992</LINK>). In four of the trials, women were treated with oral antibiotic alone (<LINK REF="STD-Garcia_x002d_Burguillo-1995" TYPE="STUDY">Garcia-Burguillo 1995</LINK>; <LINK REF="STD-Kenyon-2001" TYPE="STUDY">Kenyon 2001</LINK>; <LINK REF="STD-McGregor-1991" TYPE="STUDY">McGregor 1991</LINK>; <LINK REF="STD-Mercer-1992" TYPE="STUDY">Mercer 1992</LINK>). In three of the trials, women were treated with intravenous antibiotic alone (<LINK REF="STD-Fuhr-2006" TYPE="STUDY">Fuhr 2006</LINK>; <LINK REF="STD-Kurki--1992" TYPE="STUDY">Kurki 1992</LINK>; <LINK REF="STD-Lockwood-1993a" TYPE="STUDY">Lockwood 1993a</LINK>). In six of the trials, women were treated with a combination of intravenous and oral antibiotics (<LINK REF="STD-Cox-1995" TYPE="STUDY">Cox 1995</LINK>; <LINK REF="STD-Ernest-1994" TYPE="STUDY">Ernest 1994</LINK>; <LINK REF="STD-Johnston-1990" TYPE="STUDY">Johnston 1990</LINK>; <LINK REF="STD-Mercer-1997" TYPE="STUDY">Mercer 1997</LINK>; <LINK REF="STD-Ovalle_x002d_Salas-1997" TYPE="STUDY">Ovalle-Salas 1997</LINK>; <LINK REF="STD-Svare-1997a" TYPE="STUDY">Svare 1997a</LINK>).</P>
<P>The six non-placebo controlled but randomised studies, which contributed data to the outcome measure perinatal death alone, were: <LINK REF="STD-Amon-1988a" TYPE="STUDY">Amon 1988a</LINK>; <LINK REF="STD-Camli-1997" TYPE="STUDY">Camli 1997</LINK>; <LINK REF="STD-Christmas-1992" TYPE="STUDY">Christmas 1992</LINK>; <LINK REF="STD-Magwali-1999" TYPE="STUDY">Magwali 1999</LINK>; <LINK REF="STD-Morales-1989" TYPE="STUDY">Morales 1989</LINK>; <LINK REF="STD-Owen-1993a" TYPE="STUDY">Owen 1993a</LINK>.</P>
<P>Two trials compared three versus five days of ampicillin (<LINK REF="STD-Lewis-2003" TYPE="STUDY">Lewis 2003</LINK>; <LINK REF="STD-Segel-2003" TYPE="STUDY">Segel 2003</LINK>).</P>
<P>Outcomes were divided into primary and secondary. Primary outcomes, as listed above, were chosen based on importance and ability to predict longer term neonatal morbidity. Additional outcome measures chosen included maternal infection, prolongation of pregnancy and measures of neonatal mortality and morbidity. One study had undertaken follow-up past discharge from hospital (<LINK REF="STD-Kurki--1992" TYPE="STUDY">Kurki 1992</LINK>) but the results are not reported by treatment group but rather by duration of membrane rupture. One study has undertaken long-term follow-up at seven years of age in the UK (<LINK REF="STD-Kenyon-2001" TYPE="STUDY">Kenyon 2001</LINK>). The study evaluated functional impairment, behaviour, respiratory symptoms, hospital admissions, convulsions and other specific medical conditions. These are the only data on long-term follow-up from any of the included trials. Seven-year assessment was not specifically a prespecified outcome, but is captured under the outcome of long-term health after at least two years.</P>
<P>For details of included and excluded studies, <I>see </I>
<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-11-23 17:07:33 +0000" MODIFIED_BY="[Empty name]">
<P>The method of randomisation was described in all trials with the exception of <LINK REF="STD-Amon-1988a" TYPE="STUDY">Amon 1988a</LINK>, <LINK REF="STD-Camli-1997" TYPE="STUDY">Camli 1997</LINK>, <LINK REF="STD-Cox-1995" TYPE="STUDY">Cox 1995</LINK>, <LINK REF="STD-Kurki--1992" TYPE="STUDY">Kurki 1992</LINK>, <LINK REF="STD-Fuhr-2006" TYPE="STUDY">Fuhr 2006</LINK>, <LINK REF="STD-Magwali-1999" TYPE="STUDY">Magwali 1999</LINK>, <LINK REF="STD-Morales-1989" TYPE="STUDY">Morales 1989</LINK> and <LINK REF="STD-Ovalle_x002d_Salas-1997" TYPE="STUDY">Ovalle-Salas 1997</LINK>. All trials had matched placebos and were blinded apart from the six non-placebo controlled studies described above. No detail on losses to follow-up or exclusions were available from two trials (<LINK REF="STD-Cox-1995" TYPE="STUDY">Cox 1995</LINK>; <LINK REF="STD-Johnston-1990" TYPE="STUDY">Johnston 1990</LINK>). The protocols were only available for one study (<LINK REF="STD-Kenyon-2001" TYPE="STUDY">Kenyon 2001</LINK>) to allow assessment of selective reporting. Lack of information that would allow fuller assessment may reflect changes in reporting of trials.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-11-26 10:55:17 +0000" MODIFIED_BY="Denise Atherton">
<P>We included 22 trials involving 6872 women and their babies.</P>
<P>We adopted a random-effects model, as we expected heterogeneity due to variability in participant characteristics, different antibiotics, year of the study and different countries etc.</P>
<SUBSECTION>
<HEADING LEVEL="3">Any antibiotic versus placebo</HEADING>
<P>We included 16 trials in this comparison, which randomised more than 6300 women and their babies.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary Outcomes</HEADING>
<P>No maternal deaths occurred in the three trials reporting this outcome, and there were no data reported on serious maternal morbidity.</P>
<P>There was no significant difference between groups in perinatal death (risk ratio (RR) 0.93, 95% confidence interval (CI) 0.76 to 1.14, 12 trials, data for 6301 babies). Neonatal infection (RR 0.67, 95% CI 0.52 to 0.85) (12 trials/1680 babies) was statistically significantly reduced in the babies whose mothers received antibiotics. Only one trial (<LINK REF="STD-Kenyon-2001" TYPE="STUDY">Kenyon 2001</LINK>) assessed the use of surfactant and it found a statistically significant reduction (RR 0.83, 95% CI 0.72 to 0.96) (one trial/4809 babies) as was the numbers of babies requiring oxygen therapy overall (RR 0.88, 95% CI 0.81 to 0.96) (one trial/4809 babies). There were no clear differences between groups for other neonatal outcomes including neonatal respiratory distress syndrome (RR 0.95, 95% CI 0.83 to 1.09), necrotising enterocolitis (RR 1.09, 95% CI 0.65 to 1.83), and the number of babies requiring ventilation (RR 0.90, 95% CI 0.80 to 1.02). There was a significant reduction in the number of babies with an abnormal cerebral ultrasound scan prior to discharge from hospital (RR 0.81, 95% CI 0.68 to 0.98; Tau²<SUP> </SUP>= 0.00, I²<SUP> </SUP>= 0%) (12 trials/6289 babies).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary Outcomes</HEADING>
<P>Thre was no evidence of any difference between groups for birth before 37 weeks' gestation and there were no reports of major adverse drug reactions. The use of antibiotics following preterm rupture of membranes (PROM) was associated with a statistically significant reduction in chorioamnionitis (RR 0.66, 95% CI 0.46 to 0.96; Tau²<SUP> </SUP>= 0.14, I²<SUP> </SUP>= 45%) (11 trials/1559 women). The rate of caesarean section was similar in the two groups (RR 0.96, 95% CI 0.88 to 1.05). The mean maternal length of hospital stay and the interval between randomisation and the birth were not reported in any of the trials included in this comparison.</P>
<P>There was a significant reduction in the numbers of babies born within 48 hours (RR 0.71, 95% CI 0.58 to 0.87; Tau²<SUP> </SUP>= 0.03, I²<SUP> </SUP>= 50%) (seven trials/5927 babies) and seven days (RR 0.79, 95% CI 0.71 to 0.89; Tau²<SUP> </SUP>= 0.01, I²<SUP> </SUP>= 65%) (seven trials/5965 babies) of randomisation. The babies in the treatment groups spent 5.05 days less in neonatal intensive care (mean difference (MD) -5.05, 95% CI -9.77 to -0.33) (three trials/225 babies) and their birthweight was greater by 54 g (MD 53.83, 95% CI 7.06 to 100.60) (12 trials/6374 babies).</P>
<P>Long-term follow-up at seven years of age has been completed by one study (ORACLE - <LINK REF="REF-Kenyon-2008a" TYPE="REFERENCE">Kenyon 2008a</LINK>) and showed that antibiotics seemed to have little effect on the health of the children (RR 1.01, 95% CI 0.91 to 1.12) (one trial/3171 children).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup comparisons</HEADING>
<P>These were undertaken for the primary outcomes only and show no evidence of differences in treatment effects between the subgroups, with the exception of necrotising enterocolitis, where there is a strong suggestion that this is increased with beta lactum antibiotics (including co-amoxiclav) (RR 4.72, 95% CI 1.57 to 14.23).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Additional comparisons</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Erythromycin versus co-amoxiclav</HEADING>
<P>We included one trial (<LINK REF="STD-Kenyon-2001" TYPE="STUDY">Kenyon 2001</LINK>), involving 2415 women that focused on this comparison. Delivery within 48 hours was less common after co-amoxiclav (RR 1.14, 95% CI 1.02 to 1.28) but the difference was not statistically significant at seven days (RR 1.06, 95% CI 0.99 to 1.13). There was no significant difference in any index of neonatal morbidity except for necrotising enterocolitis, which was statistically significantly less frequent after erythromycin (RR 0.46, 95% CI 0.23 to 0.94). Long-term follow-up has been completed by one study (<LINK REF="STD-Kenyon-2001" TYPE="STUDY">Kenyon 2001</LINK>) and showed little effect on the health of children (RR 0.89, 95% CI 0.79 to 1.01) (one trial/1612 children).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Perinatal mortality alone</HEADING>
<P>No statistically significant reduction in perinatal mortality prior to discharge from hospital could be found when additional data were included from the six studies that were randomised but not placebo controlled (RR 0.89, 95% CI 0.74 to 1.08) (18 trials/6872 babies). Subgroup comparison of this group alone also shows no statistical difference.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Differing regimens</HEADING>
<P>Two trials (<LINK REF="STD-Lewis-2003" TYPE="STUDY">Lewis 2003</LINK>; <LINK REF="STD-Segel-2003" TYPE="STUDY">Segel 2003</LINK>) compared three versus seven-day regimens of ampicillin treatment (130 women). From the limited available outcome data, there was no obvious disadvantage to the three-day regimen.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-11-23 17:08:20 +0000" MODIFIED_BY="Denise Atherton">
<P>This review shows that routine antibiotic administration to women with PROM reduces some markers of maternal and neonatal morbidity. This does not translate into a statistically significant reduction in perinatal mortality. Most trials, however, report fewer deaths in the treatment group and the summary result shows a trend towards a beneficial effect. We included all randomised trials in the evaluation of perinatal death as this outcome is unlikely to be influenced by knowledge of the treatment allocation. Such a reduction in major markers of maternal and neonatal morbidity when antibiotics are administered makes a reduction in death possible, even if the result was statistically non-significant from pooling of available data.</P>
<P>By far the largest trial included is the UK MRC ORACLE (<LINK REF="STD-Kenyon-2001" TYPE="STUDY">Kenyon 2001</LINK>), which randomised 4826 women. The significant increase in neonatal necrotising enterocolitis found in the co-amoxiclav arm of this trial is plausible since co-amoxiclav is known to select for <I>Enterobacter</I>, <I>Citrobacter</I> and <I>Pseudomonas</I> (<LINK REF="REF-Hoy-2001" TYPE="REFERENCE">Hoy 2001</LINK>). One suggested mechanism of pathogenesis of neonatal necrotising enterocolitis is abnormal microbial colonisation of the intestinal tract by one or several species unhindered by competitors. Co-amoxiclav, because of its large spectrum may influence such colonisation. Furthermore, the immature gut is sensitive to bacterial toxins, resulting in mucosal damage and the initiation of necrotising enterocolitis.</P>
<P>Particularly in the light of the UK MRC ORACLE's finding of reduced abnormal cerebral ultrasound scans before discharge from hospital, it is important that long-term follow-up is undertaken. The UK MRC ORACLE Children Study followed up children, who were born to women with PROM randomised within the UK to the MRC ORACLE trial, at seven years of age and found no evidence of either benefit or harm. This same study also assessed long-term outcomes in children born to women with spontaneous preterm labour (SPL) and intact membranes randomised to the original ORACLE trial (<LINK REF="REF-Kenyon-2008b" TYPE="REFERENCE">Kenyon 2008b</LINK>) and found evidence of harm. The prescription of erythromycin (with or without co-amoxiclav) was associated with a statistically significant increase in the proportions of children with any level of functional impairment from 38% to 42%. Similarly, there was a statistically significant increase in the proportions of children with cerebral palsy from 1.7% to 3.3% associated with erythromycin and from 1.9% to 3.2% with co-amoxiclav. There was a suggestion that more children who developed cerebral palsy had been born to mothers who had received both antibiotics. In the light of these findings, it is important to be certain about the diagnosis of ruptured membranes before prescribing antibiotics.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-10-17 14:24:39 +0100" MODIFIED_BY="Denise Atherton">
<IMPLICATIONS_PRACTICE MODIFIED="2013-10-17 14:24:39 +0100" MODIFIED_BY="Denise Atherton">
<P>Routine prescription of antibiotics for women with preterm rupture of the membranes is associated with prolongation of pregnancy and improvements in a number of short-term neonatal morbidities, but no significant reduction in perinatal mortality. Despite lack of evidence of longer term benefit in childhood, the advantages on short-term morbidities are such that we would recommend antibiotics are routinely prescribed. The antibiotic of choice is not clear but co-amoxiclav should be avoided in women due to increased risk of neonatal necrotising enterocolitis.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2009-06-23 16:05:50 +0100" MODIFIED_BY="[Empty name]">
<P>In the future there is the possibility that comparative studies may be conducted should there be developments in the pharmacology of antibiotics.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-10-18 09:34:20 +0100" MODIFIED_BY="Denise Atherton">
<P>We acknowledge assistance with the review from Therese Dowswell, Riccardo Pfister, Justus Hofmeyr, David Taylor, Ann Blackburn and Rebecca Smyth.</P>
<P>Therese Dowswell's work was financially supported by the UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), Department of Reproductive Health and Research (RHR), World Health Organization. The named authors alone are responsible for the views expressed in this publication.</P>
<P>As part of the pre-publication editorial process, the review has been commented on by two peers (an editor and referee who is external to the editorial team), a member of the Pregnancy and Childbirth Group's international panel of consumers and the Group's Statistical Adviser.</P>
<P>The National Institute for Health Research (NIHR) is the largest single funder of the Cochrane Pregnancy and Childbirth Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the NIHR, NHS or the Department of Health.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-11-23 17:08:36 +0000" MODIFIED_BY="[Empty name]">
<P>Sara Kenyon was the Co-ordinator of the ORACLE Trial and led the ORACLE Children Study, both of which are included in this review.<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2009-06-23 16:06:17 +0100" MODIFIED_BY="[Empty name]">
<P>Sara Kenyon assessed the relevant trials, abstracted the data and wrote the text of the review. Michel Boulvain and Jim Neilson checked the extracted data and helped write the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2013-10-18 15:21:02 +0100" MODIFIED_BY="Sonja L Henderson">
<P>Secondary outcome "Serious childhood disability at approximately two years" changed to "Serious childhood disability at seven years". </P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-11-22 11:19:21 +0000" MODIFIED_BY="Lynn Hampson">
<STUDIES MODIFIED="2013-11-22 11:19:21 +0000" MODIFIED_BY="Lynn Hampson">
<INCLUDED_STUDIES MODIFIED="2013-11-22 11:19:21 +0000" MODIFIED_BY="Lynn Hampson">
<STUDY DATA_SOURCE="PUB" ID="STD-Amon-1988a" MODIFIED="2009-09-23 10:54:26 +0100" MODIFIED_BY="[Empty name]" NAME="Amon 1988a" YEAR="1988">
<REFERENCE MODIFIED="2009-05-07 21:03:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Amon E, Lewis S, Sibai BM, Moretti M</AU>
<TI>Ampicillin prophylaxis in preterm premature rupture of the membranes: a prospective randomized study</TI>
<SO>Proceedings of 8th Annual Meeting of the Society of Perinatal Obstetricians; 1988 Feb 3-6; Las Vegas, Nevada, USA</SO>
<YR>1988</YR>
<PG>51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-07 21:03:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Amon E, Lewis SV, Sibai BM, Villar MA, Arheart KL</AU>
<TI>Ampicillin prophylaxis in preterm premature rupture of the membranes: a prospective randomized study</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1988</YR>
<VL>159</VL>
<PG>539-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Camli-1997" NAME="Camli 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Camli L, Mavunagacioglu S, Bostanci A, Camli S, Soylu F. Antibiotherapy in preterm premature rupture of membrane does it effect the latent period and infectious morbidity? Jinekoloji Ve Obstetrik Dergisi 1997;11:138-42&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Camli L, Mavunagacioglu S, Bostanci A, Camli S, Soylu F</AU>
<TI>Antibiotherapy in preterm premature rupture of membrane. Does it affect the latent period and infectious morbidity?</TI>
<SO>Jinekoloji Ve Obstetrik Dergisi</SO>
<YR>1997</YR>
<VL>11</VL>
<PG>138-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Christmas-1992" MODIFIED="2009-05-07 21:06:27 +0100" MODIFIED_BY="[Empty name]" NAME="Christmas 1992" YEAR="1992">
<REFERENCE MODIFIED="2009-05-07 21:06:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Christmas JT, Cox SM, Andrew W, Dax J, Leveno KJ, Gilstrap LC</AU>
<TI>Expectant management of preterm ruptured membranes: effects of antimicrobial therapy</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1992</YR>
<VL>80</VL>
<PG>759-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-07 21:06:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Christmas JT, Cox SM, Gilstrap LC, Leveno KJ, Andrews W, Dax J</AU>
<TI>Expectant management of preterm ruptured membranes: effects of antimicrobial therapy on interval to delivery</TI>
<SO>Proceedings of 10th Annual Meeting of Society of Perinatal Obstetricians; 1990 Jan 23-27; Houston, Texas, USA</SO>
<YR>1990</YR>
<PG>19</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cox-1995" NAME="Cox 1995" YEAR="">
<REFERENCE NOTES="&lt;p&gt;[8751]&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cox SM, Leveno KJ, Sherman ML, Travis L, De Plama R</AU>
<TI>Ruptured membranes at 24 to 29 weeks: a randomized double blind trial of antimicrobials versus placebo</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1995</YR>
<VL>172</VL>
<PG>412</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ernest-1994" NAME="Ernest 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;[8307]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ernest JM, Givner LB</AU>
<TI>A prospective, randomized, placebo-controlled trial of penicillin in preterm premature rupture of membranes</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1994</YR>
<VL>170</VL>
<NO>2</NO>
<PG>516-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fuhr-2006" MODIFIED="2009-05-11 11:23:20 +0100" MODIFIED_BY="[Empty name]" NAME="Fuhr 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-05-11 11:23:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fuhr NA, Becker C, van Baalen A, Bauer K, Hopp H</AU>
<TI>Antibiotic therapy for preterm premature rupture of membranes - results of a multicenter study</TI>
<SO>Journal of Perinatal Medicine</SO>
<YR>2006</YR>
<VL>34</VL>
<NO>3</NO>
<PG>203-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garcia_x002d_Burguillo-1995" MODIFIED="2013-11-22 10:11:41 +0000" MODIFIED_BY="Heather Maxwell" NAME="Garcia-Burguillo 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;[9563]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garcia-Burguillo A, Hernandez-Garcia JM, de la Fuente P</AU>
<TI>Erythromycin prophylaxis in preterm pregnancies with rupture of amniotic membranes</TI>
<TO>Profilaxis con eritromicina en gestaciones pretermino con rotura prematura de las membranas amnioticas</TO>
<SO>Clinica e Investigacion en Ginecologia y Obstetricia</SO>
<YR>1995</YR>
<VL>23</VL>
<NO>3</NO>
<PG>96-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grable-1996" NAME="Grable 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grable IA, Garcia PM, Perry D, Socol ML</AU>
<TI>Group B streptococcus and preterm premature rupture of membranes: a randomized, double-blind clinical trial of antepartum ampicillin</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1996</YR>
<VL>175</VL>
<PG>1036-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnston-1990" MODIFIED="2009-05-07 21:16:14 +0100" MODIFIED_BY="[Empty name]" NAME="Johnston 1990" YEAR="1990">
<REFERENCE MODIFIED="2009-05-07 21:16:14 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;[5777]&lt;/p&gt;" NOTES_MODIFIED="2009-05-07 21:16:14 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Johnston MM, Sanchez-Ramos L, Vaughan AJ, Todd MW, Benrubi GI</AU>
<TI>Antibiotic therapy in preterm premature rupture of membranes: a randomized, prospective, double-blind trial</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1990</YR>
<VL>163</VL>
<NO>3</NO>
<PG>743-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-07 21:16:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sanchez-Ramos L, Johnston M, Vaughn A, Benrubi GI, Todd M</AU>
<TI>High dose antibiotic therapy in preterm premature rupture of the membranes: a double blind, randomized, prospective study</TI>
<SO>Proceedings of 10th Annual Meeting of Society of Perinatal Obstetricians; 1990 Jan 23-27; Houston, Texas, USA</SO>
<YR>1990</YR>
<PG>18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kenyon-2001" MODIFIED="2013-10-03 09:16:12 +0100" MODIFIED_BY="Denise Atherton" NAME="Kenyon 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-05-07 21:07:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gilbert RE, Pike K, Kenyon SL, Tarnow-Mordi W, Taylor DJ</AU>
<TI>The effect of prepartum antibiotics on the type of neonatal bacteraemia: insights from the MRC ORACLE trials</TI>
<SO>BJOG: an international journal of obstetrics and gynaecology</SO>
<YR>2005</YR>
<VL>112</VL>
<NO>6</NO>
<PG>830-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-03 09:16:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jones DR, Pike K, Kenyon S, Pike L, Henderson B, Brocklehurst P, et al</AU>
<TI>Routine educational outcome measures in health studies: Key Stage 1 in the ORACLE Children Study follow-up of randomised trial cohorts</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>2011</YR>
<VL>96</VL>
<NO>1</NO>
<PG>25-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-07 21:09:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kenyon S, Brocklehurst P, Jones D, Marlow N, Salt A, Taylor D</AU>
<TI>MRC ORACLE children study. Long term outcomes following prescription of antibiotics to pregnant women with either spontaneous preterm labour or preterm rupture of the membranes</TI>
<SO>BMC Pregnancy &amp; Childbirth</SO>
<YR>2008</YR>
<VL>8</VL>
<PG>14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-07 21:09:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kenyon S, Pike K, Jones DR, Brocklehurst P, Marlow N, Salt A, et al</AU>
<TI>Childhood outcomes after prescription of antibiotics to pregnant women with preterm rupture of the membranes: 7-year follow-up of the ORACLE I trial</TI>
<SO>Lancet</SO>
<YR>2008</YR>
<VL>372</VL>
<NO>9646</NO>
<PG>1310-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-07 08:34:49 +0100" MODIFIED_BY="Denise Atherton" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kenyon S, Taylor DJ, Tarnow-Mordi W</AU>
<TI>ORACLE-antibiotics for preterm prelabour rupture of the membranes: short and long term outcomes</TI>
<SO>Acta Paediatrica Supplement</SO>
<YR>2002</YR>
<VL>91</VL>
<NO>437</NO>
<PG>12-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kenyon SL, Taylor DJ, Tarnow-Mordi W, for the ORACLE Collaborative Group</AU>
<TI>Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: the ORACLE 1 randomised trial</TI>
<SO>Lancet</SO>
<YR>2001</YR>
<VL>357</VL>
<PG>979-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-05-11 14:48:47 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kurki--1992" NAME="Kurki  1992" YEAR="">
<REFERENCE NOTES="&lt;p&gt;[7301]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kurki T, Hallman M, Zilliacus R, Teramo K, Ylikorkala O</AU>
<TI>Premature rupture of the membranes; effect of penicillin prophylaxis and long-term outcome of the children</TI>
<SO>American Journal of Perinatology</SO>
<YR>1992</YR>
<VL>9</VL>
<PG>11-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lewis-2003" NAME="Lewis 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lewis DF, Adair CD, Robichaux AG, Jaekle RK, Moore JA, Evans AT, et al</AU>
<TI>Antibiotic therapy in preterm premature rupture of membranes: are seven days necessary? A preliminary randomized clinical trial</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2003</YR>
<VL>188</VL>
<NO>6</NO>
<PG>1413-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lockwood-1993a" MODIFIED="2010-07-07 08:35:15 +0100" MODIFIED_BY="Denise Atherton" NAME="Lockwood 1993a" YEAR="1993">
<REFERENCE MODIFIED="2009-05-07 21:12:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lockwood CJ, Costigan K, Ghidini A, Wein R, Cetrulo C, Alvarez M, et al</AU>
<TI>Double-blind, placebo-controlled trial of piperacillin sodium in preterm membrane rupture</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1993</YR>
<VL>168</VL>
<NO>1 Pt 2</NO>
<PG>378</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-07 08:35:15 +0100" MODIFIED_BY="Denise Atherton" NOTES="&lt;p&gt;[8224]&lt;/p&gt;" NOTES_MODIFIED="2010-07-07 08:35:15 +0100" NOTES_MODIFIED_BY="Denise Atherton" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lockwood CJ, Costigan K, Ghidini A, Wein R, Chien D, Brown BL, et al</AU>
<TI>Double-blind, placebo-controlled trial of piperacillin prophylaxis in preterm membrane rupture</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1993</YR>
<VL>169</VL>
<PG>970-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Magwali-1999" NAME="Magwali 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Magwali TL, Cipato T, Majoko F, Rusakaniko S, Mujaji C</AU>
<TI>Prophylactic augmentin in prelabour preterm rupture of the membranes</TI>
<SO>International Journal of Gynecology &amp; Obstetrics</SO>
<YR>1999</YR>
<VL>65</VL>
<PG>261-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McGregor-1991" MODIFIED="2009-04-29 10:22:58 +0100" MODIFIED_BY="[Empty name]" NAME="McGregor 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;[6853]&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McGregor JA, French JI, Seo K</AU>
<TI>Antimicrobial therapy in preterm premature rupture of membranes: results of a prospective, double-blind, placebo-controlled trial of erythromycin</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1991</YR>
<VL>165</VL>
<PG>632-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-29 10:22:58 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;[4818]&lt;/p&gt;" NOTES_MODIFIED="2009-04-29 10:22:58 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>McGregor JA, French JI</AU>
<TI>Double-blind, randomized, placebo controlled, prospective evaluation of the efficacy of short course erythromycin in prolonging gestation among women with preterm rupture of membranes</TI>
<SO>Proceedings of 9th Annual Meeting of the Society of Perinatal Obstetricians; 1989 Feb 1-4; New Orleans, Louisiana, USA</SO>
<YR>1989</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mercer-1992" NAME="Mercer 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;[7145]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mercer BM, Moretti ML, Prevost RR, Sibai BM</AU>
<TI>Erythromycin therapy in preterm premature rupture of the membranes: a prospective, randomized trial of 220 patients</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1992</YR>
<VL>166</VL>
<PG>794-802</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mercer-1997" MODIFIED="2013-10-03 09:16:36 +0100" MODIFIED_BY="Denise Atherton" NAME="Mercer 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-05-07 21:05:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beazley D</AU>
<TI>Impact of amnionitis and antepartum antibiotic treatment on neonatal outcome after PPROM</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1998</YR>
<VL>178</VL>
<NO>1 Pt 2</NO>
<PG>S15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-07 21:08:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hauth JC</AU>
<TI>The NICHD-MFMU antibiotic treatment of PROM study: correlation with acute placental inflammation and prenatal morbidity</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1997</YR>
<VL>176</VL>
<NO>1 Pt 2</NO>
<PG>S53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-07 21:09:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hnat MD, Mercer BM, Thurnau G, Goldenberg R, Thom EA, Meis PJ, et al</AU>
<TI>Perinatal outcomes in women with preterm rupture of membranes between 24 and 32 weeks of gestation and a history of vaginal bleeding</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2005</YR>
<VL>193</VL>
<PG>164-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-07 08:35:34 +0100" MODIFIED_BY="Denise Atherton" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mercer B, Miodovnik M, Thurnau G, Goldenberg R, Das A, Merenstein G, et al</AU>
<TI>A multicentre randomized controlled trial of antibiotic therapy versus placebo therapy after preterm premature rupture of the membranes</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1996</YR>
<VL>174</VL>
<NO>1 Pt 2</NO>
<PG>304</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Mercer B. The NICHD-MFMU antibiotic treatment of PPROM study: evaluation of factors associated with successful outcome. American Journal of Obstetrics &amp;amp; Gynecology 1997;176(1 Pt 2):S8&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mercer B</AU>
<TI>The NICHD-MFMU antibiotic treatment of PPROM study: evaluation of factors associated with successful outcome</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1997</YR>
<VL>176</VL>
<NO>1 Pt 2</NO>
<PG>S8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-03 09:16:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mercer BM, Crouse DT, Goldenberg RL, Miodovnik M, Mapp DC, Meis PJ, et al</AU>
<TI>The antibiotic treatment of PPROM study: systemic maternal and fetal markers and perinatal outcomes</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2012</YR>
<VL>206</VL>
<NO>2</NO>
<PG>145.e1-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-07 04:27:05 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;[9537]&lt;/p&gt;" NOTES_MODIFIED="2010-07-07 04:27:05 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mercer BM, Miodovnik M, Thurnau GR, Goldenberg RL, Das AF, Ramsey RD, et al</AU>
<TI>Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes</TI>
<SO>JAMA</SO>
<YR>1997</YR>
<VL>278</VL>
<PG>989-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ramsey P</AU>
<TI>Preterm premature rupture of membranes (PPROM): latency and neonatal outcome</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2002</YR>
<VL>187</VL>
<NO>6 Pt 2</NO>
<PG>S113</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-07 21:17:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thurnau G</AU>
<TI>The NICHD-MFMU antibiotic treatment of PROM study: impact of initial amniotic fluid volume on pregnancy outcome</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1997</YR>
<VL>176</VL>
<NO>1 Pt 2</NO>
<PG>S53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morales-1989" MODIFIED="2009-05-07 21:13:28 +0100" MODIFIED_BY="[Empty name]" NAME="Morales 1989" YEAR="1989">
<REFERENCE MODIFIED="2009-05-07 21:13:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morales WJ, Angel JL, Knuppel RA</AU>
<TI>Comparison of various parameters as predictors of chorioamnionitis in preterm patients with premature rupture of membranes</TI>
<SO>Southern Medical Journal</SO>
<YR>1988</YR>
<VL>81</VL>
<PG>40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-07 21:13:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Morales WJ, Angel JL, O'Brien WF, Knuppel RA</AU>
<TI>Use of ampicillin and corticosteroids in premature rupture of membranes: a randomized study</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1989</YR>
<VL>73</VL>
<NO>5</NO>
<PG>721-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ovalle_x002d_Salas-1997" MODIFIED="2013-11-22 11:19:21 +0000" MODIFIED_BY="Lynn Hampson" NAME="Ovalle-Salas 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-07-07 08:35:46 +0100" MODIFIED_BY="Denise Atherton" NOTES="&lt;p&gt;Ovalle A, Martinez M, Gomez R, Valderrama O, Lira P, Rubio R et al. Pretem premature rupture of membranes: a prospective randomized placebo controlled trial of antibiotic treatment . American Journal of Obstetrics &amp;amp; Gynecology 1996;174(1 Pt 2):401&lt;/p&gt;" NOTES_MODIFIED="2010-07-07 08:35:46 +0100" NOTES_MODIFIED_BY="Denise Atherton" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ovalle A, Martinez M, Gomez R, Valderrama O, Lira P, Rubio R, et al</AU>
<TI>Preterm premature rupture of membranes: a prospective randomized placebo controlled trial of antibiotic treatment</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1996</YR>
<VL>174(1 Pt 2)</VL>
<PG>401</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-07 08:35:53 +0100" MODIFIED_BY="Denise Atherton" NOTES="&lt;p&gt;Ovalle A, Martinez M, Kakarieka E, Rubio R, Valderrama O, Villablanca E et al. Antibiotic administration in patients with preterm premature rupture of membranes reduces the rate of histological chorioamnionitis. American Journal of Obstetrics &amp;amp; Gynecology 1999;180(1 Pt 2):S83&lt;/p&gt;" NOTES_MODIFIED="2010-07-07 08:35:53 +0100" NOTES_MODIFIED_BY="Denise Atherton" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ovalle A, Martinez M, Kakarieka E, Rubio R, Valderrama O, Villablanca E, et al</AU>
<TI>Antibiotic administration in patients with preterm premature rupture of membranes reduces the rate of histological chorioamnionitis</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1999</YR>
<VL>180(1 Pt 2)</VL>
<PG>S83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-07 09:56:23 +0100" MODIFIED_BY="Lynn Hampson" NOTES="&lt;p&gt;[9539]&lt;/p&gt;" NOTES_MODIFIED="2010-07-07 09:56:23 +0100" NOTES_MODIFIED_BY="Lynn Hampson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ovalle-Salas A, Gomez R, Martinez MA, Rubio R, Fuentes A, Valderrama O, et al</AU>
<TI>Antibiotic therapy in patients with preterm premature rupture of membranes: a prospective, randomized, placebo-controlled study with microbiological assessment of the amniotic cavity and lower genital tract</TI>
<SO>Prenatal and Neonatal Medicine</SO>
<YR>1997</YR>
<VL>2</VL>
<PG>213-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Owen-1993a" MODIFIED="2009-09-23 11:22:17 +0100" MODIFIED_BY="[Empty name]" NAME="Owen 1993a" YEAR="1993">
<REFERENCE MODIFIED="2009-05-07 21:15:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Owen J, Groome LJ, Hauth JC</AU>
<TI>Randomised trial of prophylactic therapy after preterm amnion rupture</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1993</YR>
<VL>169</VL>
<NO>4</NO>
<PG>976-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-07 21:15:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Owen J, Groome LJ, Hauth JC</AU>
<TI>Randomized trial of prophylactic antibiotic therapy after preterm amnion rupture</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1993</YR>
<VL>168</VL>
<NO>1 Pt 2</NO>
<PG>379</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Segel-2003" NAME="Segel 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Segel S, Miles A, Clothier B, Parry S, Macones G</AU>
<TI>Optimal duration of antibiotic therapy after PPROM</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2002</YR>
<VL>187</VL>
<NO>6 Pt 2</NO>
<PG>S72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Segel SY, Miles AM, Clothier B, Parry S, Macones GA</AU>
<TI>Duration of antibiotic therapy after preterm premature rupture of fetal membranes</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2003</YR>
<VL>189</VL>
<PG>799-802</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svare-1997a" MODIFIED="2010-07-07 08:36:08 +0100" MODIFIED_BY="Denise Atherton" NAME="Svare 1997a" YEAR="">
<REFERENCE MODIFIED="2010-07-07 08:36:08 +0100" MODIFIED_BY="Denise Atherton" NOTES="&lt;p&gt;[9199]&lt;/p&gt;" NOTES_MODIFIED="2010-07-07 08:36:08 +0100" NOTES_MODIFIED_BY="Denise Atherton" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Svare J, Langhoff-Roos J, Andersen LF, Baggesen NK, Christensen HB, Heisterberg L, et al</AU>
<TI>Antibiotic treatment in preterm labor or preterm premature rupture of the membranes - a randomized controlled double-blind trial</TI>
<SO>Acta Obstetricia et Gynecologica Scandinavica Supplement</SO>
<YR>1996</YR>
<VL>75</VL>
<NO>Suppl 162</NO>
<PG>36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-09-23 11:29:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Svare J, Langhoff-Roos J, Andersen LF, Kryger-Baggesen N, Borch-Christensen H, Heisterberg L, et al</AU>
<TI>Ampicillin-metronidazole treatment in threatening preterm delivery</TI>
<SO>Acta Obstetricia et Gynecologica Scandinavica</SO>
<YR>1997</YR>
<VL>76</VL>
<NO>167:1</NO>
<PG>86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-09-23 11:30:29 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;[9540]&lt;/p&gt;" NOTES_MODIFIED="2009-09-23 11:30:29 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="BOOK">
<AU>Svare J</AU>
<SO>Preterm delivery and subclinical uro-genital infection [thesis]</SO>
<YR>1997</YR>
<PB>Department of Obstetrics and Gynaecology Rigshospitalet, University of Copenhagen</PB>
<CY>Denmark</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-11-22 10:29:34 +0000" MODIFIED_BY="Denise Atherton">
<STUDY DATA_SOURCE="PUB" ID="STD-Almeida-1996" MODIFIED="2009-06-23 14:40:47 +0100" MODIFIED_BY="[Empty name]" NAME="Almeida 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-06-23 14:40:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Almeida L, Schmauch A, Bergstrom S</AU>
<TI>A randomised study on the impact of peroral amoxicillin in women with prelabour rupture of membranes preterm</TI>
<SO>Gynecologic and Obstetric Investigation</SO>
<YR>1996</YR>
<VL>41</VL>
<PG>82-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bergstrom-1991" MODIFIED="2009-09-23 10:55:33 +0100" MODIFIED_BY="[Empty name]" NAME="Bergstrom 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-09-23 10:55:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bergstrom S</AU>
<TI>A prospective study on the perinatal outcome in Mozambican pregnant women with preterm rupture of membranes using two different methods of clinical management</TI>
<SO>Gynecologic &amp; Obstetric Investigation</SO>
<YR>1991</YR>
<VL>32</VL>
<PG>217-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blanco-1993" MODIFIED="2010-07-07 08:36:20 +0100" MODIFIED_BY="Denise Atherton" NAME="Blanco 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-07-07 08:36:20 +0100" MODIFIED_BY="Denise Atherton" NOTES="&lt;p&gt;[7487]&lt;/p&gt;" NOTES_MODIFIED="2010-07-07 08:36:20 +0100" NOTES_MODIFIED_BY="Denise Atherton" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blanco J, Iams J, Artal R, Baker J, Hibbard J, McGregor J, et al</AU>
<TI>Multicenter double-blind prospective random trial of ceftizoxime vs placebo in women with preterm premature ruptured membranes (pPROM)</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1993</YR>
<VL>168</VL>
<PG>378</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cardamakis-1990" MODIFIED="2009-05-15 10:08:56 +0100" MODIFIED_BY="[Empty name]" NAME="Cardamakis 1990" YEAR="1990">
<REFERENCE MODIFIED="2009-05-15 10:08:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Cardamakis E, Minaretzis D, Papageorgiou J, Karaiskakis P, Kioses E, Michalas S</AU>
<TI>Premature rupture of the membranes. II. Chemioprophylaxis</TI>
<SO>Proceedings of 12th European Congress of Perinatal Medicine; 1990 Sept 11-14; Lyon, France</SO>
<YR>1990</YR>
<PG>45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carroll-2000" NAME="Carroll 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Carroll E, Heywood P, Besinger R, Muraskas J, Fisher S, Gianopoulos JG. A prospective randomized double blind trial of ampicillin with and without sulbactam in preterm premature rupture of the membranes [abstract]. American Journal of Obstetrics &amp;amp; Gynecology 2000;182(1 Pt 2):S61&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carroll E, Heywood P, Besinger R, Muraskas J, Fisher S, Gianopoulos JG</AU>
<TI>A prospective randomized double blind trial of ampicillin with and without sulbactam in preterm premature rupture of the membranes [abstract]</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2000</YR>
<VL>182</VL>
<NO>1 Pt 2</NO>
<PG>S61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Debodinance-1990" MODIFIED="2013-11-22 10:23:19 +0000" MODIFIED_BY="Heather Maxwell" NAME="Debodinance 1990" YEAR="1990">
<REFERENCE MODIFIED="2013-11-22 10:23:19 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Debodinance P, Parmentier D, Devulder G, Closset P, Querleu D, Crepin G</AU>
<TI>Can one reduce the risk of neonatal infection after premature rupture of membranes?</TI>
<TO>Peut-on reduire le risque infectieux neonatal dans les ruptures prematurees des membranes?</TO>
<SO>Journal de Gynecologie, Obstetrique et Biologie de la Reproduction</SO>
<YR>1990</YR>
<VL>19</VL>
<PG>533-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dunlop-1986" NAME="Dunlop 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;[2977]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dunlop PDM, Crowley PA, Lamont RF, Hawkins DF</AU>
<TI>Preterm ruptured membranes, no contractions</TI>
<SO>Journal of Obstetrics and Gynaecology</SO>
<YR>1986</YR>
<VL>7</VL>
<PG>92-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fortunato-1990" NAME="Fortunato 1990" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fortunato SJ, Welt SI, Eggleston M, Cole J, Bryant EC, Dodson MG</AU>
<TI>Prolongation of the latency period in preterm premature rupture of the membranes using prophylactic antibiotics and tocolysis</TI>
<SO>Journal of Perinatology</SO>
<YR>1990</YR>
<VL>3</VL>
<PG>252-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gordon-1974" MODIFIED="2013-11-22 10:23:54 +0000" MODIFIED_BY="[Empty name]" NAME="Gordon 1974" YEAR="1974">
<REFERENCE MODIFIED="2013-11-22 10:23:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Gordon M, Weingold AB</AU>
<TI>Treatment of patients with premature rupture of the fetal membranes: (a) prior to 32 weeks; (b) after 32 weeks. Premature rupture of the membranes - a rational approach to management</TI>
<SO>Controversy in Obstetrics &amp; Gynecology II</SO>
<YR>1974</YR>
<PG>42-4</PG>
<ED>Reid DE, Christian CD</ED>
<PB>WB Saunders Company</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haas-2010" MODIFIED="2013-10-03 09:16:50 +0100" MODIFIED_BY="[Empty name]" NAME="Haas 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-10-03 09:16:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Haas D</AU>
<TI>Preterm premature rupture of membranes: erythromycin versus azithromycin a randomized trial comparing their efficacy to prolong latency (PEACE trial)</TI>
<SO>http://clinicaltrials.gov/show/NCT01556334 (accessed 25 June 2012)</SO>
<YR>2010</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS>
<IDENTIFIER TYPE="CTG" VALUE="NCT01556334"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Halis-2001" MODIFIED="2009-05-15 10:19:23 +0100" MODIFIED_BY="[Empty name]" NAME="Halis 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-05-15 10:19:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Halis, Ragosch, Hundertmark, Weitzel, Hopp</AU>
<TI>Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes - a randomized controlled trial</TI>
<SO>11th European Congress of Clinical Microbiology and Infectious Diseases; 2001 April 1-4; Istanbul, Turkey</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hernandez-2011" MODIFIED="2013-10-07 10:33:07 +0100" MODIFIED_BY="[Empty name]" NAME="Hernandez 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-10-07 10:33:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hernandez y Ballinas A, Lopez Faran JA, Gamez Guevara C</AU>
<TI>[Comparison of maternal and perinatal outcomes in the conservative treatment preterm premature membrane rupture between the use of erythromycin and clindamycin]. [Spanish]</TI>
<SO>Ginecologia y Obstetricia de Mexico</SO>
<YR>2011</YR>
<VL>79</VL>
<NO>7</NO>
<PG>403-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Julien-2002" NAME="Julien 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Julien S, Khandelwal M, Olasewere T</AU>
<TI>Randomised trial comparing long term versus short term antibiotic prophylaxis in preterm premature rupture of membranes (PPROM)</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2002</YR>
<VL>187</VL>
<NO>6 Pt 2</NO>
<PG>S66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kim-2008" MODIFIED="2009-05-11 12:11:48 +0100" MODIFIED_BY="[Empty name]" NAME="Kim 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-05-11 12:11:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Kim YH, Song TB, Kim CH, Kim JW, Cho MY, Yang SY, et al</AU>
<TI>Changes of lipid peroxidation and protein carbonyls formation by antibiotic therapy in the maternal venous plasma of preterm premature rupture of membranes</TI>
<SO>55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26-29; San Diego, USA</SO>
<YR>2008</YR>
<PG>Abstract no: 398</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kwak-2013" MODIFIED="2013-10-07 10:33:12 +0100" MODIFIED_BY="[Empty name]" NAME="Kwak 2013" YEAR="2013">
<REFERENCE MODIFIED="2013-10-07 10:33:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kwak HM, Shin MY, Cha HH, Choi SJ, Lee JH, Kim JS, et al</AU>
<TI>The efficacy of cefazolin plus macrolide (erythromycin or clarithromycin) versus cefazolin alone in neonatal morbidity and placental inflammation for women with preterm premature rupture of membranes</TI>
<SO>Placenta</SO>
<YR>2013</YR>
<VL>34</VL>
<NO>4</NO>
<PG>346-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lebherz-1963" NAME="Lebherz 1963" YEAR="1963">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lebherz TB, Hellman LP, Madding R, Anctil A, Arje SL</AU>
<TI>Double-blind study of premature rupture of the membranes</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1963</YR>
<VL>87</VL>
<NO>2</NO>
<PG>218-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lewis-1995" NAME="Lewis 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;[8925]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lewis DF, Fontenot MT, Brooks GG, Wise R, Perkins MB, Heymann AR</AU>
<TI>Latency period after preterm premature rupture of membranes: a comparison of ampicillin with and without sulbactam</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1995</YR>
<VL>86</VL>
<NO>3</NO>
<PG>392-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lewis-1996" NAME="Lewis 1996" YEAR="">
<REFERENCE NOTES="&lt;p&gt;[9501]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lewis DF, Brody K, Edwards MS, Brouillette RM, Burlison S, London S</AU>
<TI>Preterm premature ruptured membranes: a randomized trial of steroids after treatment with antibiotics</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1996</YR>
<VL>88</VL>
<NO>5</NO>
<PG>801-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lovett-1997" MODIFIED="2013-11-22 10:29:34 +0000" MODIFIED_BY="Heather Maxwell" NAME="Lovett 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Lovett S, Weiss J, Diogo M, Williams P, Garite T. A prospective randomized clinical trial of antibiotic therapy for preterm premature rupture of membranes. American Journal of Obstetrics &amp;amp; Gynecology 1996;174:306&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lovett S, Weiss J, Diogo M, Williams P, Garite T</AU>
<TI>A prospective randomized clinical trial of antibiotic therapy for preterm premature rupture of membranes</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1996</YR>
<VL>174</VL>
<PG>306</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-11-22 10:29:34 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lovett SM, Weiss JD, Diogo MJ, Williams PT, Garite TJ</AU>
<TI>A prospective, double-blind, randomized, controlled clinical trial of ampicillin-sulbactam for preterm premature rupture of membranes in women receiving antenatal corticosteroid therapy</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1997</YR>
<VL>176</VL>
<NO>5</NO>
<PG>1030-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matsuda-1993a" NAME="Matsuda 1993a" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;[8347]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matsuda Y, Ikenoue T, Ibara S, Sameshima H, Kuraya K, Hokanishi H</AU>
<TI>The efficacy of prophylactic antibiotic and tocolytic therapy for premature rupture of the membranes</TI>
<SO>Acta Obstetricia et Gynecologica Japonica</SO>
<YR>1993</YR>
<VL>45</VL>
<NO>10</NO>
<PG>1109-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matsuda-1993b" NAME="Matsuda 1993b" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;[8083]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matsuda Y, Ikenoue T, Hokanishi H</AU>
<TI>Premature rupture of the membranes - aggressive versus conservative approach: effect of tocolytic and antibiotic therapy</TI>
<SO>Gynecologic and Obstetric Investigation</SO>
<YR>1993</YR>
<VL>36</VL>
<PG>102-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mbu-1998" NAME="Mbu 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mbu RE, Tchio R, Leke RG, Tamba NE, Njoh N</AU>
<TI>Premature rupture of membranes: maternal and fetal outcome in the absence of antibiotic prophylaxis</TI>
<TO>Rupture prematuree des membranes: devenir maternal et foetal en l'absence de la prophylaxie antibiotique</TO>
<SO>African Journal of Reproductive Health</SO>
<YR>1998</YR>
<VL>2</VL>
<PG>26-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McCaul-1992" NAME="McCaul 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;[7213]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McCaul JF, Perry KG, Moore JL, Martin RW, Bucovaz ET, Morrison JC</AU>
<TI>Adjunctive antibiotic treatment of women with preterm rupture of membranes or preterm labor</TI>
<SO>International Journal of Gynecology &amp; Obstetrics</SO>
<YR>1992</YR>
<VL>38</VL>
<PG>19-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Norri-1991" NAME="Norri 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;[6743]&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Norri L, Yla-Outinen A, Tuimala R</AU>
<TI>Prophylactic antibiotics in premature rupture of membranes</TI>
<SO>Proceedings of 13th World Congress of Gynaecology and Obstetrics (FIGO);1991 September; Singapore</SO>
<YR>1991</YR>
<PG>80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ogasawara-1996" MODIFIED="2009-05-11 12:13:50 +0100" MODIFIED_BY="[Empty name]" NAME="Ogasawara 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-05-11 12:13:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ogasawara KK, Goodwin TM</AU>
<TI>The efficacy of treating ureaplasma urealyticum in patients with preterm labor or preterm premature rupture of membranes</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1996</YR>
<VL>174</VL>
<NO>1 Pt 2</NO>
<PG>401</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ogasawara-1997" MODIFIED="2009-05-11 12:16:21 +0100" MODIFIED_BY="[Empty name]" NAME="Ogasawara 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-05-11 12:16:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ogasawara KK, Goodwin TM</AU>
<TI>The efficacy of prophylactic erythromycin in preventing vertical transmission of ureaplasma urealyticum</TI>
<SO>American Journal of Perinatology</SO>
<YR>1997</YR>
<VL>14</VL>
<NO>4</NO>
<PG>233-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ogasawara-1999" MODIFIED="2009-09-23 11:00:14 +0100" MODIFIED_BY="[Empty name]" NAME="Ogasawara 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-05-11 12:19:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ogasawara KK, Goodwin TM</AU>
<TI>Efficacy of azithromycin in reducing lower genital ureaplasma urealyticum colonization in women at risk for preterm delivery</TI>
<SO>Journal of Maternal Fetal Medicine</SO>
<YR>1999</YR>
<VL>8</VL>
<PG>12-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ovalle-2002" MODIFIED="2009-04-29 10:23:20 +0100" MODIFIED_BY="[Empty name]" NAME="Ovalle 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-04-29 10:23:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ovalle A, Martinez MA, Kakarieka E, Gomez R, Rubio R, Valderrama O, et al</AU>
<TI>Antibiotic administration in patients with preterm premature rupture of the membranes reduces the rate of histological chorioamnionitis: a prospective, randomised, controlled study</TI>
<SO>Journal of Maternal-Fetal &amp; Neonatal Medicine</SO>
<YR>2002</YR>
<VL>12</VL>
<PG>35-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spitzer-1993" NAME="Spitzer 1993" YEAR="">
<REFERENCE NOTES="&lt;p&gt;[9538]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spitzer D, Zajc M, Gregg A, Steiner H, Staudach A</AU>
<TI>Antepartum antibiotic therapy and subsequent neonatal morbidity in patients with preterm premature rupture of the membranes</TI>
<SO>International Journal of Experimental and Clinical Chemotherapy</SO>
<YR>1993</YR>
<VL>6</VL>
<NO>1</NO>
<PG>35-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2013-10-07 10:33:12 +0100" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-11-22 10:40:41 +0000" MODIFIED_BY="Lynn Hampson">
<ADDITIONAL_REFERENCES MODIFIED="2013-11-22 10:38:04 +0000" MODIFIED_BY="Lynn Hampson">
<REFERENCE ID="REF-Alderson-2004" NAME="Alderson 2004" TYPE="OTHER">
<AU>Alderson P, Green S, Higgins JPT, editors</AU>
<TI>Cochrane Reviewers' Handbook 4.2.2 [updated March 2004]</TI>
<SO>The Cochrane Library, Issue 1, 2004. Chichester, UK: John Wiley &amp; Sons, Ltd</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Amon-1988b" MODIFIED="2009-09-23 10:54:19 +0100" MODIFIED_BY="[Empty name]" NAME="Amon 1988b" TYPE="CONFERENCE_PROC">
<AU>Amon E, Lewis S, Sibai BM, Moretti M</AU>
<TI>Ampicillin prophylaxis in preterm premature rupture of the membranes: a prospective randomized study</TI>
<SO>Proceedings of 8th Annual Meeting of the Society of Perinatal Obstetricians; 1988 Feb 3-6; Las Vegas, Nevada, USA</SO>
<YR>1988</YR>
<PG>51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Beazley-1998" MODIFIED="2009-09-23 10:54:06 +0100" MODIFIED_BY="[Empty name]" NAME="Beazley 1998" TYPE="JOURNAL_ARTICLE">
<AU>Beazley D</AU>
<TI>Impact of amnionitis and antepartum antibiotic treatment on neonatal outcome after PPROM</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1998</YR>
<VL>178</VL>
<NO>1 Pt 2</NO>
<PG>S15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bejar-1981" NAME="Bejar 1981" TYPE="JOURNAL_ARTICLE">
<AU>Bejar R, Curbelo V, Davi SC, Gluck L</AU>
<TI>Premature labour bacterial sources of phospholipase</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1981</YR>
<VL>57</VL>
<PG>479</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Christmas-1990" MODIFIED="2009-09-23 10:54:06 +0100" MODIFIED_BY="[Empty name]" NAME="Christmas 1990" TYPE="CONFERENCE_PROC">
<AU>Christmas JT, Cox SM, Gilstrap LC, Leveno KJ, Andrews W, Dax J</AU>
<TI>Expectant management of preterm ruptured membranes: effects of antimicrobial therapy on interval to delivery</TI>
<SO>Proceedings of 10th Annual Meeting of Society of Perinatal Obstetricians; 1990 Jan 23-27; Houston, Texas, USA</SO>
<YR>1990</YR>
<PG>19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Costeloe-2012" MODIFIED="2013-10-17 14:44:22 +0100" MODIFIED_BY="[Empty name]" NAME="Costeloe 2012" TYPE="JOURNAL_ARTICLE">
<AU>Costeloe KL, Hennessy EM, Haider S, Stacey F, Marlow N, Draper ES</AU>
<TI>Short term outcomes after extreme preterm birth in England: comparison of two birth cohorts in 1995 and 2006 (the EPICURE studies)</TI>
<SO>BMJ</SO>
<YR>2012</YR>
<VL>345</VL>
<PG>e7976</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dale-1989" MODIFIED="2013-11-22 10:32:10 +0000" MODIFIED_BY="[Empty name]" NAME="Dale 1989" TYPE="JOURNAL_ARTICLE">
<AU>Dale PO, Tanbo T, Bendvold E, Moe N</AU>
<TI>Duration of the latency period in preterm premature rupture of the membranes. Maternal and neonatal consequences of expectant management</TI>
<SO>European Journal of Obstetrics, Gynecology, and Reproductive Biology</SO>
<YR>1989</YR>
<VL>30</VL>
<PG>257-62</PG>
<IDENTIFIERS MODIFIED="2013-10-18 11:41:11 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Dammann-1997" MODIFIED="2013-11-22 10:34:51 +0000" MODIFIED_BY="[Empty name]" NAME="Dammann 1997" TYPE="JOURNAL_ARTICLE">
<AU>Dammann O, Leviton A</AU>
<TI>Maternal intrauterine infection, cytokines, and brain damage in the preterm newborn</TI>
<SO>Pediatric Research</SO>
<YR>1997</YR>
<VL>42</VL>
<NO>1</NO>
<PG>1-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dammann-2005" MODIFIED="2013-11-22 10:33:52 +0000" MODIFIED_BY="[Empty name]" NAME="Dammann 2005" TYPE="JOURNAL_ARTICLE">
<AU>Dammann O, Leviton A, Gappa M, Dammann CE</AU>
<TI>Lung and brain damage in preterm newborns, and their association with gestational age, prematurity subgroup, infection/inflammation and long term outcome</TI>
<SO>BJOG: an international journal of obstetrics and gynaecology</SO>
<YR>2005</YR>
<VL>112</VL>
<NO>Suppl 1</NO>
<PG>4-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" MODIFIED="2009-04-29 12:18:50 +0100" MODIFIED_BY="[Empty name]" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne DR, Altman DG, Higgins JPT, Curtin F, Vaillancourt JM</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<PG>140-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gilbert-2005" MODIFIED="2009-09-23 10:54:06 +0100" MODIFIED_BY="[Empty name]" NAME="Gilbert 2005" TYPE="JOURNAL_ARTICLE">
<AU>Gilbert RE, Pike K, Kenyon SL, Tarnow-Mordi W, Taylor DJ</AU>
<TI>The effect of prepartum antibiotics on the type of neonatal bacteraemia: insights from the MRC ORACLE trials</TI>
<SO>BJOG: an international journal of obstetrics and gynaecology</SO>
<YR>2005</YR>
<VL>112</VL>
<NO>6</NO>
<PG>830-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goldenberg-2008" MODIFIED="2009-09-23 10:37:09 +0100" MODIFIED_BY="[Empty name]" NAME="Goldenberg 2008" TYPE="JOURNAL_ARTICLE">
<AU>Goldenberg RL, Culhane JF, Iams JD, Romero R</AU>
<TI>Epidemiology and causes of preterm birth</TI>
<SO>Lancet</SO>
<YR>2008</YR>
<VL>371</VL>
<NO>9606</NO>
<PG>75-84</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="18177778"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hauth-1997" MODIFIED="2009-09-23 10:54:06 +0100" MODIFIED_BY="[Empty name]" NAME="Hauth 1997" TYPE="JOURNAL_ARTICLE">
<AU>Hauth JC</AU>
<TI>The NICHD-MFMU antibiotic treatment of PROM study: correlation with acute placental inflammation and prenatal morbidity</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1997</YR>
<VL>176</VL>
<NO>1 Pt 2</NO>
<PG>S53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2013-10-03 09:06:54 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hnat-2005" MODIFIED="2009-09-23 10:54:06 +0100" MODIFIED_BY="[Empty name]" NAME="Hnat 2005" TYPE="JOURNAL_ARTICLE">
<AU>Hnat MD, Mercer BM, Thurnau G, Goldenberg R, Thom EA, Meis PJ, et al</AU>
<TI>Perinatal outcomes in women with preterm rupture of membranes between 24 and 32 weeks of gestation and a history of vaginal bleeding</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2005</YR>
<VL>193</VL>
<PG>164-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hoy-2001" NAME="Hoy 2001" TYPE="JOURNAL_ARTICLE">
<AU>Hoy CM</AU>
<TI>The role of infection in necrotising enterocolitis</TI>
<SO>Reviews in Medical Microbiology</SO>
<YR>2001</YR>
<VL>12</VL>
<PG>121-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kenyon-2008a" MODIFIED="2009-09-23 10:39:11 +0100" MODIFIED_BY="[Empty name]" NAME="Kenyon 2008a" TYPE="JOURNAL_ARTICLE">
<AU>Kenyon S, Pike K, Jones DR, Brocklehurst P, Marlow N, Salt A, et al</AU>
<TI>Childhood outcomes after prescription of antibiotics to pregnant women with preterm rupture of the membranes: 7-year follow-up of the ORACLE I trial</TI>
<SO>Lancet</SO>
<YR>2008</YR>
<VL>372</VL>
<NO>9646</NO>
<PG>1310-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kenyon-2008b" MODIFIED="2009-09-23 10:40:33 +0100" MODIFIED_BY="[Empty name]" NAME="Kenyon 2008b" TYPE="JOURNAL_ARTICLE">
<AU>Kenyon S, Pike K, Jones DR, Brocklehurst P, Marlow N, Salt A, et al</AU>
<TI>Childhood outcomes after prescription of antibiotics to pregnant women with spontaneous preterm labour: 7-year follow-up of the ORACLE II trial</TI>
<SO>Lancet</SO>
<YR>2008</YR>
<VL>372</VL>
<NO>9646</NO>
<PG>1319-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kenyon-2008c" MODIFIED="2009-09-23 11:06:57 +0100" MODIFIED_BY="[Empty name]" NAME="Kenyon 2008c" TYPE="JOURNAL_ARTICLE">
<AU>Kenyon S, Brocklehurst P, Jones D, Marlow N, Salt A, Taylor D</AU>
<TI>MRC ORACLE children study. Long term outcomes following prescription of antibiotics to pregnant women with either spontaneous preterm labour or preterm rupture of the membranes</TI>
<SO>BMC Pregnancy &amp; Childbirth</SO>
<YR>2008</YR>
<VL>8</VL>
<PG>14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-King-2002" MODIFIED="2013-11-22 10:36:28 +0000" MODIFIED_BY="Sonja Henderson" NAME="King 2002" TYPE="COCHRANE_REVIEW">
<AU>King J, Flenady V</AU>
<TI>Prophylactic antibiotics for inhibiting preterm labour with intact membranes</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-02-20 11:49:23 +0000" MODIFIED_BY="Sonja Henderson">
<IDENTIFIER MODIFIED="2008-02-20 11:49:23 +0000" MODIFIED_BY="Sonja Henderson" TYPE="DOI" VALUE="10.1002/14651858.CD000246"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kotecha-1996" MODIFIED="2010-07-07 10:04:38 +0100" MODIFIED_BY="Lynn Hampson" NAME="Kotecha 1996" TYPE="JOURNAL_ARTICLE">
<AU>Kotecha S</AU>
<TI>Cytokines in chronic lung disease of prematurity</TI>
<SO>European Journal of Pediatrics</SO>
<YR>1996</YR>
<VL>155 Suppl 2</VL>
<PG>S14-S17</PG>
<IDENTIFIERS MODIFIED="2009-09-23 10:44:01 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="8839740"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lockwood-1993b" MODIFIED="2009-09-23 11:20:46 +0100" MODIFIED_BY="[Empty name]" NAME="Lockwood 1993b" TYPE="JOURNAL_ARTICLE">
<AU>Lockwood CJ, Costigan K, Ghidini A, Wein R, Cetrulo C, Alvarez M, et al</AU>
<TI>Double-blind, placebo-controlled trial of piperacillin sodium in preterm membrane rupture</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1993</YR>
<VL>168</VL>
<NO>1 Pt 2</NO>
<PG>378</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marlow-2005" MODIFIED="2009-09-23 10:47:28 +0100" MODIFIED_BY="[Empty name]" NAME="Marlow 2005" TYPE="JOURNAL_ARTICLE">
<AU>Marlow N, Wolke D, Bracewell MA, Samara M</AU>
<TI>Neurologic and developmental disability at six years of age after extremely preterm birth</TI>
<SO>New England Journal of Medicine</SO>
<YR>2005</YR>
<VL>352</VL>
<NO>1</NO>
<PG>9-19</PG>
<IDENTIFIERS MODIFIED="2009-09-23 10:44:13 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="15635108"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-McGregor-1997" NAME="McGregor 1997" NOTES="&lt;p&gt;No volume.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>McGregor J, French J</AU>
<TI>Evidence-based prevention of preterm birth and rupture of membranes: infection and inflammation</TI>
<SO>Journal of the Society of Obstetricians and Gynaecologists of Canada</SO>
<YR>1997</YR>
<VL>19</VL>
<PG>835-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Morales-1988" MODIFIED="2009-09-23 10:54:06 +0100" MODIFIED_BY="[Empty name]" NAME="Morales 1988" TYPE="JOURNAL_ARTICLE">
<AU>Morales WJ, Angel JL, Knuppel RA</AU>
<TI>Comparison of various parameters as predictors of chorioamnionitis in preterm patients with premature rupture of membranes</TI>
<SO>Southern Medical Journal</SO>
<YR>1988</YR>
<VL>81</VL>
<PG>40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Owen-1993b" MODIFIED="2009-09-23 11:22:26 +0100" MODIFIED_BY="[Empty name]" NAME="Owen 1993b" TYPE="JOURNAL_ARTICLE">
<AU>Owen J, Groome LJ, Hauth JC</AU>
<TI>Randomized trial of prophylactic antibiotic therapy after preterm amnion rupture</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1993</YR>
<VL>168</VL>
<NO>1 Pt 2</NO>
<PG>379</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2011" MODIFIED="2013-10-03 09:06:40 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 2011" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2011</YR>
<EN>5.1</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Romero-2007" MODIFIED="2013-10-17 14:39:06 +0100" MODIFIED_BY="[Empty name]" NAME="Romero 2007" TYPE="JOURNAL_ARTICLE">
<AU>Romero R, Gotsch F, Pineles B, Kusanovic JP</AU>
<TI>Inflammation in pregnancy: its roles in reproductive physiology, obstetrical complications, and fetal injury</TI>
<SO>Nutrition Reviews</SO>
<YR>2007</YR>
<VL>65</VL>
<PG>S194-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Saigal-2008" MODIFIED="2009-09-23 10:47:47 +0100" MODIFIED_BY="[Empty name]" NAME="Saigal 2008" TYPE="JOURNAL_ARTICLE">
<AU>Saigal S, Doyle LW</AU>
<TI>An overview of mortality and sequelae of preterm birth from infancy to adulthood</TI>
<SO>Lancet</SO>
<YR>2008</YR>
<VL>371</VL>
<NO>9608</NO>
<PG>261-9</PG>
<IDENTIFIERS MODIFIED="2009-09-23 10:44:28 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="18207020"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sanchez_x002d_Ramos-1990" MODIFIED="2009-09-23 10:54:06 +0100" MODIFIED_BY="[Empty name]" NAME="Sanchez-Ramos 1990" TYPE="CONFERENCE_PROC">
<AU>Sanchez-Ramos L, Johnston M, Vaughn A, Benrubi GI, Todd M</AU>
<TI>High dose antibiotic therapy in preterm premature rupture of the membranes: a double blind, randomized, prospective study</TI>
<SO>Proceedings of 10th Annual Meeting of Society of Perinatal Obstetricians; 1990 Jan 23-27; Houston, Texas, USA</SO>
<YR>1990</YR>
<PG>18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Speer-2003" MODIFIED="2013-11-22 10:37:33 +0000" MODIFIED_BY="[Empty name]" NAME="Speer 2003" TYPE="JOURNAL_ARTICLE">
<AU>Speer CP</AU>
<TI>Inflammation and bronchopulmonary dysplasia</TI>
<SO>Seminars in Neonatology</SO>
<YR>2003</YR>
<VL>8 No. 1</VL>
<PG>29-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Svare-1997b" MODIFIED="2009-09-23 11:30:51 +0100" MODIFIED_BY="[Empty name]" NAME="Svare 1997b" TYPE="JOURNAL_ARTICLE">
<AU>Svare J, Langhoff-Roos J, Andersen LF, Kryger-Baggesen N, Borch-Christensen H, Heisterberg L, et al</AU>
<TI>Ampicillin-metronidazole treatment in threatening preterm delivery</TI>
<SO>Acta Obstetricia et Gynecologica Scandinavica</SO>
<YR>1997</YR>
<VL>76</VL>
<NO>167:1</NO>
<PG>86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Taylor-2001" MODIFIED="2009-09-23 11:31:08 +0100" MODIFIED_BY="[Empty name]" NAME="Taylor 2001" TYPE="JOURNAL_ARTICLE">
<AU>Taylor HG, Klein N, Minich NM, Hack M</AU>
<TI>Long-term family outcomes for children with very low birth weights</TI>
<SO>Archives of Pediatrics &amp; Adolescent Medicine</SO>
<YR>2001</YR>
<VL>155</VL>
<NO>2</NO>
<PG>155-61</PG>
<IDENTIFIERS MODIFIED="2009-09-23 10:44:40 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="11177090"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Thurnau-1997" MODIFIED="2009-09-23 10:54:06 +0100" MODIFIED_BY="[Empty name]" NAME="Thurnau 1997" TYPE="JOURNAL_ARTICLE">
<AU>Thurnau G</AU>
<TI>The NICHD-MFMU antibiotic treatment of PROM study: impact of initial amniotic fluid volume on pregnancy outcome</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1997</YR>
<VL>176</VL>
<NO>1 Pt 2</NO>
<PG>S53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wu-2002" MODIFIED="2013-11-22 10:38:04 +0000" MODIFIED_BY="[Empty name]" NAME="Wu 2002" TYPE="JOURNAL_ARTICLE">
<AU>Wu YW</AU>
<TI>Systematic review of chorioamnionitis and cerebral palsy</TI>
<SO>Mental Retardation and Developmental Disabilities Research Reviews</SO>
<YR>2002</YR>
<VL>8</VL>
<NO>1</NO>
<PG>25-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yoon-2000" MODIFIED="2010-07-07 08:36:55 +0100" MODIFIED_BY="Denise Atherton" NAME="Yoon 2000" TYPE="JOURNAL_ARTICLE">
<AU>Yoon BH, Romero R, Park JS, Kim M, Oh SY, Kin CJ, et al</AU>
<TI>The relationship among inflammatory lesions of the umbilical cord (funisitis), umbilical cord plasma interleukin 6 concentration, amniotic fluid infection, and neonatal sepsis</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2000</YR>
<VL>183</VL>
<NO>5</NO>
<PG>1124-9</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-11-22 10:40:41 +0000" MODIFIED_BY="Lynn Hampson">
<REFERENCE ID="REF-Crowley-1995" NAME="Crowley 1995" TYPE="OTHER">
<AU>Crowley P</AU>
<TI>Antibiotics for preterm prelabour rupture of membranes. [revised 05 May 1994]</TI>
<SO>In: Enkin MW, Keirse MJNC, Renfrew MJ, Neilson JP, Crowther C (eds.) Pregnancy and Childbirth Module. In: The Cochrane Pregnancy and Childbirth Database [database on disk and CDROM]. The Cochrane Collaboration; Issue 2, Oxford: Update Software; 1995</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kenyon-2001" MODIFIED="2010-07-07 10:09:01 +0100" MODIFIED_BY="Lynn Hampson" NAME="Kenyon 2001" TYPE="COCHRANE_REVIEW">
<AU>Kenyon S, Boulvain M</AU>
<TI>Antibiotics for preterm premature rupture of membranes</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>3</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kenyon-2003" MODIFIED="2013-11-22 10:40:41 +0000" MODIFIED_BY="[Empty name]" NAME="Kenyon 2003" TYPE="COCHRANE_REVIEW">
<AU>Kenyon S, Boulvain M, Neilson JP</AU>
<TI>Antibiotics for preterm rupture of membranes</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>2</NO>
<PG>Kenyon S, Boulvain M, Neilson JP. Antibiotics for preterm rupture of membranes. Cochrane Database of Systematic Reviews 2003, Issue 2. Art. No.: CD001058. DOI: 10.1002/14651858.CD001058.</PG>
<IDENTIFIERS MODIFIED="2009-09-23 11:41:44 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-09-23 11:41:44 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001058"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kenyon-2004" MODIFIED="2013-10-17 14:51:33 +0100" MODIFIED_BY="[Empty name]" NAME="Kenyon 2004" TYPE="JOURNAL_ARTICLE">
<AU>Kenyon S, Boulvain M, Neilson J</AU>
<TI>Antibiotics for preterm rupture of the membranes: a systematic review</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>2004</YR>
<VL>104</VL>
<NO>5 Pt 1</NO>
<PG>1051-7</PG>
<IDENTIFIERS MODIFIED="2013-10-17 14:51:33 +0100" MODIFIED_BY="Sonja L Henderson">
<IDENTIFIER MODIFIED="2013-10-17 14:51:33 +0100" MODIFIED_BY="Sonja L Henderson" TYPE="DOI" VALUE="10.1002/14651858.CD001058"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kenyon-2010" MODIFIED="2013-11-22 10:39:50 +0000" MODIFIED_BY="Sonja L Henderson" NAME="Kenyon 2010" TYPE="COCHRANE_REVIEW">
<AU>Kenyon S, Boulvain M, Neilson JP</AU>
<TI>Antibiotics for preterm rupture of membranes</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>8</NO>
<IDENTIFIERS MODIFIED="2013-10-17 14:50:11 +0100" MODIFIED_BY="Sonja L Henderson">
<IDENTIFIER MODIFIED="2013-10-17 14:50:11 +0100" MODIFIED_BY="Sonja L Henderson" TYPE="DOI" VALUE="10.1002/14651858.CD001058.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2009-09-23 12:16:12 +0100" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-11-25 09:57:50 +0000" MODIFIED_BY="Lynn Hampson">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-11-25 09:57:50 +0000" MODIFIED_BY="Denise Atherton" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-11-22 11:15:31 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Amon-1988a">
<CHAR_METHODS MODIFIED="2013-11-22 11:15:31 +0000" MODIFIED_BY="Heather Maxwell">
<P>Randomised trial. No mention of method of randomisation. Not placebo-controlled or blinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-29 14:03:18 +0000" MODIFIED_BY="[Empty name]">
<P>82 women treatment 43 control 39. Inclusions: 20-34 weeks' pregnant. PPROM confirmed by sterile speculum. Singleton pregnancy only.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-22 10:58:56 +0000" MODIFIED_BY="Heather Maxwell">
<P>Treatment group: ampicillin 1 g IV every 6 hours for 24 hours. Maintained on oral 500 mg ampicillin 6-hourly until delivery. In labour they were recommenced on 1 g IV ampicillin.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death only included.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-22 10:59:41 +0000" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-Camli-1997">
<CHAR_METHODS MODIFIED="2009-10-29 14:03:42 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised trial - no mention of the method of randomisation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-29 14:03:45 +0000" MODIFIED_BY="[Empty name]">
<P>31 women with premature rupture of the membranes between 28-34 weeks gestation. PPROM confirmed by speculum. Exclusions: women who go into active labour within 24 hours or who need induction of labour. Multiple pregnancy and fetal malformations. Women with serious medical conditions or who need antibiotic treatment for a known infection. Women who have received antibiotics in the last 10 days or who are allergic to penicillin.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-22 10:59:41 +0000" MODIFIED_BY="Denise Atherton">
<P>Treatment group oral ampicillin 1 g 4 x daily.<BR/>No placebo arm or tocolysis used.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death only included.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-25 09:56:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Christmas-1992">
<CHAR_METHODS MODIFIED="2013-11-25 09:56:55 +0000" MODIFIED_BY="Sonja L Henderson">
<P>Randomised trial. Using sequentially numbered sealed envelopes. Not placebo-controlled or blinded. The control group received IV fluids without antibiotics for first 24 hours.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-29 14:04:13 +0000" MODIFIED_BY="[Empty name]">
<P>94 women randomised 48 treatment, 46 control. Inclusions: singleton pregnancies 20-34 weeks with PPROM confirmed by sterile speculum.<BR/>Exclusions: penicillin allergy. Prior antibiotic therapy. Clinical evidence of intra-amniotic infection. Evidence of labour or fetal distress.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment: 24 hours IV ampicillin 2 g every 6 hours for 4 doses; gentamycin 90 mg loading dose 60 mg every 8 hours for 3 doses. Then oral amoxicillin + clavulanic acid. 500 mg 3 x day for 7 days. Control IV fluids without antibiotics for 24 hours.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death only included.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-22 11:16:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cox-1995">
<CHAR_METHODS>
<P>Randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-29 14:04:33 +0000" MODIFIED_BY="[Empty name]">
<P>62 women PPROM between 24 and 29 weeks' pregnant. Not stated whether multiple pregnancy included.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-22 11:16:55 +0000" MODIFIED_BY="Heather Maxwell">
<P>Co-amoxiclav 3 g 6-hourly for 4 doses then co-amoxiclav 500 mg 6-hourly for 5 days or matching placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Prolongation of pregnancy.<BR/>Neonatal mortality and morbidity.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Data extracted from abstract only. Further data requested from Dr Cox but not made available.<BR/>Study took place between May 1991 and April 1994 in Dallas, Texas.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-25 09:57:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ernest-1994">
<CHAR_METHODS MODIFIED="2013-11-25 09:57:50 +0000" MODIFIED_BY="Heather Maxwell">
<P>Randomised double-blind, placebo-controlled trial. A table of random numbers was used. Drugs and placebo were prepared by research nurses. The authors specify that participants and caregivers were blinded as to group.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>148 women at 21-37 weeks with premature rupture of the membranes preterm confirmed with positive nitrazine test and 'ferning' of amniotic fluid or by seeing vaginal pool of amniotic fluid from os. No tocolytics or steroids given. Multiple pregnancies included.<BR/>Exclusions are not clearly stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-22 11:01:10 +0000" MODIFIED_BY="Heather Maxwell">
<P>4-hourly IV 1 million units benzylpenicillin for 12-24 hours - oral 250 mg penicillin twice daily before delivery or a matched placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Latency period, infection complications and neonatal <BR/>outcomes studies. Data on death not included.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-15 16:16:49 +0100" MODIFIED_BY="[Empty name]">
<P>Study conducted from March 2 1989 to May 29 1991, in a single site (North Carolina, USA). 148 women.<BR/>71 placebo.<BR/>77 treatment.<BR/>4 women were excluded because of protocol violation in placebo arm (antibiotics given).</P>
<P>Information on neonatal death not given.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-22 11:02:02 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fuhr-2006">
<CHAR_METHODS MODIFIED="2013-11-22 11:01:51 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised double-blind, placebo-controlled trial - multicentre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-29 14:05:33 +0000" MODIFIED_BY="[Empty name]">
<P>105 pregnant women with PROM between 24+0 and 32+6 weeks.</P>
<P>Exclusion criteria not clearly stated nor whether multiple pregnancy included.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-22 11:02:02 +0000" MODIFIED_BY="[Empty name]">
<P>Metzlocillin 2 g given 3 x day for 7 days or placebo.</P>
<P>All women given corticosteroids and tocolytics IV.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-29 14:05:41 +0000" MODIFIED_BY="[Empty name]">
<P>Prolongation of pregnancy and neonatal mortality and morbidity.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-10-29 14:05:44 +0000" MODIFIED_BY="[Empty name]">
<P>5 centres in Germany - dates not given.</P>
<P>47 women in treatment arm and 58 in control.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-22 11:02:56 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garcia_x002d_Burguillo-1995">
<CHAR_METHODS MODIFIED="2013-11-22 11:02:36 +0000" MODIFIED_BY="Heather Maxwell">
<P>Randomised double-blind, placebo-controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-29 14:06:21 +0000" MODIFIED_BY="[Empty name]">
<P>60 singleton pregnancy women. Preterm PROM under 36 weeks' pregnant. Ruptured membranes confirmed by sterile speculum examination, ferning test and nitrazine test.<BR/>No steroids or tocolytics given after randomisation.</P>
<P>Exclusions: &gt; 37/40.<BR/>Discrepancy of over 2 standard deviations between scan and dates EDD.<BR/>Bleeding.<BR/>Contractions.<BR/>Fetal distress.<BR/>Fetal malformation.<BR/>Fetal death.<BR/>Chorioamnionitis on admission.<BR/>Antibiotics given during previous 10 days.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-22 11:02:56 +0000" MODIFIED_BY="Heather Maxwell">
<P>Erythromycin 500 mg 6-hourly orally until delivery. Matched placebo given until delivery.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Maternal morbidity. Neonatal mortality and morbidity.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-17 14:33:46 +0100" MODIFIED_BY="Sonja L Henderson">
<P>60 women recruited during 1992 from single centre in Madrid, Spain.<BR/>No losses to follow-up.</P>
<P>Paper in Spanish and data extracted with help from Dr Pigem.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-22 11:16:17 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Grable-1996">
<CHAR_METHODS>
<P>60 women randomised to double blind placebo controlled trial. Randomisation based on random numbers tables with blocks providing 1:1 ratio and balancing every 6 women. Randomisation conducted in pharmacy.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-22 10:09:59 +0000" MODIFIED_BY="[Empty name]">
<P>60 women randomised. Inclusions &lt;= 35 weeks with documented PPROM.<BR/>Exclusions: digital examination of cx, non-reassuring stress test, presence of chorioamnionitis, abruptio placenta, pre-eclampsia, multiple pregnancy and penicillin allergy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-22 11:16:17 +0000" MODIFIED_BY="Heather Maxwell">
<P>IV ampicillin 2 g every 6 hours for 24 hours followed by 500 mg oral ampicillin until delivery or discharge. Matched placebos.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Maternal morbidity. Neonatal mortality and morbidity.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Study divided into GBS positive and negative patients. Unclear whether clinician knew of positive culture.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-22 11:04:29 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Johnston-1990">
<CHAR_METHODS MODIFIED="2013-11-22 11:04:12 +0000" MODIFIED_BY="Heather Maxwell">
<P>Randomised double-blind, placebo-controlled trial. Randomisation table generated by consecutive coin toss, the randomisation schedule kept in pharmacy.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-22 11:04:29 +0000" MODIFIED_BY="[Empty name]">
<P>85 women randomised. Inclusions: mothers with singleton gestations between 20-34 weeks with PPROM confirmed by sterile speculum for pooling, ferning and nitrazine paper testing.<BR/>Exclusions: penicillin allergy, taking antibiotics at the time of PPROM, had fever &gt; 100.4 degrees Fahrenheit, had signs of chorioamnionitis, were in active labour (defined by 3 or more contractions per 10-minute period for 1 hour or presented with cervical dilatation &gt; 3 cm confirmed at the time of sterile speculum. Fetal indications for exclusion were the presence of fetal distress, defined as repetitive late deceleration or sustained bradycardia, or congenital abnormality on ultrasound.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>IV mezlocillin for 48 hours followed by oral ampicillin until delivery or matched (IV + oral) placebo.<BR/>No doses noted. After randomisation no tocolytic steroids given.<BR/>Study drugs discontinued if infection diagnosed.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Not clearly defined other than maternal or perinatal morbidity and mortality.<BR/>Outcomes looked at included length of pregnancy, maternal infectious morbidity, mode of delivery. Neonatal outcomes - stillbirth, neonatal death, birthweight Apgar, cord pH, positive blood culture, RDS, IVH, NEC, NICU stay over 30 days.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-17 14:33:56 +0100" MODIFIED_BY="Sonja L Henderson">
<P>Single centre - University Medical Centre - Jacksonville Florida.<BR/>85 women randomised.<BR/>All women had infection screen on admission. No digital examination allowed.<BR/>No comment as to losses to follow-up or recruitment period.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-22 11:05:14 +0000" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-Kenyon-2001">
<CHAR_METHODS MODIFIED="2013-11-22 11:05:14 +0000" MODIFIED_BY="Heather Maxwell">
<P>Randomised double-blind, placebo-controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-17 14:34:01 +0100" MODIFIED_BY="[Empty name]">
<P>4826 women under 37 weeks' pregnant with PROM. Multiple pregnancies included.</P>
<P>UK follow-up at 7 years of age of the 4378 children of the 4148 eligible women who joined the ORACLE trial using a parental questionnaire. Exclusions 661 women (246 due to perinatal death, 376 randomised outside UK and 39 women withdrew).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Co-amoxiclav 375 mg QDS, erythromycin 250 mg QDS orally for 10 days or until delivery matched placebo (2 x 2 factorial design).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-07 08:34:13 +0100" MODIFIED_BY="Denise Atherton">
<P>Primary outcome: neonatal death or abnormal brain scans on discharge from hospital or oxygenation at 36 weeks' postconceptual age.<BR/>Secondary outcomes include prolongation of pregnancy, neonatal infection, respiratory outcomes.</P>
<P>Functional impairment was assessed using the Mark III Multi-Attribute Health Status classification system. Primary outcome was defined as any level of functional impairment (severe, moderate or mild). Other outcomes included death, behaviour (using the Strengths and Difficulties questionnaire) prespecified questions on respiratory symptoms, hospital admissions, convulsions, other prespecified medical conditions and demographic data. Educational attainment was evaluated for children in England using data from National Cirriculum Tests at 7 years of age (Key Stage 1).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-17 14:34:07 +0100" MODIFIED_BY="[Empty name]">
<P>Multicentre trial (161 centres, 135 in the UK). Randomised 4826 women. 2 women lost to follow-up and 15 women were excluded due to protocol violations. 4809 women analysed. For twin pregnancies adverse outcomes were considered present if one twin affected. Consumers involved in drawing up of protocol and information for women.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-22 11:06:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kurki--1992">
<CHAR_METHODS MODIFIED="2013-11-22 11:06:33 +0000" MODIFIED_BY="Heather Maxwell">
<P>Randomised double-blind, placebo-controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-29 14:09:20 +0000" MODIFIED_BY="[Empty name]">
<P>101 women randomised between 23-36 weeks' pregnant with visible leakage of amniotic fluid who did not go into labour within 12 hours of admission. Sterile speculum, digital examination and infection screening was performed on admission. Multiple pregnancies included.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 doses of IV penicillin (5 mu) or matched placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Prolongation of pregnancy. Infection, neonatal morbidity and mortality. Long-term development at 2 years.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Department of Obstetrics and Gynaecology, Helsinki, Finland.<BR/>No mention of where the study was conducted. Sealed envelope randomisation.<BR/>Results in 76 women not randomised but admitted during the same period are also reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-10-29 14:09:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lewis-2003">
<CHAR_METHODS>
<P>Randomised trial looking at 3 or 7 days antibiotic therapy. Randomised using table of arbitrary numbers in blocks of 10. Indicator cards placed in sealed envelopes which were sequentially numbered and stored on an area away from the enrolment site.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-29 14:09:55 +0000" MODIFIED_BY="[Empty name]">
<P>84 singleton pregnancies were randomised between 24-34 weeks' gestation. Exclusions included known infection, absence of cervical cerclage, not penicillin allergic. Corticosteroids given to all participants.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Ampicillin-sulbactam 3 g intravenously every six hours for either 3 or 7 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome was latency period between membrane rupture and delivery. Infection and neonatal morbidity and mortality.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-15 16:16:49 +0100" MODIFIED_BY="[Empty name]">
<P>3 study sites in Tennessee USA. </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-22 11:17:08 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lockwood-1993a">
<CHAR_METHODS MODIFIED="2013-11-22 11:07:29 +0000" MODIFIED_BY="Heather Maxwell">
<P>Randomised double-blind placebo-controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-29 14:10:40 +0000" MODIFIED_BY="[Empty name]">
<P>75 women randomised with a single fetus at 24-34 completed weeks (accurate gestational age), admitted with PROM. No digital examination unless active labour. Women had infection screening.<BR/>Exclusions: abruption, lethal fetal abnormalities clinical chorioamnionitis, maternal illness, diabetes, PIH, lupus, severe maternal disease, fetal growth retardation, fetal distress, cervical cerclage, active herpes. Women having received antibiotics for existing infection were also excluded.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-22 11:17:08 +0000" MODIFIED_BY="Heather Maxwell">
<P>Piperacillin 3 g IV 6-hourly 72 hours or placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Prolongation of pregnancy.<BR/>Neonatal outcomes.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-17 14:34:36 +0100" MODIFIED_BY="Sonja L Henderson">
<P>Recruitment in 3 centres (USA) from January 1987 to January 1992. 75 women were randomised (treatment 38, placebo 37).<BR/>3 babies (1 in the experimental group and 2 in controls) were lost to follow-up.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-22 11:08:02 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Magwali-1999">
<CHAR_METHODS MODIFIED="2013-11-22 11:08:02 +0000" MODIFIED_BY="Heather Maxwell">
<P>Randomised trial not placebo-controlled. Randomisation by opening sealed consecutive opaque envelopes in admission room.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-29 14:11:15 +0000" MODIFIED_BY="[Empty name]">
<P>171 women randomised 84 in treatment group 87 in no treatment group. Inclusion PROM 26-36 weeks' gestation drainage of liquor confirmed by sterile speculum. Exclusions: clinical signs of chorioamnionitis, multiple pregnancy, those with any contraindication to continuing the pregnancy and those who had just completed a course of antibiotics for another reason.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Co-amoxiclav for 5 days. No mention of daily frequency or mg of drugs.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death only included.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-22 11:08:26 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McGregor-1991">
<CHAR_METHODS MODIFIED="2013-11-22 11:08:26 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised double-blind placebo-controlled trial.<BR/>Computer-generated random number list. Sequentially numbered bottles.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-29 14:11:43 +0000" MODIFIED_BY="[Empty name]">
<P>65 women with singleton pregnancies.<BR/>Women between 23-34 completed weeks' gestation with PROM. Sterile speculum. No corticosteroids administered.<BR/>Exclusions: active labour, presence of maternal or fetal complication to necessitate delivery (fetal distress, prolapsed cord, pregnancy-induced hypertension, abruptio placentae) placenta praevia, cervical cerclage, known infection requiring antibiotic treatment, use of vaginal or oral antibiotics in last 2 weeks, presence of known uterine or fetal abnormality, history of vaginal bleeding in last month, serious existing maternal disease, history of allergy or intolerance to erythromycin.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Erythromycin 333 mg 3 x daily or placebo 7 days or until active labour started.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Prolongation of pregnancy. Maternal and neonatal infectious morbidity.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-10-29 14:12:07 +0000" MODIFIED_BY="[Empty name]">
<P>July 1986-June 1988 University Hospital Denver.<BR/>65 women recruited (10 excluded - 15%).<BR/>55 analysed - (28 treatment, 27 placebo).</P>
<P>No replies received to letter requesting breakdown between stillbirths and neonatal deaths and asking if Blanco's paper has ever been published.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-22 11:09:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mercer-1992">
<CHAR_METHODS MODIFIED="2013-11-22 11:09:09 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised double-blind, placebo-controlled trial.<BR/>Computerised random number tables. Administered by the pharmacy.<BR/>Stratified at 30 weeks. gestational age.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-29 14:12:32 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusions: 220 women 20-34/6 weeks pregnant with PPROM - sterile speculum and evaluation of cervix. Amniocentesis done for infection screen. Multiple pregnancies included.<BR/>Exclusions: PPROM &gt; 72 hours duration, cervical dilatation &gt; 4 cm, progressive labour, vaginal bleeding, temperature 99 degrees Fahrenheit or greater, active infection requiring antibiotic therapy, antibiotic therapy within 1 week prior to admission, active hepatic disease, erythromycin allergy, cervical cerclage or medical condition requiring delivery. IUGR (&lt; 10 centile), congenital abnormalities, evidence of fetal distress, unsuccessful tocolysis on admission for preterm labour.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-22 11:09:32 +0000" MODIFIED_BY="Heather Maxwell">
<P>Oral 333 mg erythromycin. 8-hourly from randomisation to delivery with matched placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Not clearly stated.<BR/>Prolongation of pregnancy. Reduction of infectious morbidity.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-17 14:34:47 +0100" MODIFIED_BY="Sonja L Henderson">
<P>Single centre (Memphis, Tennessee, USA).<BR/>March 1989-August 1990.<BR/>Women had infection screen before randomisation.<BR/>220 randomised, (treatment 106, placebo 114) 3 lost to follow-up.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-22 11:18:40 +0000" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-Mercer-1997">
<CHAR_METHODS MODIFIED="2013-11-22 11:09:55 +0000" MODIFIED_BY="Heather Maxwell">
<P>Randomised double-blind, placebo-controlled trial. Urn randomisation scheme (a procedure to increase the likelihood of obtaining an equal number of subjects in each arm), stratified by centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-07 08:34:13 +0100" MODIFIED_BY="Denise Atherton">
<P>614 women with PPROM at 24-32 weeks' gestation. Inclusion criteria: membrane rupture within 36 hours of randomisation; cervical dilatation 3 cm or less on usual examination; &lt; 5 contractions in 6 minutes.<BR/>Exclusion criteria: non-reassuring, fetal testing; vaginal bleeding; maternal or fetal indication for delivery, cervical cerclage in place, antibiotics within the last 5 days, corticosteroids within last 7 days, allergy to penicillin or erythromycin, maternal infection or medical disease, ultrasound evidence of placenta praevia, fetal weight &lt; 10th centile for gestational age, malformation. Previous successful tocolysis was not an exclusion criterion.<BR/>Tocolysis and corticosteroids were prohibited after randomisation.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-22 11:10:30 +0000" MODIFIED_BY="Heather Maxwell">
<P>Ampicillin 2 g 6-hourly and erythromycin 250 mg 6-hourly IV for 48 hours, then oral amoxacillin 250 mg every 8 hours and erythromycin 333 mg 8-hourly for 5 days and a matching placebo regimen.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-22 11:10:51 +0000" MODIFIED_BY="[Empty name]">
<P>Composite primary outcome included pregnancies complicated by at least 1 of the following: fetal or infant death, respiratory distress, severe intraventricular haemorrhage, stage 2 or 3 NEC, or sepsis within 72 hours of birth. These perinatal morbidities were also assessed separately and pregnancy prolongation assessed.<BR/>For twin pregnancies adverse outcomes considered present if 1 twin affected.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-22 11:18:40 +0000" MODIFIED_BY="Sonja L Henderson">
<P>11 centres - USA.<BR/>February 1992-January 1995.<BR/>1867 women screened.<BR/>804 eligible.<BR/>614 agreed to participate.<BR/>29 twin gestations.<BR/>GBS positive: 118/614.<BR/>3 women lost to follow-up.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-10-29 14:14:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Morales-1989">
<CHAR_METHODS MODIFIED="2009-10-29 14:14:19 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised trial not placebo controlled. RCT of antenatal steroids + ampicillin. 4 groups - GP1 - neither, GP2 steroids only, GP3 antibiotic only, GP4 both. Randomised by using sealed envelopes into 1 of groups.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-29 14:14:27 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised: 41 = GP1, 43 = GP2, 37 = GP3, 44 = GP4.<BR/>Inclusion criteria 26-34 weeks' pregnant singleton gestation. PROM confirmed by sterile speculum L/S ratio less than 2.0.<BR/>Exclusions: In labour within 12 hours of randomisation women with uterine tenderness, foul smelling lochia or fetal tachycardia on admission, women allergic to penicillin, with congenital abnormality with L/S ratio greater than 2.0 or not obtained.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 g IV ampicillin every 6 hours until results of cervical cultures negative.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death only included.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-22 11:12:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ovalle_x002d_Salas-1997">
<CHAR_METHODS MODIFIED="2013-11-22 11:12:15 +0000" MODIFIED_BY="Heather Maxwell">
<P>Randomised double-blind, placebo-controlled trial. No comment as to method of randomisation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-29 14:15:08 +0000" MODIFIED_BY="[Empty name]">
<P>88 women.<BR/>Inclusions: women with PPROM 24-34 weeks, PPROM diagnosed with sterile speculum-pooling, ferning and nitrazine tests.<BR/>No digital examination performed.<BR/>Exclusions: labour, significant haemorrhage, abruptio placentae, use of antibiotics within 30 days before screening for study, fetal anomaly or death, multiple gestation, documented allergy to clindamycin or gentamicin, uterine abnormality, presence of IUCD, fetal distress, clinical chorioamnionitis, maternal medical complications necessitating delivery or any condition precluding expectant management and intrauterine growth retardation (&lt; 10th centile for gestational age).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Clindamycin 600 mg IV every 6 hours for 48 hours + 4 mg/kg/day gentamycin IV for 48 hours followed by Clindamycin 300 mg orally every 6 hours for 5 days + gentamycin 2 mg/kg/day IM every 12 hours for 5 days.<BR/>Matching placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Prolongation of pregnancy, maternal infection related morbidity, birthweight, neonatal morbidity and admission to neonatal intensive care unit.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-22 11:12:50 +0000" MODIFIED_BY="[Empty name]">
<P>November 1990-September 1994. 3 sites: 2 Chile, 1 USA.<BR/>Women had infection screen.<BR/>88 women randomised<BR/>(treatment 42, control 46).<BR/>1 lost to follow-up in placebo arm.<BR/>Trial stopped after intermediate evaluation showed treatment group had better outcome.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-22 11:13:40 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Owen-1993a">
<CHAR_METHODS MODIFIED="2013-11-22 11:13:06 +0000" MODIFIED_BY="Heather Maxwell">
<P>Randomised not placebo-controlled. Randomised using sealed opaque envelopes determined by computer algorithm.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-17 14:35:09 +0100" MODIFIED_BY="[Empty name]">
<P>118 randomised 1 lost to follow-up. 59 treatment 58 controls. Inclusions 24 to 34 weeks' gestation. PPROM confirmed by speculum. Exclusions in labour, clinical evidence of infection suspected fetal compromise, membrane rupture over 2 days, fetal abnormality, antibiotics in last 7 days, multiple pregnancy, cervical cerclage, prompt delivery required.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-22 11:13:40 +0000" MODIFIED_BY="Heather Maxwell">
<P>IV 1 g ampicillin 6-hourly for 24 hours then 500 mg ampicillin orally every 6 hours. If allergic to penicillin 500 mg erythromycin used 6-hourly. Treatment continued with delivery or diagnosis of chorioamnionitis.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death only included.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-22 11:14:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Segel-2003">
<CHAR_METHODS MODIFIED="2013-11-22 11:14:16 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised double-blind, placebo-controlled trial of 3 or 7 days treatment. Pharmacy provided randomisation with a computer-generated random number table in blocks of 4.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>48 women randomised: 24 in each arm-analysis on 23 in each arm. Women 24-33 weeks with clinically confirmed ruptured membranes. Exclusions included penicillin allergy, active labour, suspected infection, multiple pregnancy, known medical maternal or fetal problems and exposure to antibiotics within 1 week before admission.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-22 11:14:34 +0000" MODIFIED_BY="[Empty name]">
<P>For first 48 hours all women received parenteral ampicillin 2 g every 6 hours. Women were then randomly selected to receive either 3 or 7 days oral ampicillin. Women allocated the 3-day course received a matching placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome of prolongation of pregnancy for at least 7 days. Secondary outcomes included rated of chorioamnionitis, postpartum endometritis and neonatal morbidity and mortality.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-10-29 14:16:29 +0000" MODIFIED_BY="[Empty name]">
<P>Study took place between September 1999 - December 2001, Pennsylvania USA.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-22 11:17:29 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Svare-1997a">
<CHAR_METHODS MODIFIED="2013-11-22 11:14:58 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised double-blind, placebo-controlled trial. Block randomisation done using computer-generated numbers.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>67 women randomised. 26 + 0 - 33 + 6 rupture of membranes, leakage of amniotic fluid at vaginal speculum examination. Preceding onset of uterine contractions. Singleton pregnancies.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-22 11:17:29 +0000" MODIFIED_BY="[Empty name]">
<P>Ampicillin 2 g IV 6-hourly. 24 hours - pivampicillin 500 g orally 8-hourly for 7 days plus IV metronidazole 500 mg every 8 hours for 24 hours, followed by metronidazole 400 mg orally every 8 hours for 7 days or identical placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Latency period from admission - delivery. Gestational age at delivery. Preterm delivery less than 37/40 maternal - neonatal infection birthweight.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>October 1991-April 1994. 6 centres around Copenhagen.<BR/>67 women randomised.<BR/>30 antibiotics.<BR/>37 placebo.<BR/>Data sent from Mr Svare and extracted from PhD thesis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>cx: cervix<BR/>EDD: expected date of delivery<BR/>GBS: group B Streptococcus<BR/>GP: group<BR/>IM: intramuscular<BR/>IUCD: intrauterine contraceptive device<BR/>IUGR: intrauterine growth retardation<BR/>IV: intravenous<BR/>IVH: intraventricular haemorrhage<BR/>L/S: lecithin/sphingomyelin<BR/>NEC: necrotising enterocolitis<BR/>NICU: neonatal intensive care unit<BR/>PIH: pregnancy induced hypertension<BR/>PPROM: preterm prelabour rupture of membranes<BR/>PROM: premature rupture of membranes<BR/>QDS: four times per day<BR/>RCT: randomised controlled trial<BR/>RDS: respiratory distress syndrome</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-11-25 09:55:05 +0000" MODIFIED_BY="Lynn Hampson" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-09-23 11:58:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Almeida-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-23 11:58:35 +0100" MODIFIED_BY="[Empty name]">
<P>Joint venture between Mozambique (where women were recruited), Sweden and Norway.<BR/>Data (apart from birthweight and caesarean section rates in the paper) supplied additionally by authors but numbers of women different from paper. Author written to for clarification but no response received.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-29 14:17:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bergstrom-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-29 14:17:37 +0000" MODIFIED_BY="[Empty name]">
<P>Random allocation to 2 management protocols (conservative versus induction).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-25 09:54:13 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Blanco-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-25 09:54:13 +0000" MODIFIED_BY="Heather Maxwell">
<P>Abstract only - data requested.<BR/>Following comments received during the publication of this review in 2004, we wrote to Brian Mercer who included these data in a Lancet review in 1995 and James McGregor who was listed as an author.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-07-07 08:34:14 +0100" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-Cardamakis-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-07-07 08:34:14 +0100" MODIFIED_BY="Denise Atherton">
<P>Abstract only - study randomised but no mention of whether blinded. Comparison of ampicillin versus ceftriaxone (doses not given). Minimal data expressed as P values.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-29 14:17:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carroll-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-29 14:17:50 +0000" MODIFIED_BY="[Empty name]">
<P>Abstract only containing no usable data (P values only).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-22 11:21:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Debodinance-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-22 11:21:10 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised trial of antibiotic treatment (mezlocillin) for women with PPROM. Not placebo-controlled and no clinical outcomes reported. Mortality data requested from author.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-22 12:05:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dunlop-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-22 12:05:12 +0000" MODIFIED_BY="[Empty name]">
<P>Study of 48 women with PPROM 26 to 34 weeks of pregnancy, given either oral ritodrine or cephalexin or both or neither (factorial design) - not placebo-controlled. No concealment of allocation for some participants (Latin Square method).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-22 12:05:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fortunato-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-22 12:05:38 +0000" MODIFIED_BY="[Empty name]">
<P>Study that investigated active versus passive management of women with PPROM. 55 women were recruited when admitted and given antibiotics. The control group were women who presented with PPROM. 1985-1987 before use of active protocol. Excluded as not double-blinded, randomised or controlled.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-29 14:18:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gordon-1974">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-29 14:18:13 +0000" MODIFIED_BY="[Empty name]">
<P>Participants allocated to treatment or no treatment group on the arbitrary basis of the last digit of the admission number (unsatisfactory concealment of allocation). No mention of blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-03 09:17:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Haas-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-03 09:17:40 +0100" MODIFIED_BY="[Empty name]">
<P>This was a trial registration. The trial did not take place and no results are available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-06-23 16:15:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Halis-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-06-23 16:15:52 +0100" MODIFIED_BY="[Empty name]">
<P>Abstract containing no usable data. GBS prophylaxis also given for carriers.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-07 10:34:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hernandez-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-07 10:34:33 +0100" MODIFIED_BY="[Empty name]">
<P>Study comparing two macrolide antibiotics: i.e. comparison of similar antibiotics - so excluded as this antibiotic comparison was not included in this review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Julien-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study compared antibiotic versus placebo only after 48 hour intravenous antibiotic treatment to all.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-22 12:06:19 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kim-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-22 12:06:19 +0000" MODIFIED_BY="[Empty name]">
<P>Study was neither randomised nor placebo-controlled.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-07 10:36:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kwak-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-07 10:36:51 +0100" MODIFIED_BY="[Empty name]">
<P>Study comparing a beta-lactam antibiotic with the same antibiotic plus macrolide. This antibiotic comparison was not included in this review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-22 12:06:29 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Lebherz-1963">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-22 12:06:29 +0000" MODIFIED_BY="Heather Maxwell">
<P>Double-blind randomised controlled trial of 1912 women but no mention of gestation at recruitment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-07 10:34:40 +0100" MODIFIED_BY="Lynn Hampson" STUDY_ID="STD-Lewis-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-07 10:34:40 +0100" MODIFIED_BY="Lynn Hampson">
<P>Study comparing treatment of women with PROM at 25 to 35 weeks' gestation in a randomised blinded trial comparing ampicillin-sulbactam with ampicillin: i.e. comparison of similar antibiotics - so excluded as this antibiotic comparison was not included in this review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-29 14:18:47 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lewis-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-29 14:18:47 +0000" MODIFIED_BY="[Empty name]">
<P>This is a randomised trial of corticosteroids in women with PPROM after a minimum of 12 hours ampicillin sulbactam.</P>
<P>77 women were enrolled. No statistically significant difference in latency period was noted. Neonatal and maternal infectious morbidity were similar. A significant reduction in the incidence of RDS, 18.4% versus 43.6%, was observed in the steroid group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-25 09:54:35 +0000" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-Lovett-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-25 09:54:35 +0000" MODIFIED_BY="Denise Atherton">
<P>Double-blind, placebo-controlled trial of 112 women with PPROM 23 to 25 weeks' gestation to receive ampicillin/sulbactam or ampicillin or placebo.</P>
<P>Excluded because of a high rate of exclusions (52/164: 32%). Further information has been requested from the authors.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-22 12:07:04 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Matsuda-1993a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-22 12:07:04 +0000" MODIFIED_BY="Heather Maxwell">
<P>Comparative study; not placebo-controlled.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-29 14:19:20 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Matsuda-1993b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-29 14:19:20 +0000" MODIFIED_BY="[Empty name]">
<P>Prospective study, not randomised, of conservative versus aggressive management of women with PPROM. Aggressive management: IV antibiotics + tocolytics. Conservative management consisted of bedrest only.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mbu-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation by alternation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-22 12:07:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McCaul-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-22 12:07:25 +0000" MODIFIED_BY="[Empty name]">
<P>Double-blind, placebo-controlled trial of 84 women with PPROM (19 to 34 weeks' pregnant) who received ampicillin or placebo. 112 randomised - 12 non-compliant so excluded and 26 removed from study (does not add up). Letter sent to Mr McCaul to get excluded women's data; in the meantime, excluded.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-22 12:07:36 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Norri-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-22 12:07:36 +0000" MODIFIED_BY="Heather Maxwell">
<P>Abstract only - does not say whether study was placebo-controlled nor could any publication be found.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-29 14:19:40 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ogasawara-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-29 14:19:40 +0000" MODIFIED_BY="[Empty name]">
<P>Abstract only - data in further publication.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-25 09:54:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ogasawara-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-25 09:54:49 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised prospective study of 51 women with either PROM or SPL. Not placebo-controlled and all women were given IV ampicillin 2 g every 6 hours until GBS status known.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-25 09:55:05 +0000" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-Ogasawara-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-25 09:55:05 +0000" MODIFIED_BY="Denise Atherton">
<P>Randomised, double-blind, placebo-controlled trial of 60 women between 22 and 34 weeks pregnant with either PROM or SPL. All women were given IV ampicillin 2 g every 6 hours until GBS status known</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-22 12:07:57 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ovalle-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-22 12:07:57 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised placebo-controlled study looking at chorioamnionitis. No clear details of method of randomisation. 100 women recruited -71 analysed-excluded as large number lost to follow-up.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-22 12:08:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Spitzer-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-22 12:08:18 +0000" MODIFIED_BY="[Empty name]">
<P>Comparison of neonatal infection rates in 2 groups of women, with PPROM. Both groups were treated with tocolytic and steroid therapy. The first group was given antibiotic therapy continuously from onset of PPROM until delivery. The second group received antibiotic therapy for the first 3 days after PPROM and for a 3-day period around each successive dose of corticosteroids. The study was neither randomised, nor placebo-controlled or blinded.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>GBS: group B Streptococcus<BR/>IV: intravenous<BR/>PPROM: preterm prelabour rupture of membranes<BR/>PROM: premature rupture of membranes<BR/>RDS: respiratory distress syndrome<BR/>SPL: spontaneous preterm labour<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2013-10-07 10:33:12 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES>
<P>
<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-11-22 11:15:21 +0000" MODIFIED_BY="Denise Atherton">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-11-22 11:03:06 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:03:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Amon-1988a">
<DESCRIPTION>
<P>No information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:03:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Camli-1997">
<DESCRIPTION>
<P>No information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:04:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Christmas-1992">
<DESCRIPTION>
<P>No information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:04:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cox-1995">
<DESCRIPTION>
<P>No information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:05:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ernest-1994">
<DESCRIPTION>
<P>Table of random numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:05:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fuhr-2006">
<DESCRIPTION>
<P>No information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-22 11:03:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Garcia_x002d_Burguillo-1995">
<DESCRIPTION>
<P>Computer-generated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-23 16:10:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grable-1996">
<DESCRIPTION>
<P>Randomisation based on random numbers tables with blocks providing 1:1 ratio and balancing every 6 women.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:07:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnston-1990">
<DESCRIPTION>
<P>Randomisation table generated by consecutive coin toss.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:08:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kenyon-2001">
<DESCRIPTION>
<P>By computer using randomly generated blocks of 4.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:09:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kurki--1992">
<DESCRIPTION>
<P>No information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-23 16:12:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lewis-2003">
<DESCRIPTION>
<P>Randomised using table of arbitrary numbers in blocks of 10.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:11:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lockwood-1993a">
<DESCRIPTION>
<P>Computer-generated randomisation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:11:23 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Magwali-1999">
<DESCRIPTION>
<P>No information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:12:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McGregor-1991">
<DESCRIPTION>
<P>Computer-generated random number list.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:12:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mercer-1992">
<DESCRIPTION>
<P>Computerised random number tables.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-23 16:13:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mercer-1997">
<DESCRIPTION>
<P>Urn randomisation scheme (a procedure to increase the likelihood of obtaining an equal number of subjects in each arm), stratified by centre.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:14:36 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morales-1989">
<DESCRIPTION>
<P>No information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:15:29 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ovalle_x002d_Salas-1997">
<DESCRIPTION>
<P>No information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 04:47:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Owen-1993a">
<DESCRIPTION>
<P>By computer algorithm.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:16:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Segel-2003">
<DESCRIPTION>
<P>Computer-generated random number table in blocks of 4.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:17:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Svare-1997a">
<DESCRIPTION>
<P>Block randomisation done using computer-generated numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-10-29 14:17:14 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:03:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Amon-1988a">
<DESCRIPTION>
<P>No information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:03:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Camli-1997">
<DESCRIPTION>
<P>No information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-23 16:07:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Christmas-1992">
<DESCRIPTION>
<P>Using sequentially numbered sealed envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:04:51 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cox-1995">
<DESCRIPTION>
<P>No information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:05:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ernest-1994">
<DESCRIPTION>
<P>Stated that nurses were not involved in the preparation or release of either antibiotic or placebo.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:05:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fuhr-2006">
<DESCRIPTION>
<P>No information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:06:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Garcia_x002d_Burguillo-1995">
<DESCRIPTION>
<P>No information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-23 16:10:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grable-1996">
<DESCRIPTION>
<P>Randomisation and preparation of drugs conducted in pharmacy.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-23 16:11:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnston-1990">
<DESCRIPTION>
<P>The randomisation schedule kept in pharmacy.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:08:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kenyon-2001">
<DESCRIPTION>
<P>Sequentially numbered drug boxes of identical appearance.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:09:37 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kurki--1992">
<DESCRIPTION>
<P>Stated as being by sealed envelope.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-23 16:12:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lewis-2003">
<DESCRIPTION>
<P>Indicator cards placed in sealed envelopes which were sequentially numbered and stored on an area away from the enrolment site</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:11:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lockwood-1993a">
<DESCRIPTION>
<P>Same deposited in pharmacy.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:11:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Magwali-1999">
<DESCRIPTION>
<P>Stated as being by sealed envelope.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-23 16:13:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McGregor-1991">
<DESCRIPTION>
<P>Sequentially numbered bottles.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-23 16:13:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mercer-1992">
<DESCRIPTION>
<P>Administered by the pharmacy.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:14:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mercer-1997">
<DESCRIPTION>
<P>Treatment given by pharmacy.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:14:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morales-1989">
<DESCRIPTION>
<P>States as sealed envelopes into 1 of 4 groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:15:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ovalle_x002d_Salas-1997">
<DESCRIPTION>
<P>No information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:15:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Owen-1993a">
<DESCRIPTION>
<P>Sealed opaque envelope.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:16:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Segel-2003">
<DESCRIPTION>
<P>Study medicine given by pharmacy in identical packs.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:17:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Svare-1997a">
<DESCRIPTION>
<P>No information available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2013-11-22 11:15:21 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-10-29 14:03:33 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Amon-1988a">
<DESCRIPTION>
<P>Not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-10-29 14:03:58 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Camli-1997">
<DESCRIPTION>
<P>Not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-10-29 14:04:25 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Christmas-1992">
<DESCRIPTION>
<P>Not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-10-29 14:04:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cox-1995">
<DESCRIPTION>
<P>Stated as double blind study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-10-29 14:05:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ernest-1994">
<DESCRIPTION>
<P>Patients and staff blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-22 11:02:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fuhr-2006">
<DESCRIPTION>
<P>Stated as double-blind trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-22 11:03:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Garcia_x002d_Burguillo-1995">
<DESCRIPTION>
<P>Stated as double-blind trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-22 11:03:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grable-1996">
<DESCRIPTION>
<P>Double-blind trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-10-29 14:07:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnston-1990">
<DESCRIPTION>
<P>Randomisation schedule stated as not being available to clinicians.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-22 11:06:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kenyon-2001">
<DESCRIPTION>
<P>Stated that clinicians remained blind to treatment allocation in all but 9 cases and that all staff and participants remained blind to treatment allocation.</P>
<P>For the follow-up study all participants bar 1 women and all Study staff remained blind to treatment allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-22 11:06:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kurki--1992">
<DESCRIPTION>
<P>Stated as double-blind trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-10-29 14:10:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lewis-2003">
<DESCRIPTION>
<P>Stated that all carers were unaware of the randomisation process.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-10-29 14:11:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lockwood-1993a">
<DESCRIPTION>
<P>Stated all healthcare providers were blinded to allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-10-29 14:11:26 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Magwali-1999">
<DESCRIPTION>
<P>Not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-22 11:08:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McGregor-1991">
<DESCRIPTION>
<P>Stated as double-blind trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-10-29 14:13:01 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mercer-1992">
<DESCRIPTION>
<P>States that all involved remained blind to treatment allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-10-29 14:14:01 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mercer-1997">
<DESCRIPTION>
<P>States all involved remained blinded to treatment allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-10-29 14:14:44 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Morales-1989">
<DESCRIPTION>
<P>Not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-22 11:12:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ovalle_x002d_Salas-1997">
<DESCRIPTION>
<P>Stated as double-blind trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-10-29 14:15:50 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Owen-1993a">
<DESCRIPTION>
<P>Not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-22 11:14:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Segel-2003">
<DESCRIPTION>
<P>Stated as double-blind trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-22 11:15:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Svare-1997a">
<DESCRIPTION>
<P>Stated as double-blind trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-11-22 11:08:51 +0000" MODIFIED_BY="Denise Atherton" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-07 08:34:13 +0100" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Amon-1988a">
<DESCRIPTION>
<P>Data appear complete.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-07 08:34:13 +0100" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Camli-1997">
<DESCRIPTION>
<P>Data appear complete.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-07 08:34:13 +0100" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Christmas-1992">
<DESCRIPTION>
<P>Data appear complete.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-07 08:34:13 +0100" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Cox-1995">
<DESCRIPTION>
<P>Data appear complete.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-10-29 14:05:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ernest-1994">
<DESCRIPTION>
<P>Data excluded for 4 women who were treated with antibiotics outside the protocol.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-22 11:02:18 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fuhr-2006">
<DESCRIPTION>
<P>Data appear complete.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-07 08:34:13 +0100" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Garcia_x002d_Burguillo-1995">
<DESCRIPTION>
<P>Data appear complete.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-22 11:03:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grable-1996">
<DESCRIPTION>
<P>Data appear complete.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-07 08:34:13 +0100" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Johnston-1990">
<DESCRIPTION>
<P>Data appear complete.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-17 14:34:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kenyon-2001">
<DESCRIPTION>
<P>2 women lost to follow-up and 15 protocol violations.</P>
<P>In the follow-up study outcome data were determined for 75% of eligible children.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-07 08:34:13 +0100" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Kurki--1992">
<DESCRIPTION>
<P>Data appear complete.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-07 08:34:13 +0100" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Lewis-2003">
<DESCRIPTION>
<P>Data appear complete.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-07 08:34:13 +0100" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Lockwood-1993a">
<DESCRIPTION>
<P>Data appear complete.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-17 14:34:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Magwali-1999">
<DESCRIPTION>
<P>Minimal loss to follow-up - 2 in the treatment and 1 in the no treatment group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-22 11:08:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McGregor-1991">
<DESCRIPTION>
<P>Data appear complete after 10 exclusions.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-07 08:34:13 +0100" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Mercer-1992">
<DESCRIPTION>
<P>Data appear complete.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-10-29 14:14:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mercer-1997">
<DESCRIPTION>
<P>Only 3 withdrawals (2 in placebo and 1 in treatment arm).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-07 08:34:13 +0100" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Morales-1989">
<DESCRIPTION>
<P>Data appear complete.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-17 14:31:28 +0100" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Ovalle_x002d_Salas-1997">
<DESCRIPTION>
<P>Data appear complete with 1 loss to follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-17 14:35:16 +0100" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Owen-1993a">
<DESCRIPTION>
<P>Data appear complete - 1 woman lost to follow-up in control group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-07 08:34:14 +0100" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Segel-2003">
<DESCRIPTION>
<P>Data appear complete.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-07 08:34:14 +0100" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Svare-1997a">
<DESCRIPTION>
<P>Data appear complete.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-10-17 14:34:30 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:03:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Amon-1988a">
<DESCRIPTION>
<P>Protocol not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:03:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Camli-1997">
<DESCRIPTION>
<P>Protocol not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:04:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Christmas-1992">
<DESCRIPTION>
<P>Protocol not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:04:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cox-1995">
<DESCRIPTION>
<P>Protocol not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:05:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ernest-1994">
<DESCRIPTION>
<P>Protocol not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:05:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fuhr-2006">
<DESCRIPTION>
<P>Protocol not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:06:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Garcia_x002d_Burguillo-1995">
<DESCRIPTION>
<P>Protocol not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:07:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grable-1996">
<DESCRIPTION>
<P>Protocol not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:07:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Johnston-1990">
<DESCRIPTION>
<P>Protocol not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-17 14:34:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kenyon-2001">
<DESCRIPTION>
<P>No selective reporting.</P>
<P>Protocol published for follow-up study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:09:41 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kurki--1992">
<DESCRIPTION>
<P>Protocol not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:10:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lewis-2003">
<DESCRIPTION>
<P>Protocol not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:11:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lockwood-1993a">
<DESCRIPTION>
<P>Protocol not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:11:29 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Magwali-1999">
<DESCRIPTION>
<P>Protocol not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:12:18 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McGregor-1991">
<DESCRIPTION>
<P>Protocol not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:13:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mercer-1992">
<DESCRIPTION>
<P>Protocol not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:14:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mercer-1997">
<DESCRIPTION>
<P>No protocol available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:14:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morales-1989">
<DESCRIPTION>
<P>Protocol not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:15:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ovalle_x002d_Salas-1997">
<DESCRIPTION>
<P>Protocol not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:15:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Owen-1993a">
<DESCRIPTION>
<P>Protocol not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:16:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Segel-2003">
<DESCRIPTION>
<P>Protocol not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:17:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Svare-1997a">
<DESCRIPTION>
<P>Protocol not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2009-10-29 14:16:42 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:03:36 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Amon-1988a">
<DESCRIPTION>
<P>No information available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:04:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Camli-1997">
<DESCRIPTION>
<P>No information available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:04:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Christmas-1992">
<DESCRIPTION>
<P>No information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:04:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cox-1995">
<DESCRIPTION>
<P>No information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:05:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ernest-1994">
<DESCRIPTION>
<P>No information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:05:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fuhr-2006">
<DESCRIPTION>
<P>No information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:06:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Garcia_x002d_Burguillo-1995">
<DESCRIPTION>
<P>No information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:07:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grable-1996">
<DESCRIPTION>
<P>No information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:07:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Johnston-1990">
<DESCRIPTION>
<P>No information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:09:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kenyon-2001">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:09:41 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kurki--1992">
<DESCRIPTION>
<P>No information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:10:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lewis-2003">
<DESCRIPTION>
<P>No information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:11:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lockwood-1993a">
<DESCRIPTION>
<P>No information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:11:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Magwali-1999">
<DESCRIPTION>
<P>No information available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:12:18 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McGregor-1991">
<DESCRIPTION>
<P>No information available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:13:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mercer-1992">
<DESCRIPTION>
<P>No information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:14:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mercer-1997">
<DESCRIPTION>
<P>No information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:14:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morales-1989">
<DESCRIPTION>
<P>No information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-23 16:14:31 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ovalle_x002d_Salas-1997">
<DESCRIPTION>
<P>Trial stopped after intermediate evaluation showed treatment group had better outcome.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:15:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Owen-1993a">
<DESCRIPTION>
<P>No information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 14:16:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Segel-2003">
<DESCRIPTION>
<P>No information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-23 16:15:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Svare-1997a">
<DESCRIPTION>
<P>No information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-12-18 12:03:24 +0000" MODIFIED_BY="Denise Atherton">
<COMPARISON ID="CMP-001" MODIFIED="2013-12-18 12:03:24 +0000" MODIFIED_BY="Denise Atherton" NO="1">
<NAME>Any antibiotic versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-12-18 11:44:15 +0000" MODIFIED_BY="Denise Atherton" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="738" TOTAL_2="788" WEIGHT="0.0" Z="0.0">
<NAME>Maternal death</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-04-20 13:08:43 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="3" TAU2="0.0" TOTAL_1="369" TOTAL_2="394" WEIGHT="0.0" Z="0.0">
<NAME>Any antibiotic versus placebo</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="418" O_E="0.0" SE="0.0" STUDY_ID="STD-Johnston-1990" TOTAL_1="40" TOTAL_2="45" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="419" O_E="0.0" SE="0.0" STUDY_ID="STD-Mercer-1997" TOTAL_1="299" TOTAL_2="312" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="420" O_E="0.0" SE="0.0" STUDY_ID="STD-Svare-1997a" TOTAL_1="30" TOTAL_2="37" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-07-07 08:37:24 +0100" MODIFIED_BY="Denise Atherton" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="45" WEIGHT="0.0" Z="0.0">
<NAME>All penicillin (excluding co-amoxiclav) versus placebo</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-04-16 11:03:16 +0100" MODIFIED_BY="[Empty name]" ORDER="317" O_E="0.0" SE="0.0" STUDY_ID="STD-Johnston-1990" TOTAL_1="40" TOTAL_2="45" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-04-16 10:58:23 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Beta lactum (including co-amoxiclav) versus placebo </NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.01.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-04-16 10:58:48 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Macrolide (including erythromycin) versus placebo</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.01.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-04-16 11:03:50 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="329" TOTAL_2="349" WEIGHT="0.0" Z="0.0">
<NAME>Other antibiotic versus placebo</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-04-16 11:03:28 +0100" MODIFIED_BY="[Empty name]" ORDER="318" O_E="0.0" SE="0.0" STUDY_ID="STD-Mercer-1997" TOTAL_1="299" TOTAL_2="312" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-04-16 11:03:50 +0100" MODIFIED_BY="[Empty name]" ORDER="319" O_E="0.0" SE="0.0" STUDY_ID="STD-Svare-1997a" TOTAL_1="30" TOTAL_2="37" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-12-18 11:44:51 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Serious maternal morbidity</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-04-21 16:27:37 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Any antibiotic versus placebo</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-04-21 16:27:37 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>All penicillin (excluding co-amoxiclav) versus placebo</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-04-21 16:32:14 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Beta lactum (including co-amoxiclav) versus placebo</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.02.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-04-21 16:27:29 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Macrolide (including erythromycin) versus placebo</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.02.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-04-21 16:27:26 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Other antibiotic versus placebo</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="17.577542534372373" CI_END="1.1144840444860733" CI_START="0.7797498428691052" CI_STUDY="95" CI_TOTAL="95" DF="24" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9322117562915309" ESTIMABLE="YES" EVENTS_1="475" EVENTS_2="276" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.04707385528260343" LOG_CI_START="-0.10804470408744245" LOG_EFFECT_SIZE="-0.030485424402419505" METHOD="MH" MODIFIED="2013-12-18 11:45:23 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8230081259005723" P_Q="0.8924301136944839" P_Z="0.4410728686192834" Q="1.1115830068014159" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="7441" TOTAL_2="3972" WEIGHT="500.00000000000006" Z="0.7703827849460905">
<NAME>Perinatal death/death before discharge</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="8.733599606572016" CI_END="1.1432973657487169" CI_START="0.7572454629639274" DF="11" EFFECT_SIZE="0.930460500522094" ESTIMABLE="YES" EVENTS_1="276" EVENTS_2="138" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.05815920284273125" LOG_CI_START="-0.12076332006263175" LOG_EFFECT_SIZE="-0.03130205860995028" MODIFIED="2010-04-20 13:04:53 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.646467201658365" P_Z="0.4928507010842179" STUDIES="12" TAU2="0.0" TOTAL_1="4315" TOTAL_2="1986" WEIGHT="100.0" Z="0.6857818291542268">
<NAME>Any antibiotic versus placebo</NAME>
<DICH_DATA CI_END="1.6145911815529068" CI_START="0.024774073125760646" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.20806257615844104" LOG_CI_START="-1.6060025848304786" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="551" O_E="0.0" SE="1.0655908553322622" STUDY_ID="STD-Cox-1995" TOTAL_1="31" TOTAL_2="31" VAR="1.135483870967742" WEIGHT="0.9728015660093716"/>
<DICH_DATA CI_END="1.9031160339754112" CI_START="0.08407264567351506" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.27946526825494583" LOG_CI_START="-1.075345285599021" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="552" O_E="0.0" SE="0.7958224257542215" STUDY_ID="STD-Garcia_x002d_Burguillo-1995" TOTAL_1="30" TOTAL_2="30" VAR="0.6333333333333333" WEIGHT="1.7441060334565306"/>
<DICH_DATA CI_END="3.7481195757668" CI_START="0.009379703419095869" EFFECT_SIZE="0.1875" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5738134376766014" LOG_CI_START="-2.027810893549126" LOG_EFFECT_SIZE="-0.7269987279362623" ORDER="553" O_E="0.0" SE="1.5282070104101297" STUDY_ID="STD-Grable-1996" TOTAL_1="31" TOTAL_2="29" VAR="2.3354166666666667" WEIGHT="0.4729779073780422"/>
<DICH_DATA CI_END="3.5437267409652202" CI_START="0.20089417569089793" EFFECT_SIZE="0.84375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.549460225780937" LOG_CI_START="-0.6970326541027743" LOG_EFFECT_SIZE="-0.07378621416091867" ORDER="554" O_E="0.0" SE="0.7321960878829598" STUDY_ID="STD-Johnston-1990" TOTAL_1="40" TOTAL_2="45" VAR="0.536111111111111" WEIGHT="2.0603946923735186"/>
<DICH_DATA CI_END="1.2025975776944275" CI_START="0.7379127667429695" EFFECT_SIZE="0.9420255335365854" ESTIMABLE="YES" EVENTS_1="226" EVENTS_2="82" LOG_CI_END="0.08012032474230664" LOG_CI_START="-0.13199497579401087" LOG_EFFECT_SIZE="-0.02593732552585209" ORDER="555" O_E="0.0" SE="0.1245975775227045" STUDY_ID="STD-Kenyon-2001" TOTAL_1="3584" TOTAL_2="1225" VAR="0.015524556324526359" WEIGHT="71.1518232640702"/>
<DICH_DATA CI_END="15.87886789416035" CI_START="0.06520587696874873" EFFECT_SIZE="1.0175438596491229" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2008195355693063" LOG_CI_START="-1.1857132597884146" LOG_EFFECT_SIZE="0.007553137890445907" ORDER="556" O_E="0.0" SE="1.4018611775209884" STUDY_ID="STD-Kurki--1992" TOTAL_1="57" TOTAL_2="58" VAR="1.9652147610405324" WEIGHT="0.5620762217717845"/>
<DICH_DATA CI_END="4.377819176530504" CI_START="0.2043971430909409" EFFECT_SIZE="0.9459459459459459" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6412578193020794" LOG_CI_START="-0.6895251787355181" LOG_EFFECT_SIZE="-0.024133679716719363" ORDER="557" O_E="0.0" SE="0.7817085205293665" STUDY_ID="STD-Lockwood-1993a" TOTAL_1="37" TOTAL_2="35" VAR="0.611068211068211" WEIGHT="1.8076549685424574"/>
<DICH_DATA CI_END="212.52014022610007" CI_START="0.7413216397613307" EFFECT_SIZE="12.551724137931034" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.3274000937961477" LOG_CI_START="-0.1299933222959482" LOG_EFFECT_SIZE="1.0987033857500998" ORDER="558" O_E="0.0" SE="1.4434850569060902" STUDY_ID="STD-McGregor-1991" TOTAL_1="28" TOTAL_2="27" VAR="2.0836491095111787" WEIGHT="0.5301278813278405"/>
<DICH_DATA CI_END="1.7141104165113343" CI_START="0.24291910861073102" EFFECT_SIZE="0.6452830188679245" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.23403879409655265" LOG_CI_START="-0.6145383211858607" LOG_EFFECT_SIZE="-0.19024976354465403" ORDER="559" O_E="0.0" SE="0.49845839804135544" STUDY_ID="STD-Mercer-1992" TOTAL_1="106" TOTAL_2="114" VAR="0.24846077457795432" WEIGHT="4.44577414576656"/>
<DICH_DATA CI_END="2.0574676079868497" CI_START="0.5896522994999839" EFFECT_SIZE="1.1014492753623188" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" LOG_CI_END="0.31333300656556795" LOG_CI_START="-0.22940400347849588" LOG_EFFECT_SIZE="0.04196450154353604" ORDER="560" O_E="0.0" SE="0.3188064062914116" STUDY_ID="STD-Mercer-1997" TOTAL_1="299" TOTAL_2="312" VAR="0.1016375246924446" WEIGHT="10.868038071552084"/>
<DICH_DATA CI_END="3.2601867025518723" CI_START="0.4376122170388178" EFFECT_SIZE="1.1944444444444444" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.5132424717140303" LOG_CI_START="-0.35891056208943173" LOG_EFFECT_SIZE="0.07716595481229925" ORDER="561" O_E="0.0" SE="0.5123070092832982" STUDY_ID="STD-Ovalle_x002d_Salas-1997" TOTAL_1="42" TOTAL_2="43" VAR="0.26245847176079734" WEIGHT="4.208667681577172"/>
<DICH_DATA CI_END="8.24504025965545" CI_START="0.18448801500147877" EFFECT_SIZE="1.2333333333333334" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.9161927805995209" LOG_CI_START="-0.7340318419048558" LOG_EFFECT_SIZE="0.09108046934733258" ORDER="562" O_E="0.0" SE="0.9693501120026962" STUDY_ID="STD-Svare-1997a" TOTAL_1="30" TOTAL_2="37" VAR="0.9396396396396396" WEIGHT="1.1755575661744402"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9978374820302323" CI_END="1.9717354828351847" CI_START="0.3067714641847547" DF="3" EFFECT_SIZE="0.7777352898347765" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.2948486519589317" LOG_CI_START="-0.5131850408230384" LOG_EFFECT_SIZE="-0.10916819443205342" MODIFIED="2010-04-16 11:15:24 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8017752373005349" P_Z="0.596392030050388" STUDIES="4" TAU2="0.0" TOTAL_1="165" TOTAL_2="167" WEIGHT="100.00000000000003" Z="0.5295960583213568">
<NAME>All penicillin (excluding co-amoxiclav) versus placebo</NAME>
<DICH_DATA CI_END="3.7481195757668" CI_START="0.009379703419095869" EFFECT_SIZE="0.1875" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5738134376766014" LOG_CI_START="-2.027810893549126" LOG_EFFECT_SIZE="-0.7269987279362623" MODIFIED="2010-04-16 11:13:19 +0100" MODIFIED_BY="[Empty name]" ORDER="320" O_E="0.0" SE="1.5282070104101297" STUDY_ID="STD-Grable-1996" TOTAL_1="31" TOTAL_2="29" VAR="2.3354166666666667" WEIGHT="9.64650000549335"/>
<DICH_DATA CI_END="3.5437267409652202" CI_START="0.20089417569089793" EFFECT_SIZE="0.84375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.549460225780937" LOG_CI_START="-0.6970326541027743" LOG_EFFECT_SIZE="-0.07378621416091867" MODIFIED="2010-04-16 11:14:50 +0100" MODIFIED_BY="[Empty name]" ORDER="321" O_E="0.0" SE="0.7321960878829598" STUDY_ID="STD-Johnston-1990" TOTAL_1="40" TOTAL_2="45" VAR="0.536111111111111" WEIGHT="42.0222532622722"/>
<DICH_DATA CI_END="15.87886789416035" CI_START="0.06520587696874873" EFFECT_SIZE="1.0175438596491229" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2008195355693063" LOG_CI_START="-1.1857132597884146" LOG_EFFECT_SIZE="0.007553137890445907" MODIFIED="2010-04-16 11:15:09 +0100" MODIFIED_BY="[Empty name]" ORDER="322" O_E="0.0" SE="1.4018611775209884" STUDY_ID="STD-Kurki--1992" TOTAL_1="57" TOTAL_2="58" VAR="1.9652147610405324" WEIGHT="11.463681901056416"/>
<DICH_DATA CI_END="4.377819176530504" CI_START="0.2043971430909409" EFFECT_SIZE="0.9459459459459459" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6412578193020794" LOG_CI_START="-0.6895251787355181" LOG_EFFECT_SIZE="-0.024133679716719363" MODIFIED="2010-04-16 11:15:24 +0100" MODIFIED_BY="[Empty name]" ORDER="323" O_E="0.0" SE="0.7817085205293665" STUDY_ID="STD-Lockwood-1993a" TOTAL_1="37" TOTAL_2="35" VAR="0.611068211068211" WEIGHT="36.86756483117805"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.17410960901702" CI_END="2.5555980901800304" CI_START="0.152611228880844" DF="1" EFFECT_SIZE="0.6245101801155145" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="46" I2="54.004158950747204" ID="CMP-001.03.03" LOG_CI_END="0.4074925549083007" LOG_CI_START="-0.8164135105385661" LOG_EFFECT_SIZE="-0.2044604778151327" MODIFIED="2010-04-21 16:56:33 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.14035080070400463" P_Z="0.5125667282485522" STUDIES="2" TAU2="0.6868958877758684" TOTAL_1="1236" TOTAL_2="644" WEIGHT="100.00000000000001" Z="0.6548462894220503">
<NAME>Beta lactum (including co-amoxiclav) versus placebo</NAME>
<DICH_DATA CI_END="1.6145911815529068" CI_START="0.024774073125760646" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.20806257615844104" LOG_CI_START="-1.6060025848304786" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2010-04-16 11:18:03 +0100" MODIFIED_BY="[Empty name]" ORDER="324" O_E="0.0" SE="1.0655908553322622" STUDY_ID="STD-Cox-1995" TOTAL_1="31" TOTAL_2="31" VAR="1.135483870967742" WEIGHT="28.3617154278793"/>
<DICH_DATA CI_END="1.4113027354509118" CI_START="0.6807899579924129" EFFECT_SIZE="0.9802044327497217" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="41" LOG_CI_END="0.1496201833032132" LOG_CI_START="-0.16698685894674561" LOG_EFFECT_SIZE="-0.008683337821766217" MODIFIED="2010-04-21 16:56:33 +0100" MODIFIED_BY="[Empty name]" ORDER="325" O_E="0.0" SE="0.1859765438477609" STUDY_ID="STD-Kenyon-2001" TOTAL_1="1205" TOTAL_2="613" VAR="0.03458727486155814" WEIGHT="71.63828457212071"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.822735920480287" CI_END="1.6017170644388372" CI_START="0.4279787820371592" DF="3" EFFECT_SIZE="0.8279498284356774" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="56" I2="37.79464500098036" ID="CMP-001.03.04" LOG_CI_END="0.20458580250655042" LOG_CI_START="-0.36857776153028127" LOG_EFFECT_SIZE="-0.08199597951186538" MODIFIED="2010-04-20 13:14:18 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.1852471965117508" P_Z="0.5749479176459917" STUDIES="4" TAU2="0.1734649745512203" TOTAL_1="1354" TOTAL_2="784" WEIGHT="100.0" Z="0.5607794242483047">
<NAME>Macrolide (including erythromycin) versus placebo</NAME>
<DICH_DATA CI_END="1.9031160339754112" CI_START="0.08407264567351506" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.27946526825494583" LOG_CI_START="-1.075345285599021" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2010-04-16 11:23:32 +0100" MODIFIED_BY="[Empty name]" ORDER="326" O_E="0.0" SE="0.7958224257542215" STUDY_ID="STD-Garcia_x002d_Burguillo-1995" TOTAL_1="30" TOTAL_2="30" VAR="0.6333333333333333" WEIGHT="14.049710464351916"/>
<DICH_DATA CI_END="1.276995759392264" CI_START="0.6057116653246958" EFFECT_SIZE="0.8794835007173601" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="41" LOG_CI_END="0.10618945507422381" LOG_CI_START="-0.21773406223341257" LOG_EFFECT_SIZE="-0.05577230357959437" MODIFIED="2010-04-20 13:14:18 +0100" MODIFIED_BY="[Empty name]" ORDER="327" O_E="0.0" SE="0.19027427751377635" STUDY_ID="STD-Kenyon-2001" TOTAL_1="1190" TOTAL_2="613" VAR="0.036204300683389576" WEIGHT="54.06267855041419"/>
<DICH_DATA CI_END="212.52014022610007" CI_START="0.7413216397613307" EFFECT_SIZE="12.551724137931034" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.3274000937961477" LOG_CI_START="-0.1299933222959482" LOG_EFFECT_SIZE="1.0987033857500998" MODIFIED="2010-04-16 11:21:44 +0100" MODIFIED_BY="[Empty name]" ORDER="328" O_E="0.0" SE="1.4434850569060902" STUDY_ID="STD-McGregor-1991" TOTAL_1="28" TOTAL_2="27" VAR="2.0836491095111787" WEIGHT="5.022024676974043"/>
<DICH_DATA CI_END="1.7141104165113343" CI_START="0.24291910861073102" EFFECT_SIZE="0.6452830188679245" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.23403879409655265" LOG_CI_START="-0.6145383211858607" LOG_EFFECT_SIZE="-0.19024976354465403" MODIFIED="2010-04-16 11:21:39 +0100" MODIFIED_BY="[Empty name]" ORDER="329" O_E="0.0" SE="0.49845839804135544" STUDY_ID="STD-Mercer-1992" TOTAL_1="106" TOTAL_2="114" VAR="0.24846077457795432" WEIGHT="26.865586308259847"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.018406267467037406" CI_END="1.8786445940671734" CI_START="0.6763084651104468" DF="2" EFFECT_SIZE="1.1271837658082238" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="26" I2="0.0" ID="CMP-001.03.05" LOG_CI_END="0.2738446271283333" LOG_CI_START="-0.16985517663240104" LOG_EFFECT_SIZE="0.05199472524796614" MODIFIED="2010-04-16 11:28:21 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.9908390857828081" P_Z="0.6459794947181176" STUDIES="3" TAU2="0.0" TOTAL_1="371" TOTAL_2="391" WEIGHT="100.00000000000001" Z="0.4593546718223158">
<NAME>Other antibiotic versus placebo</NAME>
<DICH_DATA CI_END="2.0574676079868497" CI_START="0.5896522994999839" EFFECT_SIZE="1.1014492753623188" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" LOG_CI_END="0.31333300656556795" LOG_CI_START="-0.22940400347849588" LOG_EFFECT_SIZE="0.04196450154353604" MODIFIED="2010-04-16 11:28:21 +0100" MODIFIED_BY="[Empty name]" ORDER="330" O_E="0.0" SE="0.3188064062914116" STUDY_ID="STD-Mercer-1997" TOTAL_1="299" TOTAL_2="312" VAR="0.1016375246924446" WEIGHT="66.83432984959985"/>
<DICH_DATA CI_END="3.180995592315797" CI_START="0.4278883989651203" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.5025630673361425" LOG_CI_START="-0.3686694880749162" LOG_EFFECT_SIZE="0.06694678963061322" MODIFIED="2010-04-16 11:28:12 +0100" MODIFIED_BY="[Empty name]" ORDER="331" O_E="0.0" SE="0.511766315719159" STUDY_ID="STD-Ovalle_x002d_Salas-1997" TOTAL_1="42" TOTAL_2="42" VAR="0.26190476190476186" WEIGHT="25.936435065131914"/>
<DICH_DATA CI_END="8.24504025965545" CI_START="0.18448801500147877" EFFECT_SIZE="1.2333333333333334" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.9161927805995209" LOG_CI_START="-0.7340318419048558" LOG_EFFECT_SIZE="0.09108046934733258" MODIFIED="2010-04-16 11:28:09 +0100" MODIFIED_BY="[Empty name]" ORDER="332" O_E="0.0" SE="0.9693501120026962" STUDY_ID="STD-Svare-1997a" TOTAL_1="30" TOTAL_2="37" VAR="0.9396396396396396" WEIGHT="7.229235085268243"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.46315643398533" CI_END="0.7937865876500302" CI_START="0.559857009418959" CI_STUDY="95" CI_TOTAL="95" DF="23" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6666385715503014" ESTIMABLE="YES" EVENTS_1="170" EVENTS_2="282" I2="0.0" I2_Q="7.501613478716174" ID="CMP-001.04" LOG_CI_END="-0.10029624349737612" LOG_CI_START="-0.2519228800473349" LOG_EFFECT_SIZE="-0.17610956177235548" METHOD="MH" MODIFIED="2013-12-18 11:46:07 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.9626886222524866" P_Q="0.36387978686216926" P_Z="5.291825936592646E-6" Q="4.324399754886105" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1646" TOTAL_2="1714" WEIGHT="500.0" Z="4.552872849530244">
<NAME>Neonatal infection including pneumonia</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.231578216992665" CI_END="0.8533096580244035" CI_START="0.5208038850837861" DF="11" EFFECT_SIZE="0.6666385715503014" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="141" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="-0.06889333885937164" LOG_CI_START="-0.28332578468533937" LOG_EFFECT_SIZE="-0.17610956177235548" MODIFIED="2010-04-21 16:29:26 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8574743845053571" P_Z="0.001284738235652101" STUDIES="12" TAU2="0.0" TOTAL_1="823" TOTAL_2="857" WEIGHT="100.0" Z="3.2193672657829557">
<NAME>Any antibiotic versus placebo</NAME>
<DICH_DATA CI_END="7.879512141972564" CI_START="0.014101267833479788" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8964993290875" LOG_CI_START="-1.8507418385268246" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="492" O_E="0.0" SE="1.613743060919757" STUDY_ID="STD-Cox-1995" TOTAL_1="31" TOTAL_2="31" VAR="2.6041666666666665" WEIGHT="0.6092386215005869"/>
<DICH_DATA CI_END="3.56891408335329" CI_START="0.00851829190321925" EFFECT_SIZE="0.17435897435897435" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5525360930454063" LOG_CI_START="-2.069647481685932" LOG_EFFECT_SIZE="-0.7585556943202629" ORDER="493" O_E="0.0" SE="1.540283611815222" STUDY_ID="STD-Ernest-1994" TOTAL_1="77" TOTAL_2="67" VAR="2.372473604826546" WEIGHT="0.66873616925815"/>
<DICH_DATA CI_END="1.382734766959299" CI_START="0.022476325273777523" EFFECT_SIZE="0.1762917933130699" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.14073888271743915" LOG_CI_START="-1.648274691491513" LOG_EFFECT_SIZE="-0.753767904387037" MODIFIED="2009-05-12 10:29:43 +0100" MODIFIED_BY="[Empty name]" ORDER="329" O_E="0.0" SE="1.0508754292503548" STUDY_ID="STD-Fuhr-2006" TOTAL_1="47" TOTAL_2="58" VAR="1.1043391678021173" WEIGHT="1.4366590956973722"/>
<DICH_DATA CI_END="2.6921683779126004" CI_START="0.23772658695895926" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4301022187434325" LOG_CI_START="-0.6239222447595453" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="494" O_E="0.0" SE="0.6191391873668903" STUDY_ID="STD-Garcia_x002d_Burguillo-1995" TOTAL_1="30" TOTAL_2="30" VAR="0.38333333333333336" WEIGHT="4.138849330846378"/>
<DICH_DATA CI_END="1.0221993846189465" CI_START="0.09209298901046323" EFFECT_SIZE="0.3068181818181818" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="0.009535615166785905" LOG_CI_START="-1.0357734311491484" LOG_EFFECT_SIZE="-0.5131189079911813" ORDER="495" O_E="0.0" SE="0.6140197081692101" STUDY_ID="STD-Johnston-1990" TOTAL_1="40" TOTAL_2="45" VAR="0.377020202020202" WEIGHT="4.2081535728230435"/>
<DICH_DATA CI_END="8.153974850938733" CI_START="0.01410055344782869" EFFECT_SIZE="0.3390804597701149" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9113693676366951" LOG_CI_START="-1.850763840917606" LOG_EFFECT_SIZE="-0.46969723664045554" ORDER="496" O_E="0.0" SE="1.6224907194846905" STUDY_ID="STD-Kurki--1992" TOTAL_1="57" TOTAL_2="58" VAR="2.632476134813949" WEIGHT="0.6026869110704811"/>
<DICH_DATA CI_END="2.4218599962236005" CI_START="0.09236844140937658" EFFECT_SIZE="0.47297297297297297" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.38414903367699244" LOG_CI_START="-1.0344763844383935" LOG_EFFECT_SIZE="-0.32516367538070057" ORDER="497" O_E="0.0" SE="0.8333075929100517" STUDY_ID="STD-Lockwood-1993a" TOTAL_1="37" TOTAL_2="35" VAR="0.6944015444015444" WEIGHT="2.284785975706781"/>
<DICH_DATA CI_END="17.021979772595813" CI_START="0.0743523971305363" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2310100701029338" LOG_CI_START="-1.1287050252081712" LOG_EFFECT_SIZE="0.05115252244738129" ORDER="498" O_E="0.0" SE="1.38610832776385" STUDY_ID="STD-McGregor-1991" TOTAL_1="24" TOTAL_2="27" VAR="1.9212962962962963" WEIGHT="0.8257752399857352"/>
<DICH_DATA CI_END="1.4592603971084088" CI_START="0.40697973057153053" EFFECT_SIZE="0.7706422018348624" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="19" LOG_CI_END="0.1641327963051194" LOG_CI_START="-0.3904272200626033" LOG_EFFECT_SIZE="-0.11314721187874195" ORDER="499" O_E="0.0" SE="0.325751298730754" STUDY_ID="STD-Mercer-1992" TOTAL_1="109" TOTAL_2="114" VAR="0.10611390862477293" WEIGHT="14.951469894186769"/>
<DICH_DATA CI_END="1.006655601952622" CI_START="0.5098611892833756" EFFECT_SIZE="0.7164179104477612" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="67" LOG_CI_END="0.0028809146904725355" LOG_CI_START="-0.292548045340951" LOG_EFFECT_SIZE="-0.14483356532523925" ORDER="500" O_E="0.0" SE="0.17353643351939557" STUDY_ID="STD-Mercer-1997" TOTAL_1="299" TOTAL_2="312" VAR="0.030114893758631595" WEIGHT="52.68353004576135"/>
<DICH_DATA CI_END="2.66713910342731" CI_START="0.3930001025053964" EFFECT_SIZE="1.0238095238095237" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.42604566671180744" LOG_CI_START="-0.4056073363484353" LOG_EFFECT_SIZE="0.010219165181686028" ORDER="501" O_E="0.0" SE="0.48851709074634586" STUDY_ID="STD-Ovalle_x002d_Salas-1997" TOTAL_1="42" TOTAL_2="43" VAR="0.2386489479512735" WEIGHT="6.648086755788743"/>
<DICH_DATA CI_END="1.1381062847288776" CI_START="0.2558198452269065" EFFECT_SIZE="0.5395833333333333" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="16" LOG_CI_END="0.056182821563329814" LOG_CI_START="-0.5920657681520007" LOG_EFFECT_SIZE="-0.26794147329433543" ORDER="502" O_E="0.0" SE="0.3807844304810564" STUDY_ID="STD-Svare-1997a" TOTAL_1="30" TOTAL_2="37" VAR="0.1449967824967825" WEIGHT="10.942028387374627"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6973135830159931" CI_END="0.683040038258761" CI_START="0.1341289660872307" DF="4" EFFECT_SIZE="0.3026804488694804" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="25" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="-0.16555383821422026" LOG_CI_START="-0.8724774230924749" LOG_EFFECT_SIZE="-0.5190156306533474" MODIFIED="2010-04-16 11:37:12 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9516598014780573" P_Z="0.0040024496315297885" STUDIES="5" TAU2="0.0" TOTAL_1="258" TOTAL_2="263" WEIGHT="99.99999999999999" Z="2.877968610055906">
<NAME>All penicillin (excluding co-amoxiclav) versus placebo</NAME>
<DICH_DATA CI_END="3.56891408335329" CI_START="0.00851829190321925" EFFECT_SIZE="0.17435897435897435" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5525360930454063" LOG_CI_START="-2.069647481685932" LOG_EFFECT_SIZE="-0.7585556943202629" MODIFIED="2010-04-16 11:37:12 +0100" MODIFIED_BY="[Empty name]" ORDER="333" O_E="0.0" SE="1.540283611815222" STUDY_ID="STD-Ernest-1994" TOTAL_1="77" TOTAL_2="67" VAR="2.372473604826546" WEIGHT="7.268064235446991"/>
<DICH_DATA CI_END="1.382734766959299" CI_START="0.022476325273777523" EFFECT_SIZE="0.1762917933130699" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.14073888271743915" LOG_CI_START="-1.648274691491513" LOG_EFFECT_SIZE="-0.753767904387037" MODIFIED="2010-04-16 11:36:50 +0100" MODIFIED_BY="[Empty name]" ORDER="334" O_E="0.0" SE="1.0508754292503548" STUDY_ID="STD-Fuhr-2006" TOTAL_1="47" TOTAL_2="58" VAR="1.1043391678021173" WEIGHT="15.614125677621153"/>
<DICH_DATA CI_END="1.0221993846189465" CI_START="0.09209298901046323" EFFECT_SIZE="0.3068181818181818" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="0.009535615166785905" LOG_CI_START="-1.0357734311491484" LOG_EFFECT_SIZE="-0.5131189079911813" MODIFIED="2010-04-16 11:36:47 +0100" MODIFIED_BY="[Empty name]" ORDER="335" O_E="0.0" SE="0.6140197081692101" STUDY_ID="STD-Johnston-1990" TOTAL_1="40" TOTAL_2="45" VAR="0.377020202020202" WEIGHT="45.735720431919624"/>
<DICH_DATA CI_END="8.153974850938733" CI_START="0.01410055344782869" EFFECT_SIZE="0.3390804597701149" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9113693676366951" LOG_CI_START="-1.850763840917606" LOG_EFFECT_SIZE="-0.46969723664045554" MODIFIED="2010-04-16 11:36:45 +0100" MODIFIED_BY="[Empty name]" ORDER="336" O_E="0.0" SE="1.6224907194846905" STUDY_ID="STD-Kurki--1992" TOTAL_1="57" TOTAL_2="58" VAR="2.632476134813949" WEIGHT="6.550217237961966"/>
<DICH_DATA CI_END="2.4218599962236005" CI_START="0.09236844140937658" EFFECT_SIZE="0.47297297297297297" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.38414903367699244" LOG_CI_START="-1.0344763844383935" LOG_EFFECT_SIZE="-0.32516367538070057" MODIFIED="2010-04-16 11:36:41 +0100" MODIFIED_BY="[Empty name]" ORDER="337" O_E="0.0" SE="0.8333075929100517" STUDY_ID="STD-Lockwood-1993a" TOTAL_1="37" TOTAL_2="35" VAR="0.6944015444015444" WEIGHT="24.831872417050263"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.879512141972564" CI_START="0.014101267833479788" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.04.03" LOG_CI_END="0.8964993290875" LOG_CI_START="-1.8507418385268246" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2010-04-30 16:46:09 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.4960074614265024" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="31" WEIGHT="100.00000000000001" Z="0.6807851356720648">
<NAME>Beta lactum (including co-amoxiclav) versus placebo</NAME>
<DICH_DATA CI_END="7.879512141972564" CI_START="0.014101267833479788" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8964993290875" LOG_CI_START="-1.8507418385268246" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2010-04-16 11:38:48 +0100" MODIFIED_BY="[Empty name]" ORDER="338" O_E="0.0" SE="1.613743060919757" STUDY_ID="STD-Cox-1995" TOTAL_1="31" TOTAL_2="31" VAR="2.6041666666666665" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.07126663274482478" CI_END="1.371786948968563" CI_START="0.45372444517977917" DF="2" EFFECT_SIZE="0.7889317285580694" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="25" I2="0.0" ID="CMP-001.04.04" LOG_CI_END="0.1372866667117825" LOG_CI_START="-0.34320782174634046" LOG_EFFECT_SIZE="-0.102960577517279" MODIFIED="2010-04-16 11:40:49 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.9649940766091846" P_Z="0.400928609006196" STUDIES="3" TAU2="0.0" TOTAL_1="163" TOTAL_2="171" WEIGHT="100.0" Z="0.8399639480106078">
<NAME>Macrolide (including erythromycin) versus placebo</NAME>
<DICH_DATA CI_END="2.6921683779126004" CI_START="0.23772658695895926" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4301022187434325" LOG_CI_START="-0.6239222447595453" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2010-04-16 11:40:49 +0100" MODIFIED_BY="[Empty name]" ORDER="339" O_E="0.0" SE="0.6191391873668903" STUDY_ID="STD-Garcia_x002d_Burguillo-1995" TOTAL_1="30" TOTAL_2="30" VAR="0.38333333333333336" WEIGHT="20.781430506447713"/>
<DICH_DATA CI_END="17.021979772595813" CI_START="0.0743523971305363" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2310100701029338" LOG_CI_START="-1.1287050252081712" LOG_EFFECT_SIZE="0.05115252244738129" MODIFIED="2010-04-16 11:40:45 +0100" MODIFIED_BY="[Empty name]" ORDER="340" O_E="0.0" SE="1.38610832776385" STUDY_ID="STD-McGregor-1991" TOTAL_1="24" TOTAL_2="27" VAR="1.9212962962962963" WEIGHT="4.146270954057519"/>
<DICH_DATA CI_END="1.4592603971084088" CI_START="0.40697973057153053" EFFECT_SIZE="0.7706422018348624" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="19" LOG_CI_END="0.1641327963051194" LOG_CI_START="-0.3904272200626033" LOG_EFFECT_SIZE="-0.11314721187874195" MODIFIED="2010-04-16 11:40:42 +0100" MODIFIED_BY="[Empty name]" ORDER="341" O_E="0.0" SE="0.325751298730754" STUDY_ID="STD-Mercer-1992" TOTAL_1="109" TOTAL_2="114" VAR="0.10611390862477293" WEIGHT="75.07229853949477"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.084163387707782" CI_END="0.9518409255490623" CI_START="0.528163121594283" DF="2" EFFECT_SIZE="0.7090326328873617" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="90" I2="0.0" ID="CMP-001.04.05" LOG_CI_END="-0.021435626120556717" LOG_CI_START="-0.27723192620225656" LOG_EFFECT_SIZE="-0.14933377616140667" MODIFIED="2010-04-16 11:43:04 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.5815365250856057" P_Z="0.022111191580076163" STUDIES="3" TAU2="0.0" TOTAL_1="371" TOTAL_2="392" WEIGHT="100.0" Z="2.288452357272095">
<NAME>Other antibiotic versus placebo</NAME>
<DICH_DATA CI_END="1.006655601952622" CI_START="0.5098611892833756" EFFECT_SIZE="0.7164179104477612" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="67" LOG_CI_END="0.0028809146904725355" LOG_CI_START="-0.292548045340951" LOG_EFFECT_SIZE="-0.14483356532523925" MODIFIED="2010-04-16 11:43:04 +0100" MODIFIED_BY="[Empty name]" ORDER="342" O_E="0.0" SE="0.17353643351939557" STUDY_ID="STD-Mercer-1997" TOTAL_1="299" TOTAL_2="312" VAR="0.030114893758631595" WEIGHT="74.96911524103547"/>
<DICH_DATA CI_END="2.66713910342731" CI_START="0.3930001025053964" EFFECT_SIZE="1.0238095238095237" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.42604566671180744" LOG_CI_START="-0.4056073363484353" LOG_EFFECT_SIZE="0.010219165181686028" MODIFIED="2010-04-16 11:42:49 +0100" MODIFIED_BY="[Empty name]" ORDER="343" O_E="0.0" SE="0.48851709074634586" STUDY_ID="STD-Ovalle_x002d_Salas-1997" TOTAL_1="42" TOTAL_2="43" VAR="0.2386489479512735" WEIGHT="9.460284489179303"/>
<DICH_DATA CI_END="1.1381062847288776" CI_START="0.2558198452269065" EFFECT_SIZE="0.5395833333333333" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="16" LOG_CI_END="0.056182821563329814" LOG_CI_START="-0.5920657681520007" LOG_EFFECT_SIZE="-0.26794147329433543" MODIFIED="2010-04-16 11:42:46 +0100" MODIFIED_BY="[Empty name]" ORDER="344" O_E="0.0" SE="0.3807844304810564" STUDY_ID="STD-Svare-1997a" TOTAL_1="30" TOTAL_2="37" VAR="0.1449967824967825" WEIGHT="15.57060026978523"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="27.145960875088694" CI_END="1.4295011362109582" CI_START="0.7911093498926216" CI_STUDY="95" CI_TOTAL="95" DF="22" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0634339257982204" ESTIMABLE="YES" EVENTS_1="180" EVENTS_2="116" I2="18.956635570086004" I2_Q="49.83605611508156" ID="CMP-001.05" LOG_CI_END="0.1551845048846011" LOG_CI_START="-0.10176348265568558" LOG_EFFECT_SIZE="0.026710511114457724" METHOD="MH" MODIFIED="2013-12-18 11:46:43 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.20573520047064797" P_Q="0.09254068777360547" P_Z="0.6836494410841819" Q="7.973854705635659" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0990391657957223" TOTALS="SUB" TOTAL_1="7357" TOTAL_2="3913" WEIGHT="500.0" Z="0.4074882258790669">
<NAME>Neonatal necrotising enterocolitis</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="13.98142059965581" CI_END="1.8271538108530507" CI_START="0.646723359811394" DF="10" EFFECT_SIZE="1.0870432610743133" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="58" I2="28.476509745753752" ID="CMP-001.05.01" LOG_CI_END="0.2617751080493414" LOG_CI_START="-0.1892814519429964" LOG_EFFECT_SIZE="0.0362468280531726" MODIFIED="2010-04-21 16:40:03 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.1738408648866454" P_Z="0.7527580542983123" STUDIES="11" TAU2="0.18219613610631943" TOTAL_1="4273" TOTAL_2="1956" WEIGHT="100.0" Z="0.31500474148626106">
<NAME>Any antibiotic versus placebo</NAME>
<DICH_DATA CI_END="190.7925996704815" CI_START="0.6341965055719119" EFFECT_SIZE="11.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.2805615255850418" LOG_CI_START="-0.19777615526859124" LOG_EFFECT_SIZE="1.0413926851582251" ORDER="507" O_E="0.0" SE="1.4557878217027993" STUDY_ID="STD-Cox-1995" TOTAL_1="31" TOTAL_2="31" VAR="2.1193181818181817" WEIGHT="3.050166380096987"/>
<DICH_DATA CI_END="3.826403133932763" CI_START="0.04422084511757417" EFFECT_SIZE="0.41134751773049644" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5827907235635597" LOG_CI_START="-1.3543729617484448" LOG_EFFECT_SIZE="-0.3857911190924426" MODIFIED="2009-05-11 12:08:04 +0100" MODIFIED_BY="[Empty name]" ORDER="326" O_E="0.0" SE="1.137899537867165" STUDY_ID="STD-Fuhr-2006" TOTAL_1="47" TOTAL_2="58" VAR="1.2948153582783077" WEIGHT="4.752841546957582"/>
<DICH_DATA CI_END="14.274513691819212" CI_START="0.06130717247077439" EFFECT_SIZE="0.9354838709677419" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1545613215023336" LOG_CI_START="-1.2124887133729667" LOG_EFFECT_SIZE="-0.028963695935316617" ORDER="508" O_E="0.0" SE="1.3904169075723947" STUDY_ID="STD-Grable-1996" TOTAL_1="31" TOTAL_2="29" VAR="1.9332591768631813" WEIGHT="3.3184353045922133"/>
<DICH_DATA CI_END="4.263451212572935" CI_START="0.13193536690209684" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6297612976391056" LOG_CI_START="-0.8796387708557056" LOG_EFFECT_SIZE="-0.12493873660829995" ORDER="509" O_E="0.0" SE="0.8866290718846924" STUDY_ID="STD-Johnston-1990" TOTAL_1="40" TOTAL_2="45" VAR="0.786111111111111" WEIGHT="7.249766658277259"/>
<DICH_DATA CI_END="7.258707536982051" CI_START="1.352383162922258" EFFECT_SIZE="3.1331380208333335" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="6" LOG_CI_END="0.86085929845129" LOG_CI_START="0.13109975519083797" LOG_EFFECT_SIZE="0.49597952682106394" ORDER="510" O_E="0.0" SE="0.4286643680791882" STUDY_ID="STD-Kenyon-2001" TOTAL_1="3584" TOTAL_2="1225" VAR="0.18375314046072974" WEIGHT="19.18299077320066"/>
<DICH_DATA CI_END="95.32771154507131" CI_START="0.2353740876238835" EFFECT_SIZE="4.7368421052631575" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.97921916739248" LOG_CI_START="-0.6282413504194881" LOG_EFFECT_SIZE="0.6754889084864959" ORDER="511" O_E="0.0" SE="1.5316352153004769" STUDY_ID="STD-Lockwood-1993a" TOTAL_1="37" TOTAL_2="35" VAR="2.345906432748538" WEIGHT="2.776786702536748"/>
<DICH_DATA CI_END="2.5967822125671263" CI_START="0.10382102527167833" EFFECT_SIZE="0.5192307692307693" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.414435527662994" LOG_CI_START="-0.9837146866146176" LOG_EFFECT_SIZE="-0.2846395794758118" ORDER="512" O_E="0.0" SE="0.8212803568218495" STUDY_ID="STD-McGregor-1991" TOTAL_1="26" TOTAL_2="27" VAR="0.6745014245014245" WEIGHT="8.194258882755719"/>
<DICH_DATA CI_END="1.685242061057554" CI_START="0.30503745167007723" EFFECT_SIZE="0.7169811320754716" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.226662289914364" LOG_CI_START="-0.5156468358823217" LOG_EFFECT_SIZE="-0.14449227298397893" ORDER="513" O_E="0.0" SE="0.43603605498240733" STUDY_ID="STD-Mercer-1992" TOTAL_1="106" TOTAL_2="114" VAR="0.19012744124462097" WEIGHT="18.85457172976271"/>
<DICH_DATA CI_END="1.5702778536177027" CI_START="0.5478797650209554" EFFECT_SIZE="0.927536231884058" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="27" LOG_CI_END="0.1959765056680121" LOG_CI_START="-0.26131473917474835" LOG_EFFECT_SIZE="-0.03266911675336814" ORDER="514" O_E="0.0" SE="0.2686151408488068" STUDY_ID="STD-Mercer-1997" TOTAL_1="299" TOTAL_2="312" VAR="0.07215409389322432" WEIGHT="27.599745421334013"/>
<DICH_DATA CI_END="8.143906058223955" CI_START="0.014285425381653886" EFFECT_SIZE="0.34108527131782945" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9108327553376903" LOG_CI_START="-1.8451068229638132" LOG_EFFECT_SIZE="-0.46713703381306154" ORDER="515" O_E="0.0" SE="1.6188525504152331" STUDY_ID="STD-Ovalle_x002d_Salas-1997" TOTAL_1="42" TOTAL_2="43" VAR="2.620683579985905" WEIGHT="2.5045675544123776"/>
<DICH_DATA CI_END="9.681804404318333" CI_START="0.017244277042976947" EFFECT_SIZE="0.40860215053763443" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9859563046028171" LOG_CI_START="-1.7633550084770668" LOG_EFFECT_SIZE="-0.38869935193712496" ORDER="516" O_E="0.0" SE="1.6149590746136118" STUDY_ID="STD-Svare-1997a" TOTAL_1="30" TOTAL_2="37" VAR="2.6080928126768534" WEIGHT="2.5158690460737194"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.7067255039984832" CI_END="2.972727042609826" CI_START="0.2455210921021466" DF="2" EFFECT_SIZE="0.8543226498362015" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="0.4731550338835242" LOG_CI_START="-0.6099111927870473" LOG_EFFECT_SIZE="-0.06837807945176148" MODIFIED="2010-04-16 11:48:26 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4259803632270427" P_Z="0.8045368278846654" STUDIES="3" TAU2="0.0" TOTAL_1="124" TOTAL_2="138" WEIGHT="100.0" Z="0.24747992275496256">
<NAME>All penicillin (excluding co-amoxiclav) versus placebo</NAME>
<DICH_DATA CI_END="3.826403133932763" CI_START="0.04422084511757417" EFFECT_SIZE="0.41134751773049644" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5827907235635597" LOG_CI_START="-1.3543729617484448" LOG_EFFECT_SIZE="-0.3857911190924426" MODIFIED="2010-04-16 11:48:26 +0100" MODIFIED_BY="[Empty name]" ORDER="345" O_E="0.0" SE="1.137899537867165" STUDY_ID="STD-Fuhr-2006" TOTAL_1="47" TOTAL_2="58" VAR="1.2948153582783077" WEIGHT="31.259166142478637"/>
<DICH_DATA CI_END="4.263451212572935" CI_START="0.13193536690209684" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6297612976391056" LOG_CI_START="-0.8796387708557056" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2010-04-16 11:48:22 +0100" MODIFIED_BY="[Empty name]" ORDER="346" O_E="0.0" SE="0.8866290718846924" STUDY_ID="STD-Johnston-1990" TOTAL_1="40" TOTAL_2="45" VAR="0.786111111111111" WEIGHT="51.48743967127797"/>
<DICH_DATA CI_END="95.32771154507131" CI_START="0.2353740876238835" EFFECT_SIZE="4.7368421052631575" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.97921916739248" LOG_CI_START="-0.6282413504194881" LOG_EFFECT_SIZE="0.6754889084864959" MODIFIED="2010-04-16 11:48:20 +0100" MODIFIED_BY="[Empty name]" ORDER="347" O_E="0.0" SE="1.5316352153004769" STUDY_ID="STD-Lockwood-1993a" TOTAL_1="37" TOTAL_2="35" VAR="2.345906432748538" WEIGHT="17.2533941862434"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.3988094395833043" CI_END="14.231622628515664" CI_START="1.5667204243106108" DF="1" EFFECT_SIZE="4.721967158206053" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="3" I2="0.0" ID="CMP-001.05.03" LOG_CI_END="1.15325441929972" LOG_CI_START="0.19499150507621432" LOG_EFFECT_SIZE="0.6741229621879671" MODIFIED="2010-04-21 16:54:12 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5277051663864596" P_Z="0.005822598010240485" STUDIES="2" TAU2="0.0" TOTAL_1="1236" TOTAL_2="644" WEIGHT="100.0" Z="2.7576079746559032">
<NAME>Beta lactum (including co-amoxiclav) versus placebo</NAME>
<DICH_DATA CI_END="190.7925996704815" CI_START="0.6341965055719119" EFFECT_SIZE="11.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.2805615255850418" LOG_CI_START="-0.19777615526859124" LOG_EFFECT_SIZE="1.0413926851582251" MODIFIED="2010-04-16 11:50:16 +0100" MODIFIED_BY="[Empty name]" ORDER="348" O_E="0.0" SE="1.4557878217027993" STUDY_ID="STD-Cox-1995" TOTAL_1="31" TOTAL_2="31" VAR="2.1193181818181817" WEIGHT="14.950248162881735"/>
<DICH_DATA CI_END="13.461777910952321" CI_START="1.230337915138028" EFFECT_SIZE="4.0697095435684645" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="3" LOG_CI_END="1.1291024213980028" LOG_CI_START="0.09002440780093995" LOG_EFFECT_SIZE="0.6095634145994714" MODIFIED="2010-04-21 16:54:12 +0100" MODIFIED_BY="[Empty name]" ORDER="349" O_E="0.0" SE="0.6103595687060356" STUDY_ID="STD-Kenyon-2001" TOTAL_1="1205" TOTAL_2="613" VAR="0.37253880311101784" WEIGHT="85.04975183711827"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.0347871583191974" CI_END="1.6922383851267289" CI_START="0.4542445167587782" DF="2" EFFECT_SIZE="0.8767496834858546" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="19" I2="1.7096214794245503" ID="CMP-001.05.04" LOG_CI_END="0.22846154194927507" LOG_CI_START="-0.3427103064101939" LOG_EFFECT_SIZE="-0.0571243822304594" MODIFIED="2010-04-21 16:54:25 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.361536158578744" P_Z="0.6950270400268672" STUDIES="3" TAU2="0.006664787810134564" TOTAL_1="1322" TOTAL_2="754" WEIGHT="100.0" Z="0.39204219231875304">
<NAME>Macrolide (including erythromycin) versus placebo</NAME>
<DICH_DATA CI_END="6.745097939852383" CI_START="0.5289098159007599" EFFECT_SIZE="1.8887955182072829" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" LOG_CI_END="0.8289882600759203" LOG_CI_START="-0.27661837294702646" LOG_EFFECT_SIZE="0.2761849435644469" MODIFIED="2010-04-21 16:54:25 +0100" MODIFIED_BY="[Empty name]" ORDER="350" O_E="0.0" SE="0.6494388090787773" STUDY_ID="STD-Kenyon-2001" TOTAL_1="1190" TOTAL_2="613" VAR="0.42177076673766045" WEIGHT="26.273824074342976"/>
<DICH_DATA CI_END="2.5967822125671263" CI_START="0.10382102527167833" EFFECT_SIZE="0.5192307692307693" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.414435527662994" LOG_CI_START="-0.9837146866146176" LOG_EFFECT_SIZE="-0.2846395794758118" MODIFIED="2010-04-16 11:52:26 +0100" MODIFIED_BY="[Empty name]" ORDER="351" O_E="0.0" SE="0.8212803568218495" STUDY_ID="STD-McGregor-1991" TOTAL_1="26" TOTAL_2="27" VAR="0.6745014245014245" WEIGHT="16.525541320058398"/>
<DICH_DATA CI_END="1.685242061057554" CI_START="0.30503745167007723" EFFECT_SIZE="0.7169811320754716" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.226662289914364" LOG_CI_START="-0.5156468358823217" LOG_EFFECT_SIZE="-0.14449227298397893" MODIFIED="2010-04-16 11:52:22 +0100" MODIFIED_BY="[Empty name]" ORDER="352" O_E="0.0" SE="0.43603605498240733" STUDY_ID="STD-Mercer-1992" TOTAL_1="106" TOTAL_2="114" VAR="0.19012744124462097" WEIGHT="57.20063460559862"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6100047658875971" CI_END="1.4663676395432823" CI_START="0.5354794894227647" DF="3" EFFECT_SIZE="0.8861206435518255" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="30" I2="0.0" ID="CMP-001.05.05" LOG_CI_END="0.1662428678551028" LOG_CI_START="-0.27125715938134526" LOG_EFFECT_SIZE="-0.05250714576312123" MODIFIED="2010-04-16 11:54:50 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.8941382473719554" P_Z="0.6380297275134688" STUDIES="4" TAU2="0.0" TOTAL_1="402" TOTAL_2="421" WEIGHT="100.0" Z="0.4704553518626108">
<NAME>Other antibiotic versus placebo</NAME>
<DICH_DATA CI_END="14.274513691819212" CI_START="0.06130717247077439" EFFECT_SIZE="0.9354838709677419" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1545613215023336" LOG_CI_START="-1.2124887133729667" LOG_EFFECT_SIZE="-0.028963695935316617" MODIFIED="2010-04-16 11:54:13 +0100" MODIFIED_BY="[Empty name]" ORDER="353" O_E="0.0" SE="1.3904169075723947" STUDY_ID="STD-Grable-1996" TOTAL_1="31" TOTAL_2="29" VAR="1.9332591768631813" WEIGHT="3.4161843000391734"/>
<DICH_DATA CI_END="1.5702778536177027" CI_START="0.5478797650209554" EFFECT_SIZE="0.927536231884058" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="27" LOG_CI_END="0.1959765056680121" LOG_CI_START="-0.26131473917474835" LOG_EFFECT_SIZE="-0.03266911675336814" MODIFIED="2010-04-16 11:54:28 +0100" MODIFIED_BY="[Empty name]" ORDER="354" O_E="0.0" SE="0.2686151408488068" STUDY_ID="STD-Mercer-1997" TOTAL_1="299" TOTAL_2="312" VAR="0.07215409389322432" WEIGHT="91.53146123184627"/>
<DICH_DATA CI_END="8.143906058223955" CI_START="0.014285425381653886" EFFECT_SIZE="0.34108527131782945" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9108327553376903" LOG_CI_START="-1.8451068229638132" LOG_EFFECT_SIZE="-0.46713703381306154" MODIFIED="2010-04-16 11:54:39 +0100" MODIFIED_BY="[Empty name]" ORDER="355" O_E="0.0" SE="1.6188525504152331" STUDY_ID="STD-Ovalle_x002d_Salas-1997" TOTAL_1="42" TOTAL_2="43" VAR="2.620683579985905" WEIGHT="2.52009426027013"/>
<DICH_DATA CI_END="9.681804404318333" CI_START="0.017244277042976947" EFFECT_SIZE="0.40860215053763443" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9859563046028171" LOG_CI_START="-1.7633550084770668" LOG_EFFECT_SIZE="-0.38869935193712496" MODIFIED="2010-04-16 11:54:50 +0100" MODIFIED_BY="[Empty name]" ORDER="356" O_E="0.0" SE="1.6149590746136118" STUDY_ID="STD-Svare-1997a" TOTAL_1="30" TOTAL_2="37" VAR="2.6080928126768534" WEIGHT="2.5322602078444314"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.013196937035825465" CI_END="1.0950876534334284" CI_START="0.7542209204954826" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9088113214500567" ESTIMABLE="YES" EVENTS_1="337" EVENTS_2="152" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.03944888253587617" LOG_CI_START="-0.12250142535159039" LOG_EFFECT_SIZE="-0.041526271407857133" METHOD="MH" MODIFIED="2013-12-18 11:47:18 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.9934232536502823" P_Q="0.9934232655929242" P_Z="0.3148376000090679" Q="0.013196912992413214" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="5979" TOTAL_2="2451" WEIGHT="300.0" Z="1.005123082917389">
<NAME>Oxygen treatment &gt; 36 weeks' postconceptual age</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.173090566992895" CI_START="0.7035260567310317" DF="0" EFFECT_SIZE="0.908460115131579" ESTIMABLE="YES" EVENTS_1="202" EVENTS_2="76" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="0.06933154257324456" LOG_CI_START="-0.15271981282065236" LOG_EFFECT_SIZE="-0.04169413512370388" MODIFIED="2010-04-21 16:51:12 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.46170820593689177" STUDIES="1" TAU2="0.0" TOTAL_1="3584" TOTAL_2="1225" WEIGHT="100.0" Z="0.736036968241376">
<NAME>Any antibiotic versus placebo</NAME>
<DICH_DATA CI_END="1.173090566992895" CI_START="0.7035260567310317" EFFECT_SIZE="0.908460115131579" ESTIMABLE="YES" EVENTS_1="202" EVENTS_2="76" LOG_CI_END="0.06933154257324456" LOG_CI_START="-0.15271981282065236" LOG_EFFECT_SIZE="-0.04169413512370388" MODIFIED="2010-04-21 16:51:12 +0100" MODIFIED_BY="[Empty name]" ORDER="536" O_E="0.0" SE="0.13043406533031146" STUDY_ID="STD-Kenyon-2001" TOTAL_1="3584" TOTAL_2="1225" VAR="0.017013045398591956" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-04-16 11:59:35 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>All penicillin (excluding co-amoxiclav) versus placebo</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.355892568622008" CI_START="0.629292510439579" DF="0" EFFECT_SIZE="0.9237169687704739" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="38" I2="0.0" ID="CMP-001.06.03" LOG_CI_END="0.13222528045805293" LOG_CI_START="-0.20114743700210694" LOG_EFFECT_SIZE="-0.034461078272026976" MODIFIED="2010-04-21 16:54:44 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.6853253922403021" STUDIES="1" TAU2="0.0" TOTAL_1="1205" TOTAL_2="613" WEIGHT="100.0" Z="0.4052069575229139">
<NAME>Beta lactum (including co-amoxiclav) versus placebo</NAME>
<DICH_DATA CI_END="1.355892568622008" CI_START="0.629292510439579" EFFECT_SIZE="0.9237169687704739" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="38" LOG_CI_END="0.13222528045805293" LOG_CI_START="-0.20114743700210694" LOG_EFFECT_SIZE="-0.034461078272026976" MODIFIED="2010-04-21 16:54:44 +0100" MODIFIED_BY="[Empty name]" ORDER="357" O_E="0.0" SE="0.19582478445766374" STUDY_ID="STD-Kenyon-2001" TOTAL_1="1205" TOTAL_2="613" VAR="0.038347346207890466" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3175384758807895" CI_START="0.6075533185548964" DF="0" EFFECT_SIZE="0.8946926138876603" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="38" I2="0.0" ID="CMP-001.06.04" LOG_CI_END="0.11976330670714443" LOG_CI_START="-0.21641560260525888" LOG_EFFECT_SIZE="-0.048326147949057215" MODIFIED="2010-04-21 16:54:50 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.5730981004174034" STUDIES="1" TAU2="0.0" TOTAL_1="1190" TOTAL_2="613" WEIGHT="100.0" Z="0.5634946563746959">
<NAME>Macrolide (including erythromycin) versus placebo</NAME>
<DICH_DATA CI_END="1.3175384758807895" CI_START="0.6075533185548964" EFFECT_SIZE="0.8946926138876603" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="38" LOG_CI_END="0.11976330670714443" LOG_CI_START="-0.21641560260525888" LOG_EFFECT_SIZE="-0.048326147949057215" MODIFIED="2010-04-21 16:54:50 +0100" MODIFIED_BY="[Empty name]" ORDER="358" O_E="0.0" SE="0.19747315544254523" STUDY_ID="STD-Kenyon-2001" TOTAL_1="1190" TOTAL_2="613" VAR="0.03899564712043563" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.06.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-04-16 12:00:23 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Other antibiotic versus placebo</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="19.138444158247232" CI_END="0.9339266202259212" CI_START="0.6917754178009656" CI_STUDY="95" CI_TOTAL="95" DF="22" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8037832281792339" ESTIMABLE="YES" EVENTS_1="434" EVENTS_2="369" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="-0.02968724548607798" LOG_CI_START="-0.16003487467649313" LOG_EFFECT_SIZE="-0.09486106008128559" METHOD="MH" MODIFIED="2013-12-18 11:49:09 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.6367646057316543" P_Q="0.6229976537245032" P_Z="0.0043343412746253765" Q="2.6216230934165115" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="7417" TOTAL_2="3973" WEIGHT="500.0" Z="2.8527448093897743">
<NAME>Major cerebral abnormality on ultrasound before discharge</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.52144051611507" CI_END="0.9834571042656273" CI_START="0.6751365599385504" DF="10" EFFECT_SIZE="0.8148422216730205" ESTIMABLE="YES" EVENTS_1="240" EVENTS_2="184" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="-0.00724457808019192" LOG_CI_START="-0.17060837349591193" LOG_EFFECT_SIZE="-0.08892647578805195" MODIFIED="2010-04-21 16:47:55 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4834320948905203" P_Z="0.032859299794715406" STUDIES="12" TAU2="0.0" TOTAL_1="4303" TOTAL_2="1986" WEIGHT="100.0" Z="2.1337982430332696">
<NAME>Any antibiotic versus placebo</NAME>
<DICH_DATA CI_END="2.117597116585681" CI_START="0.3615536657107181" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.3258433369390321" LOG_CI_START="-0.4418272308944057" LOG_EFFECT_SIZE="-0.057991946977686754" ORDER="539" O_E="0.0" SE="0.45093349157595825" STUDY_ID="STD-Cox-1995" TOTAL_1="31" TOTAL_2="31" VAR="0.2033410138248848" WEIGHT="4.528577964961033"/>
<DICH_DATA CI_END="4.999143395047628" CI_START="0.012088876633874188" EFFECT_SIZE="0.24583333333333332" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6988955942010305" LOG_CI_START="-1.9176140543399545" LOG_EFFECT_SIZE="-0.6093592300694619" MODIFIED="2009-05-11 12:09:48 +0100" MODIFIED_BY="[Empty name]" ORDER="328" O_E="0.0" SE="1.5369507194846208" STUDY_ID="STD-Fuhr-2006" TOTAL_1="47" TOTAL_2="58" VAR="2.3622175141242936" WEIGHT="0.3898225413511847"/>
<DICH_DATA CI_END="20.897996678081547" CI_START="0.19140590658602802" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3201046558069978" LOG_CI_START="-0.7180446644790353" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="540" O_E="0.0" SE="1.1972189997378646" STUDY_ID="STD-Garcia_x002d_Burguillo-1995" TOTAL_1="30" TOTAL_2="30" VAR="1.4333333333333331" WEIGHT="0.6424504427303793"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="541" O_E="0.0" SE="0.0" STUDY_ID="STD-Grable-1996" TOTAL_1="31" TOTAL_2="29" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.0163472264245497" CI_START="0.1588352444980729" EFFECT_SIZE="0.4017857142857143" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" LOG_CI_END="0.007042106331463544" LOG_CI_START="-0.7990531241211395" LOG_EFFECT_SIZE="-0.39600550889483793" ORDER="542" O_E="0.0" SE="0.4735043286036034" STUDY_ID="STD-Johnston-1990" TOTAL_1="40" TOTAL_2="45" VAR="0.22420634920634924" WEIGHT="4.107134511755981"/>
<DICH_DATA CI_END="1.0664808119929003" CI_START="0.5936085506044214" EFFECT_SIZE="0.7956582991803278" ESTIMABLE="YES" EVENTS_1="142" EVENTS_2="61" LOG_CI_END="0.02795304607652389" LOG_CI_START="-0.2264998519110177" LOG_EFFECT_SIZE="-0.0992734029172469" ORDER="543" O_E="0.0" SE="0.1494668918400409" STUDY_ID="STD-Kenyon-2001" TOTAL_1="3584" TOTAL_2="1225" VAR="0.02234035175632248" WEIGHT="41.21894071428863"/>
<DICH_DATA CI_END="1.9317578392262862" CI_START="0.23633273769068006" EFFECT_SIZE="0.6756756756756757" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.2859526833220414" LOG_CI_START="-0.6264761141119563" LOG_EFFECT_SIZE="-0.1702617153949574" ORDER="544" O_E="0.0" SE="0.5359651922081202" STUDY_ID="STD-Lockwood-1993a" TOTAL_1="37" TOTAL_2="35" VAR="0.28725868725868725" WEIGHT="3.205631980595087"/>
<DICH_DATA CI_END="41.495013944337394" CI_START="0.6497180410100027" EFFECT_SIZE="5.1923076923076925" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.617995914867415" LOG_CI_START="-0.18727507381903852" LOG_EFFECT_SIZE="0.7153604205241881" ORDER="545" O_E="0.0" SE="1.0604251149899386" STUDY_ID="STD-McGregor-1991" TOTAL_1="26" TOTAL_2="27" VAR="1.1245014245014244" WEIGHT="0.8188923682230904"/>
<DICH_DATA CI_END="1.7783599307713132" CI_START="0.401520391967141" EFFECT_SIZE="0.8450134770889488" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="0.25001966446772417" LOG_CI_START="-0.3962923933643454" LOG_EFFECT_SIZE="-0.07313636444831062" ORDER="546" O_E="0.0" SE="0.37964690206684154" STUDY_ID="STD-Mercer-1992" TOTAL_1="106" TOTAL_2="114" VAR="0.14413177024895" WEIGHT="6.388915039270591"/>
<DICH_DATA CI_END="1.1975886951143524" CI_START="0.6388383945249424" EFFECT_SIZE="0.8746803069053708" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="68" LOG_CI_END="0.07830768774195314" LOG_CI_START="-0.19460899042141677" LOG_EFFECT_SIZE="-0.0581506513397318" ORDER="547" O_E="0.0" SE="0.1603126077125084" STUDY_ID="STD-Mercer-1997" TOTAL_1="299" TOTAL_2="312" VAR="0.02570013219158461" WEIGHT="35.83038514026542"/>
<DICH_DATA CI_END="1.5843256523009386" CI_START="0.12151791399403711" EFFECT_SIZE="0.4387755102040816" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.19984445405979798" LOG_CI_START="-0.9153596942856145" LOG_EFFECT_SIZE="-0.35775762011290835" ORDER="548" O_E="0.0" SE="0.6550764370876607" STUDY_ID="STD-Ovalle_x002d_Salas-1997" TOTAL_1="42" TOTAL_2="43" VAR="0.42912513842746397" WEIGHT="2.145867375550787"/>
<DICH_DATA CI_END="33.77374825887038" CI_START="0.4053444081796413" EFFECT_SIZE="3.7" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.5285792619327272" LOG_CI_START="-0.3921758137987371" LOG_EFFECT_SIZE="0.568201724066995" ORDER="549" O_E="0.0" SE="1.1282610393756283" STUDY_ID="STD-Svare-1997a" TOTAL_1="30" TOTAL_2="37" VAR="1.2729729729729728" WEIGHT="0.7233819210078085"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7423473389818218" CI_END="0.9582031426005074" CI_START="0.24707811991077544" DF="2" EFFECT_SIZE="0.4865706844501938" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="23" I2="0.0" ID="CMP-001.07.02" LOG_CI_END="-0.01854240912823753" LOG_CI_START="-0.6071657119947058" LOG_EFFECT_SIZE="-0.31285406056147164" MODIFIED="2010-04-16 12:07:21 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6899242516779884" P_Z="0.03721050912620562" STUDIES="3" TAU2="0.0" TOTAL_1="124" TOTAL_2="138" WEIGHT="100.0" Z="2.0834468772524986">
<NAME>All penicillin (excluding co-amoxiclav) versus placebo </NAME>
<DICH_DATA CI_END="4.999143395047628" CI_START="0.012088876633874188" EFFECT_SIZE="0.24583333333333332" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6988955942010305" LOG_CI_START="-1.9176140543399545" LOG_EFFECT_SIZE="-0.6093592300694619" MODIFIED="2010-04-16 12:07:21 +0100" MODIFIED_BY="[Empty name]" ORDER="359" O_E="0.0" SE="1.5369507194846208" STUDY_ID="STD-Fuhr-2006" TOTAL_1="47" TOTAL_2="58" VAR="2.3622175141242936" WEIGHT="5.060928729879495"/>
<DICH_DATA CI_END="1.0163472264245497" CI_START="0.1588352444980729" EFFECT_SIZE="0.4017857142857143" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" LOG_CI_END="0.007042106331463544" LOG_CI_START="-0.7990531241211395" LOG_EFFECT_SIZE="-0.39600550889483793" MODIFIED="2010-04-16 12:07:10 +0100" MODIFIED_BY="[Empty name]" ORDER="360" O_E="0.0" SE="0.4735043286036034" STUDY_ID="STD-Johnston-1990" TOTAL_1="40" TOTAL_2="45" VAR="0.22420634920634924" WEIGHT="53.32148052798145"/>
<DICH_DATA CI_END="1.9317578392262862" CI_START="0.23633273769068006" EFFECT_SIZE="0.6756756756756757" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.2859526833220414" LOG_CI_START="-0.6264761141119563" LOG_EFFECT_SIZE="-0.1702617153949574" MODIFIED="2010-04-16 12:07:07 +0100" MODIFIED_BY="[Empty name]" ORDER="361" O_E="0.0" SE="0.5359651922081202" STUDY_ID="STD-Lockwood-1993a" TOTAL_1="37" TOTAL_2="35" VAR="0.28725868725868725" WEIGHT="41.61759074213906"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.08601447851627438" CI_END="1.1572734648166065" CI_START="0.5226857651901273" DF="1" EFFECT_SIZE="0.777746981023969" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="39" I2="0.0" ID="CMP-001.07.03" LOG_CI_END="0.06343599527645812" LOG_CI_START="-0.28175932730527115" LOG_EFFECT_SIZE="-0.10916166601440647" MODIFIED="2010-04-21 16:53:17 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7693064325166681" P_Z="0.21512153278884338" STUDIES="2" TAU2="0.0" TOTAL_1="1236" TOTAL_2="644" WEIGHT="100.00000000000001" Z="1.2396050576842377">
<NAME>Beta lactum (including co-amoxiclav) versus placebo</NAME>
<DICH_DATA CI_END="2.117597116585681" CI_START="0.3615536657107181" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.3258433369390321" LOG_CI_START="-0.4418272308944057" LOG_EFFECT_SIZE="-0.057991946977686754" MODIFIED="2010-04-16 12:19:37 +0100" MODIFIED_BY="[Empty name]" ORDER="362" O_E="0.0" SE="0.45093349157595825" STUDY_ID="STD-Cox-1995" TOTAL_1="31" TOTAL_2="31" VAR="0.2033410138248848" WEIGHT="20.219947527011808"/>
<DICH_DATA CI_END="1.1778919017767493" CI_START="0.48376416530061683" EFFECT_SIZE="0.7548654798554411" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="31" LOG_CI_END="0.07110543593835339" LOG_CI_START="-0.3153663050286949" LOG_EFFECT_SIZE="-0.12213043454517075" MODIFIED="2010-04-21 16:53:17 +0100" MODIFIED_BY="[Empty name]" ORDER="363" O_E="0.0" SE="0.2270154137100155" STUDY_ID="STD-Kenyon-2001" TOTAL_1="1205" TOTAL_2="613" VAR="0.05153599806192949" WEIGHT="79.7800524729882"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.3597594525125736" CI_END="1.439485779571243" CI_START="0.6016154381823451" DF="3" EFFECT_SIZE="0.9306002729604198" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="47" I2="10.707893157158317" ID="CMP-001.07.04" LOG_CI_END="0.15820737891591086" LOG_CI_START="-0.22068102774989695" LOG_EFFECT_SIZE="-0.031236824416993082" MODIFIED="2010-04-21 16:53:38 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.33941155272176426" P_Z="0.7465650302885418" STUDIES="4" TAU2="0.028144025133444942" TOTAL_1="1352" TOTAL_2="784" WEIGHT="100.0" Z="0.32317194071714406">
<NAME>Macrolide (including erythromycin) versus placebo </NAME>
<DICH_DATA CI_END="20.897996678081547" CI_START="0.19140590658602802" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3201046558069978" LOG_CI_START="-0.7180446644790353" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2010-04-16 12:22:33 +0100" MODIFIED_BY="[Empty name]" ORDER="364" O_E="0.0" SE="1.1972189997378646" STUDY_ID="STD-Garcia_x002d_Burguillo-1995" TOTAL_1="30" TOTAL_2="30" VAR="1.4333333333333331" WEIGHT="3.389266711417809"/>
<DICH_DATA CI_END="1.2866170396680916" CI_START="0.5365304175151582" EFFECT_SIZE="0.8308484684196259" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="31" LOG_CI_END="0.10944929880134752" LOG_CI_START="-0.27040565154608676" LOG_EFFECT_SIZE="-0.0804781763723696" MODIFIED="2010-04-21 16:53:38 +0100" MODIFIED_BY="[Empty name]" ORDER="365" O_E="0.0" SE="0.2231286781464124" STUDY_ID="STD-Kenyon-2001" TOTAL_1="1190" TOTAL_2="613" VAR="0.0497864070113653" WEIGHT="63.56100465782095"/>
<DICH_DATA CI_END="41.495013944337394" CI_START="0.6497180410100027" EFFECT_SIZE="5.1923076923076925" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.617995914867415" LOG_CI_START="-0.18727507381903852" LOG_EFFECT_SIZE="0.7153604205241881" MODIFIED="2010-04-16 12:22:10 +0100" MODIFIED_BY="[Empty name]" ORDER="366" O_E="0.0" SE="1.0604251149899386" STUDY_ID="STD-McGregor-1991" TOTAL_1="26" TOTAL_2="27" VAR="1.1245014245014244" WEIGHT="4.297363566664305"/>
<DICH_DATA CI_END="1.7783599307713132" CI_START="0.401520391967141" EFFECT_SIZE="0.8450134770889488" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="0.25001966446772417" LOG_CI_START="-0.3962923933643454" LOG_EFFECT_SIZE="-0.07313636444831062" MODIFIED="2010-04-16 12:22:06 +0100" MODIFIED_BY="[Empty name]" ORDER="367" O_E="0.0" SE="0.37964690206684154" STUDY_ID="STD-Mercer-1992" TOTAL_1="106" TOTAL_2="114" VAR="0.14413177024895" WEIGHT="28.75236506409693"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.7382889507266928" CI_END="1.6361973495585844" CI_START="0.4463403876194046" DF="2" EFFECT_SIZE="0.8545764794468783" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="76" I2="26.96168899672783" ID="CMP-001.07.05" LOG_CI_END="0.21383568482141477" LOG_CI_START="-0.35033381374954053" LOG_EFFECT_SIZE="-0.06824906446406293" MODIFIED="2010-04-16 12:27:34 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.25432467497974376" P_Z="0.6353544633675927" STUDIES="4" TAU2="0.12605552071415882" TOTAL_1="402" TOTAL_2="421" WEIGHT="100.0" Z="0.47420397120704016">
<NAME>Other antibiotic versus placebo</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-04-16 12:26:46 +0100" MODIFIED_BY="[Empty name]" ORDER="369" O_E="0.0" SE="0.0" STUDY_ID="STD-Grable-1996" TOTAL_1="31" TOTAL_2="29" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.1975886951143524" CI_START="0.6388383945249424" EFFECT_SIZE="0.8746803069053708" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="68" LOG_CI_END="0.07830768774195314" LOG_CI_START="-0.19460899042141677" LOG_EFFECT_SIZE="-0.0581506513397318" MODIFIED="2010-04-16 12:27:34 +0100" MODIFIED_BY="[Empty name]" ORDER="370" O_E="0.0" SE="0.1603126077125084" STUDY_ID="STD-Mercer-1997" TOTAL_1="299" TOTAL_2="312" VAR="0.02570013219158461" WEIGHT="72.3684934604908"/>
<DICH_DATA CI_END="1.5843256523009386" CI_START="0.12151791399403711" EFFECT_SIZE="0.4387755102040816" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.19984445405979798" LOG_CI_START="-0.9153596942856145" LOG_EFFECT_SIZE="-0.35775762011290835" MODIFIED="2010-04-16 12:27:14 +0100" MODIFIED_BY="[Empty name]" ORDER="371" O_E="0.0" SE="0.6550764370876607" STUDY_ID="STD-Ovalle_x002d_Salas-1997" TOTAL_1="42" TOTAL_2="43" VAR="0.42912513842746397" WEIGHT="19.781539205421577"/>
<DICH_DATA CI_END="33.77374825887038" CI_START="0.4053444081796413" EFFECT_SIZE="3.7" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.5285792619327272" LOG_CI_START="-0.3921758137987371" LOG_EFFECT_SIZE="0.568201724066995" MODIFIED="2010-04-16 12:27:07 +0100" MODIFIED_BY="[Empty name]" ORDER="372" O_E="0.0" SE="1.1282610393756283" STUDY_ID="STD-Svare-1997a" TOTAL_1="30" TOTAL_2="37" VAR="1.2729729729729728" WEIGHT="7.84996733408763"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.07699753785860312" CI_END="1.0257106423499167" CI_START="0.9756459807317789" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0003651661281032" ESTIMABLE="YES" EVENTS_1="3104" EVENTS_2="1102" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.011024861599776324" LOG_CI_START="-0.01070774022841838" LOG_EFFECT_SIZE="1.5856068567901126E-4" METHOD="MH" MODIFIED="2013-12-18 11:48:57 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.9622328899983404" P_Q="1.0" P_Z="0.977183830282874" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3642" TOTAL_2="1289" WEIGHT="100.00000000000001" Z="0.02859972641578428">
<NAME>Birth before 37 weeks' gestation</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0287446992651696" CI_START="0.9741861583978599" EFFECT_SIZE="1.0010938250480308" ESTIMABLE="YES" EVENTS_1="3049" EVENTS_2="1041" LOG_CI_END="0.012307610469835153" LOG_CI_START="-0.011358045339218652" LOG_EFFECT_SIZE="4.7478256530823835E-4" ORDER="467" O_E="0.0" SE="0.013901323369123779" STUDY_ID="STD-Kenyon-2001" TOTAL_1="3584" TOTAL_2="1225" VAR="1.932467914129469E-4" WEIGHT="84.33082686297747"/>
<DICH_DATA CI_END="1.0718805080254385" CI_START="0.9329398123323905" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="27" LOG_CI_END="0.030146373418638774" LOG_CI_START="-0.030146373418638742" LOG_EFFECT_SIZE="0.0" ORDER="468" O_E="0.0" SE="0.035416257946127044" STUDY_ID="STD-McGregor-1991" TOTAL_1="28" TOTAL_2="27" VAR="0.001254311326906607" WEIGHT="12.992517374982262"/>
<DICH_DATA CI_END="1.1412565063051563" CI_START="0.8405186735363077" EFFECT_SIZE="0.9794117647058823" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="34" LOG_CI_END="0.05738326646294455" LOG_CI_START="-0.075452633534815" LOG_EFFECT_SIZE="-0.009034683535935268" ORDER="469" O_E="0.0" SE="0.07802846520699375" STUDY_ID="STD-Svare-1997a" TOTAL_1="30" TOTAL_2="37" VAR="0.006088441382559033" WEIGHT="2.6766557620402835"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-12-18 11:49:53 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="3913" TOTAL_2="1574" WEIGHT="0.0" Z="0.0">
<NAME>Major adverse drug reaction</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="422" O_E="0.0" SE="0.0" STUDY_ID="STD-Kenyon-2001" TOTAL_1="3584" TOTAL_2="1225" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="423" O_E="0.0" SE="0.0" STUDY_ID="STD-Mercer-1997" TOTAL_1="299" TOTAL_2="312" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="424" O_E="0.0" SE="0.0" STUDY_ID="STD-Svare-1997a" TOTAL_1="30" TOTAL_2="37" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.058750383029674" CI_END="1.0219259326163934" CI_START="0.8029964280472734" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9058713339210169" ESTIMABLE="YES" EVENTS_1="729" EVENTS_2="306" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="0.009419420043638308" LOG_CI_START="-0.09528638658035893" LOG_EFFECT_SIZE="-0.042933483268360315" METHOD="MH" MODIFIED="2013-12-18 11:50:55 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.7870400795442084" P_Q="1.0" P_Z="0.10798329971902182" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3943" TOTAL_2="1604" WEIGHT="100.00000000000001" Z="1.6073240568026645">
<NAME>Maternal infection after delivery prior to discharge</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.7529106241982273" CI_START="0.47445145421675067" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.43979211184824923" LOG_CI_START="-0.3238082178928758" LOG_EFFECT_SIZE="0.05799194697768673" ORDER="426" O_E="0.0" SE="0.4485426135725302" STUDY_ID="STD-Garcia_x002d_Burguillo-1995" TOTAL_1="30" TOTAL_2="30" VAR="0.2011904761904762" WEIGHT="1.8802228190453798"/>
<DICH_DATA CI_END="1.0158232503266955" CI_START="0.7884309702159056" EFFECT_SIZE="0.894933802480916" ESTIMABLE="YES" EVENTS_1="686" EVENTS_2="262" LOG_CI_END="0.006818148808614466" LOG_CI_START="-0.10323632461367462" LOG_EFFECT_SIZE="-0.04820908790253008" ORDER="427" O_E="0.0" SE="0.06464654246668212" STUDY_ID="STD-Kenyon-2001" TOTAL_1="3584" TOTAL_2="1225" VAR="0.004179175452896535" WEIGHT="90.51616247548456"/>
<DICH_DATA CI_END="1.4925253513570214" CI_START="0.6130105841064898" EFFECT_SIZE="0.9565217391304348" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="36" LOG_CI_END="0.17392171659266806" LOG_CI_START="-0.2125320269834413" LOG_EFFECT_SIZE="-0.01930515519538663" ORDER="428" O_E="0.0" SE="0.2270048419534894" STUDY_ID="STD-Mercer-1997" TOTAL_1="299" TOTAL_2="312" VAR="0.051531198270328704" WEIGHT="7.340852473942026"/>
<DICH_DATA CI_END="25.9074399882864" CI_START="0.23485317141313153" EFFECT_SIZE="2.466666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.41342450083262" LOG_CI_START="-0.6292035708099926" LOG_EFFECT_SIZE="0.3921104650113138" ORDER="429" O_E="0.0" SE="1.199849840454896" STUDY_ID="STD-Svare-1997a" TOTAL_1="30" TOTAL_2="37" VAR="1.4396396396396396" WEIGHT="0.2627622315280431"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="18.29333349738911" CI_END="0.9586164934539079" CI_START="0.45804403026954676" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6626375797858801" ESTIMABLE="YES" EVENTS_1="126" EVENTS_2="196" I2="45.335277458166736" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="-0.018355103036284126" LOG_CI_START="-0.3390927726860895" LOG_EFFECT_SIZE="-0.1787239378611868" METHOD="MH" MODIFIED="2013-12-18 11:51:44 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.05021260372517666" P_Q="1.0" P_Z="0.028940744026441614" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.14116778775528652" TOTALS="YES" TOTAL_1="767" TOTAL_2="792" WEIGHT="100.0" Z="2.184292738458595">
<NAME>Chorioamnionitis</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0275957437743974" CI_START="0.08186595809568209" EFFECT_SIZE="0.29004329004329005" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.011822296782396333" LOG_CI_START="-1.086896651165032" LOG_EFFECT_SIZE="-0.5375371771913179" ORDER="431" O_E="0.0" SE="0.6453929487708268" STUDY_ID="STD-Ernest-1994" TOTAL_1="77" TOTAL_2="67" VAR="0.4165320583231031" WEIGHT="6.3646513495892165"/>
<DICH_DATA CI_END="27.234348125670902" CI_START="0.33046504210308847" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4351169845729048" LOG_CI_START="-0.4808744751335797" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="432" O_E="0.0" SE="1.1254628677422753" STUDY_ID="STD-Garcia_x002d_Burguillo-1995" TOTAL_1="30" TOTAL_2="30" VAR="1.2666666666666664" WEIGHT="2.5212943658677167"/>
<DICH_DATA CI_END="1.3886816886777527" CI_START="0.1575469166145005" EFFECT_SIZE="0.46774193548387094" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.14260270888143226" LOG_CI_START="-0.802590092080028" LOG_EFFECT_SIZE="-0.3299936915992978" ORDER="433" O_E="0.0" SE="0.5552109300645849" STUDY_ID="STD-Grable-1996" TOTAL_1="31" TOTAL_2="29" VAR="0.30825917686318133" WEIGHT="7.897979777474752"/>
<DICH_DATA CI_END="0.6710135088392308" CI_START="0.06630958739298727" EFFECT_SIZE="0.2109375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="16" LOG_CI_END="-0.1732687365295487" LOG_CI_START="-1.1784236744482133" LOG_EFFECT_SIZE="-0.6758462054888811" ORDER="434" O_E="0.0" SE="0.5904329861306117" STUDY_ID="STD-Johnston-1990" TOTAL_1="40" TOTAL_2="45" VAR="0.3486111111111111" WEIGHT="7.24728053050888"/>
<DICH_DATA CI_END="1.1417405277349535" CI_START="0.018596741155669554" EFFECT_SIZE="0.1457142857142857" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.05756741724027726" LOG_CI_START="-1.730563153744956" LOG_EFFECT_SIZE="-0.8364978682523393" ORDER="435" O_E="0.0" SE="1.0503567487858056" STUDY_ID="STD-Kurki--1992" TOTAL_1="50" TOTAL_2="51" VAR="1.103249299719888" WEIGHT="2.8523917854666494"/>
<DICH_DATA CI_END="2.226342597239382" CI_START="0.5019672272335368" EFFECT_SIZE="1.0571428571428572" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.3475919958666054" LOG_CI_START="-0.29932463643316654" LOG_EFFECT_SIZE="0.02413367971671937" ORDER="436" O_E="0.0" SE="0.3800020321018618" STUDY_ID="STD-Lockwood-1993a" TOTAL_1="35" TOTAL_2="37" VAR="0.1444015444015444" WEIGHT="12.429783867894983"/>
<DICH_DATA CI_END="2.919718668951144" CI_START="0.4334749828669805" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.4653410067880409" LOG_CI_START="-0.3630359618932783" LOG_EFFECT_SIZE="0.05115252244738129" ORDER="437" O_E="0.0" SE="0.4865927319355344" STUDY_ID="STD-McGregor-1991" TOTAL_1="28" TOTAL_2="27" VAR="0.2367724867724868" WEIGHT="9.391867755940039"/>
<DICH_DATA CI_END="1.5326856427239426" CI_START="0.4969400582420458" EFFECT_SIZE="0.8727272727272727" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="22" LOG_CI_END="0.18545308921182282" LOG_CI_START="-0.3036959934491361" LOG_EFFECT_SIZE="-0.05912145211865665" ORDER="438" O_E="0.0" SE="0.2873285924820571" STUDY_ID="STD-Mercer-1992" TOTAL_1="105" TOTAL_2="112" VAR="0.08255772005772005" WEIGHT="15.865714699708294"/>
<DICH_DATA CI_END="0.926224519390331" CI_START="0.548663376291367" EFFECT_SIZE="0.7128712871287128" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="101" LOG_CI_END="-0.033283726370659635" LOG_CI_START="-0.26069402833208866" LOG_EFFECT_SIZE="-0.14698887735137414" ORDER="439" O_E="0.0" SE="0.13358193707129318" STUDY_ID="STD-Mercer-1997" TOTAL_1="299" TOTAL_2="312" VAR="0.01784413391171893" WEIGHT="22.322634937032184"/>
<DICH_DATA CI_END="0.8277931478251346" CI_START="0.045843655534952996" EFFECT_SIZE="0.19480519480519481" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.08207817285438135" LOG_CI_START="-1.3387207593792199" LOG_EFFECT_SIZE="-0.7103994661168006" ORDER="440" O_E="0.0" SE="0.738158075805816" STUDY_ID="STD-Ovalle_x002d_Salas-1997" TOTAL_1="42" TOTAL_2="45" VAR="0.5448773448773448" WEIGHT="5.173952717057274"/>
<DICH_DATA CI_END="4.3788367168456155" CI_START="0.5002241786210972" EFFECT_SIZE="1.48" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.6413587510165002" LOG_CI_START="-0.30083532022658543" LOG_EFFECT_SIZE="0.17026171539495738" ORDER="441" O_E="0.0" SE="0.5534494613840601" STUDY_ID="STD-Svare-1997a" TOTAL_1="30" TOTAL_2="37" VAR="0.30630630630630634" WEIGHT="7.932448213460014"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.131364828339987" CI_END="1.04786129426599" CI_START="0.8813072924175209" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9609827262124323" ESTIMABLE="YES" EVENTS_1="1183" EVENTS_2="564" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="0.02030379875300388" LOG_CI_START="-0.05487263627344842" LOG_EFFECT_SIZE="-0.017284418760222298" METHOD="MH" MODIFIED="2013-12-18 11:52:25 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.7129878921336242" P_Q="1.0" P_Z="0.3674489557539242" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4326" TOTAL_2="1991" WEIGHT="100.00000000000001" Z="0.9012621641828032">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.731686211708216" CI_START="0.4974579814696265" EFFECT_SIZE="0.9281385281385282" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" LOG_CI_END="0.238469198957436" LOG_CI_START="-0.3032435967002598" LOG_EFFECT_SIZE="-0.03238719887141189" ORDER="443" O_E="0.0" SE="0.31820477769091604" STUDY_ID="STD-Ernest-1994" TOTAL_1="77" TOTAL_2="67" VAR="0.1012542805453253" WEIGHT="1.9258624517608465"/>
<DICH_DATA CI_END="2.438041198591854" CI_START="0.2848370424771889" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.38704104015436036" LOG_CI_START="-0.54540353224961" LOG_EFFECT_SIZE="-0.0791812460476248" ORDER="444" O_E="0.0" SE="0.5477225575051662" STUDY_ID="STD-Garcia_x002d_Burguillo-1995" TOTAL_1="30" TOTAL_2="30" VAR="0.30000000000000004" WEIGHT="0.6500060566076692"/>
<DICH_DATA CI_END="6.096013155368681" CI_START="0.7267612258767446" EFFECT_SIZE="2.1048387096774195" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.7850458955523217" LOG_CI_START="-0.13860825120022988" LOG_EFFECT_SIZE="0.3232188221760459" ORDER="445" O_E="0.0" SE="0.5425590179642141" STUDY_ID="STD-Grable-1996" TOTAL_1="31" TOTAL_2="29" VAR="0.2943702879742924" WEIGHT="0.6624371580576449"/>
<DICH_DATA CI_END="4.324724286274782" CI_START="0.6584596060926939" EFFECT_SIZE="1.6875" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.6359584251496695" LOG_CI_START="-0.18147086214354438" LOG_EFFECT_SIZE="0.22724378150306254" ORDER="446" O_E="0.0" SE="0.48016200969626444" STUDY_ID="STD-Johnston-1990" TOTAL_1="40" TOTAL_2="45" VAR="0.23055555555555554" WEIGHT="0.8457910134172083"/>
<DICH_DATA CI_END="1.0331270100184033" CI_START="0.8417128184275411" EFFECT_SIZE="0.9325214460784313" ESTIMABLE="YES" EVENTS_1="974" EVENTS_2="357" LOG_CI_END="0.014153715865603204" LOG_CI_START="-0.07483605891183119" LOG_EFFECT_SIZE="-0.030341171523113997" ORDER="447" O_E="0.0" SE="0.05227303421075447" STUDY_ID="STD-Kenyon-2001" TOTAL_1="3584" TOTAL_2="1225" VAR="0.0027324701055987076" WEIGHT="71.36466619808607"/>
<DICH_DATA CI_END="1.6293955208939057" CI_START="0.4888661100301784" EFFECT_SIZE="0.8925" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="16" LOG_CI_END="0.2120265181279723" LOG_CI_START="-0.3108100685595107" LOG_EFFECT_SIZE="-0.049391775215769214" ORDER="448" O_E="0.0" SE="0.3071167991030717" STUDY_ID="STD-Kurki--1992" TOTAL_1="50" TOTAL_2="51" VAR="0.09432072829131652" WEIGHT="2.067433325790523"/>
<DICH_DATA CI_END="1.9657044258076743" CI_START="0.48230086343663436" EFFECT_SIZE="0.9736842105263158" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.2935182154843338" LOG_CI_START="-0.3166819605839641" LOG_EFFECT_SIZE="-0.011581872549815147" ORDER="449" O_E="0.0" SE="0.35843460396210436" STUDY_ID="STD-Lockwood-1993a" TOTAL_1="38" TOTAL_2="37" VAR="0.12847536531747059" WEIGHT="1.5178148472311341"/>
<DICH_DATA CI_END="2.6406854336333847" CI_START="0.8989643370403431" EFFECT_SIZE="1.5407407407407407" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="18" LOG_CI_END="0.4217166698272001" LOG_CI_START="-0.046257536891689204" LOG_EFFECT_SIZE="0.18772956646775543" ORDER="450" O_E="0.0" SE="0.27489036553635904" STUDY_ID="STD-Mercer-1992" TOTAL_1="105" TOTAL_2="112" VAR="0.07556471306471307" WEIGHT="2.580593627283447"/>
<DICH_DATA CI_END="1.2295739096799339" CI_START="0.7623488024871629" EFFECT_SIZE="0.9681757059614523" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="97" LOG_CI_END="0.08975463929792658" LOG_CI_START="-0.11784627756374023" LOG_EFFECT_SIZE="-0.014045819132906815" ORDER="451" O_E="0.0" SE="0.12194580620565514" STUDY_ID="STD-Mercer-1997" TOTAL_1="299" TOTAL_2="312" VAR="0.0148707796511472" WEIGHT="13.113086304607938"/>
<DICH_DATA CI_END="1.6313772251527043" CI_START="0.666935890814842" EFFECT_SIZE="1.0430839002267573" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="21" LOG_CI_END="0.21255439504387394" LOG_CI_START="-0.17591591061640288" LOG_EFFECT_SIZE="0.01831924221373553" ORDER="452" O_E="0.0" SE="0.22818938050387272" STUDY_ID="STD-Ovalle_x002d_Salas-1997" TOTAL_1="42" TOTAL_2="46" VAR="0.0520703933747412" WEIGHT="3.744965312224702"/>
<DICH_DATA CI_END="1.7199922483900623" CI_START="0.42387008146128236" EFFECT_SIZE="0.8538461538461538" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" LOG_CI_END="0.23552648964649786" LOG_CI_START="-0.3727672366868565" LOG_EFFECT_SIZE="-0.06862037352017936" ORDER="453" O_E="0.0" SE="0.35731474595072016" STUDY_ID="STD-Svare-1997a" TOTAL_1="30" TOTAL_2="37" VAR="0.12767382767382768" WEIGHT="1.5273437049328387"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.13" MODIFIED="2013-12-18 11:53:00 +0000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Days from birth till discharge of mother</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.14" MODIFIED="2013-12-18 11:53:57 +0000" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Days from randomisation to birth</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antibiotic</GRAPH_LABEL_2>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="12.113332559451873" CI_END="0.8691880777071161" CI_START="0.5811197247034802" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7107055201929322" ESTIMABLE="YES" EVENTS_1="1296" EVENTS_2="717" I2="50.46780090819615" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="-0.060886239348201636" LOG_CI_START="-0.23573438323530127" LOG_EFFECT_SIZE="-0.14831031129175148" METHOD="MH" MODIFIED="2013-12-18 11:54:49 +0000" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.05948775756193325" P_Q="1.0" P_Z="8.842640906603628E-4" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.02716114700765411" TOTALS="YES" TOTAL_1="4128" TOTAL_2="1799" WEIGHT="99.99999999999999" Z="3.32497517223234">
<NAME>Birth within 48 hours of randomisation</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7455908782585894" CI_START="0.07335876973213135" EFFECT_SIZE="0.23387096774193547" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" LOG_CI_END="-0.12749941388663003" LOG_CI_START="-1.1345479606399278" LOG_EFFECT_SIZE="-0.631023687263279" ORDER="454" O_E="0.0" SE="0.5915453013335902" STUDY_ID="STD-Grable-1996" TOTAL_1="31" TOTAL_2="29" VAR="0.34992584352984796" WEIGHT="2.7974073218358053"/>
<DICH_DATA CI_END="1.4914368335514987" CI_START="0.02357206769279248" EFFECT_SIZE="0.1875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.17360486452279125" LOG_CI_START="-1.627602320395316" LOG_EFFECT_SIZE="-0.7269987279362623" ORDER="455" O_E="0.0" SE="1.0580380165402588" STUDY_ID="STD-Johnston-1990" TOTAL_1="40" TOTAL_2="45" VAR="1.1194444444444447" WEIGHT="0.9199902007827476"/>
<DICH_DATA CI_END="0.8595678989526456" CI_START="0.7285442188758309" EFFECT_SIZE="0.7913489897088354" ESTIMABLE="YES" EVENTS_1="1153" EVENTS_2="498" LOG_CI_END="-0.06571981184979983" LOG_CI_START="-0.13754408365930987" LOG_EFFECT_SIZE="-0.10163194775455481" ORDER="456" O_E="0.0" SE="0.042189932796785644" STUDY_ID="STD-Kenyon-2001" TOTAL_1="3584" TOTAL_2="1225" VAR="0.0017799904293972887" WEIGHT="36.44866794171549"/>
<DICH_DATA CI_END="0.82270677989507" CI_START="0.28809199249250533" EFFECT_SIZE="0.4868421052631579" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="24" LOG_CI_END="-0.08475492367486294" LOG_CI_START="-0.5404688127527297" LOG_EFFECT_SIZE="-0.31261186821379633" ORDER="457" O_E="0.0" SE="0.26768859426447134" STUDY_ID="STD-Lockwood-1993a" TOTAL_1="38" TOTAL_2="37" VAR="0.07165718349928876" WEIGHT="10.674799937290212"/>
<DICH_DATA CI_END="0.9597055618474344" CI_START="0.5078245557039653" EFFECT_SIZE="0.6981132075471698" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="57" LOG_CI_END="-0.01786198829235364" LOG_CI_START="-0.29428630277523443" LOG_EFFECT_SIZE="-0.1560741455337941" ORDER="458" O_E="0.0" SE="0.16237301064966891" STUDY_ID="STD-Mercer-1992" TOTAL_1="106" TOTAL_2="114" VAR="0.02636499458743749" WEIGHT="19.70749015085686"/>
<DICH_DATA CI_END="0.9497262331270379" CI_START="0.5931798356176259" EFFECT_SIZE="0.7505720823798627" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="114" LOG_CI_END="-0.022401565844766266" LOG_CI_START="-0.2268136206727193" LOG_EFFECT_SIZE="-0.12460759325874275" ORDER="459" O_E="0.0" SE="0.12007265286192997" STUDY_ID="STD-Mercer-1997" TOTAL_1="299" TOTAL_2="312" VAR="0.01441744196530154" WEIGHT="25.370411414989665"/>
<DICH_DATA CI_END="4.220838653339612" CI_START="0.6406777782715247" EFFECT_SIZE="1.6444444444444444" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.6253987510400856" LOG_CI_START="-0.1933603391288206" LOG_EFFECT_SIZE="0.21601920595563248" ORDER="460" O_E="0.0" SE="0.4809431424880765" STUDY_ID="STD-Svare-1997a" TOTAL_1="30" TOTAL_2="37" VAR="0.23130630630630628" WEIGHT="4.081233032529213"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="16.937721477029434" CI_END="0.8887945179629707" CI_START="0.7074606893964002" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7929610219990794" ESTIMABLE="YES" EVENTS_1="2388" EVENTS_2="1221" I2="64.57610896402406" I2_Q="0.0" ID="CMP-001.16" LOG_CI_END="-0.05119863276405398" LOG_CI_START="-0.15029768704400417" LOG_EFFECT_SIZE="-0.10074815990402908" METHOD="MH" MODIFIED="2013-12-18 11:55:25 +0000" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.009514899496947948" P_Q="1.0" P_Z="6.743483565802412E-5" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.011703875470525118" TOTALS="YES" TOTAL_1="4145" TOTAL_2="1820" WEIGHT="100.0" Z="3.9851594216581785">
<NAME>Birth within 7 days of randomisation</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.023061188172243" CI_START="0.4201037403041641" EFFECT_SIZE="0.6555851063829787" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="32" LOG_CI_END="0.009901609167561368" LOG_CI_START="-0.37664345179638586" LOG_EFFECT_SIZE="-0.1833709213144122" MODIFIED="2009-05-11 12:05:30 +0100" MODIFIED_BY="[Empty name]" ORDER="324" O_E="0.0" SE="0.22705848223913377" STUDY_ID="STD-Fuhr-2006" TOTAL_1="47" TOTAL_2="58" VAR="0.051555554356739024" WEIGHT="5.356596716308827"/>
<DICH_DATA CI_END="1.1191038324373466" CI_START="0.5124617772437465" EFFECT_SIZE="0.7572964669738863" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="21" LOG_CI_END="0.048870383009649056" LOG_CI_START="-0.2903385215915729" LOG_EFFECT_SIZE="-0.12073406929096195" ORDER="461" O_E="0.0" SE="0.1992529896739159" STUDY_ID="STD-Grable-1996" TOTAL_1="31" TOTAL_2="29" VAR="0.039701753893993635" WEIGHT="6.591792733154956"/>
<DICH_DATA CI_END="0.913390649903398" CI_START="0.4898807756954582" EFFECT_SIZE="0.668918918918919" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="37" LOG_CI_END="-0.039343438444086595" LOG_CI_START="-0.3099096031507283" LOG_EFFECT_SIZE="-0.17462652079740743" ORDER="462" O_E="0.0" SE="0.15893190447279695" STUDY_ID="STD-Johnston-1990" TOTAL_1="40" TOTAL_2="45" VAR="0.02525935025935026" WEIGHT="9.167361543730568"/>
<DICH_DATA CI_END="0.9593639984700499" CI_START="0.866224188359081" EFFECT_SIZE="0.9116053427419355" ESTIMABLE="YES" EVENTS_1="2067" EVENTS_2="775" LOG_CI_END="-0.018016583096681773" LOG_CI_START="-0.062369693240434954" LOG_EFFECT_SIZE="-0.040193138168558344" ORDER="463" O_E="0.0" SE="0.026053236449876713" STUDY_ID="STD-Kenyon-2001" TOTAL_1="3584" TOTAL_2="1225" VAR="6.787711295131846E-4" WEIGHT="27.36533352144957"/>
<DICH_DATA CI_END="0.8704924596406104" CI_START="0.48404832681066234" EFFECT_SIZE="0.6491228070175439" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="33" LOG_CI_END="-0.060234986465843104" LOG_CI_START="-0.3151112767451497" LOG_EFFECT_SIZE="-0.1876731316054964" ORDER="464" O_E="0.0" SE="0.14971559456804934" STUDY_ID="STD-Lockwood-1993a" TOTAL_1="38" TOTAL_2="37" VAR="0.022414759256864522" WEIGHT="9.931676832785653"/>
<DICH_DATA CI_END="1.0177110916291128" CI_START="0.7626042258931054" EFFECT_SIZE="0.8809714973906062" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="94" LOG_CI_END="0.007624507746320926" LOG_CI_START="-0.11770079245734982" LOG_EFFECT_SIZE="-0.05503814235551442" ORDER="465" O_E="0.0" SE="0.0736167017098774" STUDY_ID="STD-Mercer-1992" TOTAL_1="106" TOTAL_2="114" VAR="0.005419418770641065" WEIGHT="19.789139245978056"/>
<DICH_DATA CI_END="0.8541063709440947" CI_START="0.669884704160039" EFFECT_SIZE="0.7564078222897285" ESTIMABLE="YES" EVENTS_1="166" EVENTS_2="229" LOG_CI_END="-0.06848803863502685" LOG_CI_START="-0.17399993857661272" LOG_EFFECT_SIZE="-0.12124398860581977" ORDER="466" O_E="0.0" SE="0.061978212318015674" STUDY_ID="STD-Mercer-1997" TOTAL_1="299" TOTAL_2="312" VAR="0.0038412988021370295" WEIGHT="21.798099406592367"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="12.615000512293548" CI_END="100.59652418322881" CI_START="7.06056870645574" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="MD" EFFECT_SIZE="53.828546444842274" ESTIMABLE="YES" I2="12.802223120955887" I2_Q="0.0" ID="CMP-001.17" MODIFIED="2013-12-18 11:56:21 +0000" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.3192315332994182" P_Q="1.0" P_Z="0.02407939746368112" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="845.1330214975691" TOTALS="YES" TOTAL_1="4355" TOTAL_2="2019" UNITS="" WEIGHT="100.00000000000001" Z="2.2558600451401984">
<NAME>Birthweight</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antibiotic</GRAPH_LABEL_2>
<CONT_DATA CI_END="181.61110733350299" CI_START="-227.61110733350299" EFFECT_SIZE="-23.0" ESTIMABLE="YES" MEAN_1="1282.0" MEAN_2="1305.0" ORDER="471" SD_1="409.0" SD_2="413.0" SE="104.39534039780796" STUDY_ID="STD-Cox-1995" TOTAL_1="31" TOTAL_2="31" WEIGHT="4.84844757892065"/>
<CONT_DATA CI_END="299.6972998949828" CI_START="-123.69729989498279" EFFECT_SIZE="88.0" ESTIMABLE="YES" MEAN_1="1896.0" MEAN_2="1808.0" ORDER="472" SD_1="556.0" SD_2="716.0" SE="108.01081120103434" STUDY_ID="STD-Ernest-1994" TOTAL_1="77" TOTAL_2="67" WEIGHT="4.550852070846675"/>
<CONT_DATA CI_END="211.26182429010055" CI_START="-507.26182429010055" EFFECT_SIZE="-148.0" ESTIMABLE="YES" MEAN_1="2022.0" MEAN_2="2170.0" ORDER="473" SD_1="607.0" SD_2="799.7" SE="183.3002173121098" STUDY_ID="STD-Garcia_x002d_Burguillo-1995" TOTAL_1="30" TOTAL_2="30" WEIGHT="1.653050514943616"/>
<CONT_DATA CI_END="563.9502946342438" CI_START="56.049705365756154" EFFECT_SIZE="310.0" ESTIMABLE="YES" MEAN_1="1897.0" MEAN_2="1587.0" ORDER="474" SD_1="600.0" SD_2="592.0" SE="129.56885771237194" STUDY_ID="STD-Johnston-1990" TOTAL_1="40" TOTAL_2="45" WEIGHT="3.229009535228654"/>
<CONT_DATA CI_END="80.80026204644525" CI_START="-18.800262046445248" EFFECT_SIZE="31.0" ESTIMABLE="YES" MEAN_1="2103.0" MEAN_2="2072.0" ORDER="475" SD_1="764.0" SD_2="769.0" SE="25.408763854470468" STUDY_ID="STD-Kenyon-2001" TOTAL_1="3584" TOTAL_2="1225" WEIGHT="38.19439106438576"/>
<CONT_DATA CI_END="212.15960371129577" CI_START="-144.15960371129577" EFFECT_SIZE="34.0" ESTIMABLE="YES" MEAN_1="2124.0" MEAN_2="2090.0" ORDER="476" SD_1="390.0" SD_2="516.0" SE="90.89942729386661" STUDY_ID="STD-Kurki--1992" TOTAL_1="50" TOTAL_2="51" WEIGHT="6.2515205073916205"/>
<CONT_DATA CI_END="445.42312267745996" CI_START="-165.42312267745996" EFFECT_SIZE="140.0" ESTIMABLE="YES" MEAN_1="1837.0" MEAN_2="1697.0" ORDER="477" SD_1="759.0" SD_2="581.0" SE="155.8309872459895" STUDY_ID="STD-Lockwood-1993a" TOTAL_1="38" TOTAL_2="37" WEIGHT="2.265873457858933"/>
<CONT_DATA CI_END="155.3678147471211" CI_START="-361.16781474712127" EFFECT_SIZE="-102.90000000000009" ESTIMABLE="YES" MEAN_1="1638.5" MEAN_2="1741.4" ORDER="478" SD_1="530.8" SD_2="444.0" SE="131.7717145745048" STUDY_ID="STD-McGregor-1991" TOTAL_1="28" TOTAL_2="27" WEIGHT="3.1269206859366614"/>
<CONT_DATA CI_END="124.66440397652747" CI_START="-216.66440397652747" EFFECT_SIZE="-46.0" ESTIMABLE="YES" MEAN_1="1771.0" MEAN_2="1817.0" ORDER="479" SD_1="653.0" SD_2="637.0" SE="87.07527552684972" STUDY_ID="STD-Mercer-1992" TOTAL_1="106" TOTAL_2="114" WEIGHT="6.756407134175423"/>
<CONT_DATA CI_END="171.69236848294017" CI_START="12.307631517059832" EFFECT_SIZE="92.0" ESTIMABLE="YES" MEAN_1="1549.0" MEAN_2="1457.0" ORDER="480" SD_1="497.0" SD_2="508.0" SE="40.66011881419424" STUDY_ID="STD-Mercer-1997" TOTAL_1="299" TOTAL_2="312" WEIGHT="22.789920190183153"/>
<CONT_DATA CI_END="412.5809355588439" CI_START="-4.580935558843919" EFFECT_SIZE="204.0" ESTIMABLE="YES" MEAN_1="1849.0" MEAN_2="1645.0" ORDER="481" SD_1="458.4" SD_2="521.4" SE="106.42080018005622" STUDY_ID="STD-Ovalle_x002d_Salas-1997" TOTAL_1="42" TOTAL_2="43" WEIGHT="4.678341018878343"/>
<CONT_DATA CI_END="483.01523891493207" CI_START="-235.01523891493207" EFFECT_SIZE="124.0" ESTIMABLE="YES" MEAN_1="1962.0" MEAN_2="1838.0" ORDER="482" SD_1="712.0" SD_2="785.0" SE="183.17440613541802" STUDY_ID="STD-Svare-1997a" TOTAL_1="30" TOTAL_2="37" WEIGHT="1.655266241250517"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.17000010708056706" CI_END="1.041774027410889" CI_START="0.9617860560158115" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0009813849833706" ESTIMABLE="YES" EVENTS_1="2605" EVENTS_2="911" I2="0.0" I2_Q="0.0" ID="CMP-001.18" LOG_CI_END="0.017773525785544905" LOG_CI_START="-0.016921523622460147" LOG_EFFECT_SIZE="4.2600108154237476E-4" METHOD="MH" MODIFIED="2013-12-18 11:57:51 +0000" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.6801119837588957" P_Q="1.0" P_Z="0.9616121589677639" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3614" TOTAL_2="1262" WEIGHT="100.0" Z="0.04813060026976156">
<NAME>Birthweight &lt; 2500 g</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0439814887124126" CI_START="0.9626181415124743" EFFECT_SIZE="1.0024746981534092" ESTIMABLE="YES" EVENTS_1="2581" EVENTS_2="880" LOG_CI_END="0.018692798071103203" LOG_CI_START="-0.016545957862775316" LOG_EFFECT_SIZE="0.001073420104163964" ORDER="483" O_E="0.0" SE="0.020699419670215366" STUDY_ID="STD-Kenyon-2001" TOTAL_1="3584" TOTAL_2="1225" VAR="4.284659746836988E-4" WEIGHT="96.93796203803424"/>
<DICH_DATA CI_END="1.1996821813768632" CI_START="0.7599654105490429" EFFECT_SIZE="0.9548387096774194" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="31" LOG_CI_END="0.07906620841793152" LOG_CI_START="-0.11920617396859969" LOG_EFFECT_SIZE="-0.0200699827753341" ORDER="484" O_E="0.0" SE="0.11646617887797009" STUDY_ID="STD-Svare-1997a" TOTAL_1="30" TOTAL_2="37" VAR="0.013564370822435327" WEIGHT="3.0620379619657636"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="13.437761678257315" CI_END="1.131083912390881" CI_START="0.8425746496465868" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9762287801553676" ESTIMABLE="YES" EVENTS_1="2583" EVENTS_2="975" I2="77.67485335854641" I2_Q="0.0" ID="CMP-001.19" LOG_CI_END="0.05349482538212357" LOG_CI_START="-0.07439161153271771" LOG_EFFECT_SIZE="-0.010448393075297083" METHOD="MH" MODIFIED="2013-12-18 11:58:26 +0000" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.003779510477294412" P_Q="1.0" P_Z="0.7487710183804199" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.015595885502290865" TOTALS="YES" TOTAL_1="3687" TOTAL_2="1336" WEIGHT="100.0" Z="0.3202602968372078">
<NAME>Neonatal intensive care</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2574807332542237" CI_START="0.9714714634538064" EFFECT_SIZE="1.105263157894737" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="28" LOG_CI_END="0.0995013396480634" LOG_CI_START="-0.012569952085882678" LOG_EFFECT_SIZE="0.043465693781090345" ORDER="485" O_E="0.0" SE="0.06583123152636107" STUDY_ID="STD-Cox-1995" TOTAL_1="31" TOTAL_2="31" VAR="0.004333751044277356" WEIGHT="28.315536874551697"/>
<DICH_DATA CI_END="1.0126091846279848" CI_START="0.932617541094159" EFFECT_SIZE="0.9717906605113636" ESTIMABLE="YES" EVENTS_1="2502" EVENTS_2="880" LOG_CI_END="0.00544186223229773" LOG_CI_START="-0.030296420396905333" LOG_EFFECT_SIZE="-0.012427279082303788" ORDER="486" O_E="0.0" SE="0.020992844123746024" STUDY_ID="STD-Kenyon-2001" TOTAL_1="3584" TOTAL_2="1225" VAR="4.406995044038979E-4" WEIGHT="35.18943455200598"/>
<DICH_DATA CI_END="0.859142451953696" CI_START="0.4714388572082176" EFFECT_SIZE="0.6364221364221364" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="37" LOG_CI_END="-0.06593482107187454" LOG_CI_START="-0.3265746246635576" LOG_EFFECT_SIZE="-0.19625472286771606" ORDER="487" O_E="0.0" SE="0.15310111081759029" STUDY_ID="STD-Ovalle_x002d_Salas-1997" TOTAL_1="42" TOTAL_2="43" VAR="0.023439950133580065" WEIGHT="14.45641804097055"/>
<DICH_DATA CI_END="1.3504724383142004" CI_START="0.9123473867693553" EFFECT_SIZE="1.11" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="30" LOG_CI_END="0.13048572513198495" LOG_CI_START="-0.03983976755867004" LOG_EFFECT_SIZE="0.045322978786657475" ORDER="488" O_E="0.0" SE="0.10005003753127732" STUDY_ID="STD-Svare-1997a" TOTAL_1="30" TOTAL_2="37" VAR="0.01001001001001" WEIGHT="22.038610532471775"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.9095522630202603" CI_END="-0.3265795290154543" CI_START="-9.766476092956577" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.046527810986015" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.20" MODIFIED="2013-12-18 11:58:56 +0000" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.6345900470778706" P_Q="1.0" P_Z="0.0361197746351294" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="110" TOTAL_2="115" UNITS="" WEIGHT="100.0" Z="2.095576511779677">
<NAME>Days in neonatal intensive care unit</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="13.334135408294083" CI_START="-12.334135408294083" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="12.3" MEAN_2="11.8" ORDER="489" SD_1="35.9" SD_2="21.9" SE="6.548148593304829" STUDY_ID="STD-Johnston-1990" TOTAL_1="40" TOTAL_2="45" WEIGHT="13.525123698467226"/>
<CONT_DATA CI_END="3.1208524370454107" CI_START="-13.12085243704541" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="9.5" MEAN_2="14.5" ORDER="490" SD_1="10.5" SD_2="18.9" SE="4.1433681950799395" STUDY_ID="STD-McGregor-1991" TOTAL_1="28" TOTAL_2="27" WEIGHT="33.780902008085185"/>
<CONT_DATA CI_END="0.002146679144448882" CI_START="-13.002146679144447" EFFECT_SIZE="-6.499999999999999" ESTIMABLE="YES" MEAN_1="6.7" MEAN_2="13.2" ORDER="491" SD_1="9.12" SD_2="19.7" SE="3.3174827345974474" STUDY_ID="STD-Ovalle_x002d_Salas-1997" TOTAL_1="42" TOTAL_2="43" WEIGHT="52.69397429344759"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.7219640020224822" CI_END="0.9866195677113485" CI_START="0.6309764368712083" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7890080477295011" ESTIMABLE="YES" EVENTS_1="234" EVENTS_2="104" I2="0.0" I2_Q="0.0" ID="CMP-001.21" LOG_CI_END="-0.00585027538838263" LOG_CI_START="-0.1999868587081393" LOG_EFFECT_SIZE="-0.10291856704826093" METHOD="MH" MODIFIED="2013-12-18 11:59:25 +0000" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.6969916591461058" P_Q="1.0" P_Z="0.03770103397098213" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3654" TOTAL_2="1307" WEIGHT="100.00000000000001" Z="2.0780903970357882">
<NAME>Positive neonatal blood culture</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.538845420772668" CI_START="0.01109334575003539" EFFECT_SIZE="0.22439024390243903" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6569453922496556" LOG_CI_START="-1.9549374509980162" LOG_EFFECT_SIZE="-0.6489960293741802" ORDER="504" O_E="0.0" SE="1.534232911152273" STUDY_ID="STD-Johnston-1990" TOTAL_1="40" TOTAL_2="45" VAR="2.353870625662778" WEIGHT="0.5524683191757099"/>
<DICH_DATA CI_END="0.9974856543050211" CI_START="0.6358305034905793" EFFECT_SIZE="0.79638671875" ESTIMABLE="YES" EVENTS_1="233" EVENTS_2="100" LOG_CI_END="-0.001093341556973062" LOG_CI_START="-0.19665864097006167" LOG_EFFECT_SIZE="-0.09887599126351734" ORDER="505" O_E="0.0" SE="0.11487602493909306" STUDY_ID="STD-Kenyon-2001" TOTAL_1="3584" TOTAL_2="1225" VAR="0.01319650110580713" WEIGHT="98.54422302474804"/>
<DICH_DATA CI_END="6.476859997071601" CI_START="0.058713292853282896" EFFECT_SIZE="0.6166666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.8113645095046578" LOG_CI_START="-1.2312635621379548" LOG_EFFECT_SIZE="-0.20994952631664862" ORDER="506" O_E="0.0" SE="1.199849840454896" STUDY_ID="STD-Svare-1997a" TOTAL_1="30" TOTAL_2="37" VAR="1.4396396396396396" WEIGHT="0.9033086560762584"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.148856765179904" CI_END="1.0861513108645118" CI_START="0.830724260235091" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9498906485597677" ESTIMABLE="YES" EVENTS_1="965" EVENTS_2="551" I2="27.387259840730515" I2_Q="0.0" ID="CMP-001.22" LOG_CI_END="0.03589033068197305" LOG_CI_START="-0.08054310633699999" LOG_EFFECT_SIZE="-0.022326387827513443" METHOD="MH" MODIFIED="2013-12-18 12:00:13 +0000" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="0.175783196315354" P_Q="1.0" P_Z="0.4522582702830412" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.012056905012704835" TOTALS="YES" TOTAL_1="4303" TOTAL_2="1984" WEIGHT="100.0" Z="0.7516554894736858">
<NAME>Neonatal respiratory distress syndrome</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6980207831168692" CI_START="0.9735223743583716" EFFECT_SIZE="1.2857142857142858" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="21" LOG_CI_END="0.22994300153675337" LOG_CI_START="-0.011654062686617218" LOG_EFFECT_SIZE="0.10914446942506807" ORDER="517" O_E="0.0" SE="0.14191531144956343" STUDY_ID="STD-Cox-1995" TOTAL_1="31" TOTAL_2="31" VAR="0.02013995562382659" WEIGHT="14.528377357009841"/>
<DICH_DATA CI_END="1.8670463907471972" CI_START="0.330305550662901" EFFECT_SIZE="0.7852998065764023" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.2711551090552467" LOG_CI_START="-0.48108412808874357" LOG_EFFECT_SIZE="-0.1049645095167484" MODIFIED="2009-05-11 12:08:50 +0100" MODIFIED_BY="[Empty name]" ORDER="327" O_E="0.0" SE="0.44186905154265793" STUDY_ID="STD-Fuhr-2006" TOTAL_1="47" TOTAL_2="58" VAR="0.19524825871120807" WEIGHT="2.256423007685201"/>
<DICH_DATA CI_END="3.0649506760372986" CI_START="0.4440890751530474" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.4864234898504567" LOG_CI_START="-0.3525299105892302" LOG_EFFECT_SIZE="0.06694678963061322" ORDER="518" O_E="0.0" SE="0.49280538030458115" STUDY_ID="STD-Garcia_x002d_Burguillo-1995" TOTAL_1="30" TOTAL_2="30" VAR="0.24285714285714288" WEIGHT="1.835003386229285"/>
<DICH_DATA CI_END="1.5345338312228851" CI_START="0.2534624464619304" EFFECT_SIZE="0.6236559139784946" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.18597646758143008" LOG_CI_START="-0.5960863775634258" LOG_EFFECT_SIZE="-0.20505495499099782" ORDER="519" O_E="0.0" SE="0.4593875865116069" STUDY_ID="STD-Grable-1996" TOTAL_1="31" TOTAL_2="29" VAR="0.21103695464095912" WEIGHT="2.096732477374136"/>
<DICH_DATA CI_END="1.5076788458484707" CI_START="0.2497545069453768" EFFECT_SIZE="0.6136363636363636" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="0.1783088413150607" LOG_CI_START="-0.6024866659694609" LOG_EFFECT_SIZE="-0.21208891232720012" ORDER="520" O_E="0.0" SE="0.45864314597902295" STUDY_ID="STD-Johnston-1990" TOTAL_1="40" TOTAL_2="45" VAR="0.21035353535353535" WEIGHT="2.10317528380555"/>
<DICH_DATA CI_END="1.0466899795905198" CI_START="0.8154786896892385" EFFECT_SIZE="0.9238795230263158" ESTIMABLE="YES" EVENTS_1="719" EVENTS_2="266" LOG_CI_END="0.019818066501417635" LOG_CI_START="-0.08858738357685896" LOG_EFFECT_SIZE="-0.034384658537720686" ORDER="521" O_E="0.0" SE="0.063677897991612" STUDY_ID="STD-Kenyon-2001" TOTAL_1="3584" TOTAL_2="1225" VAR="0.004054874692630144" WEIGHT="29.032679790408004"/>
<DICH_DATA CI_END="1.5930568013566746" CI_START="0.7428430426485144" EFFECT_SIZE="1.087837837837838" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="20" LOG_CI_END="0.20223126109678632" LOG_CI_START="-0.12910293982300158" LOG_EFFECT_SIZE="0.036564160636892364" ORDER="522" O_E="0.0" SE="0.19462734975102966" STUDY_ID="STD-Lockwood-1993a" TOTAL_1="37" TOTAL_2="35" VAR="0.03787980527110962" WEIGHT="9.367219794416416"/>
<DICH_DATA CI_END="1.5218025906039165" CI_START="0.6075401755301573" EFFECT_SIZE="0.9615384615384616" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" LOG_CI_END="0.18235831907589287" LOG_CI_START="-0.21642499767345358" LOG_EFFECT_SIZE="-0.017033339298780342" ORDER="523" O_E="0.0" SE="0.23424729426782046" STUDY_ID="STD-McGregor-1991" TOTAL_1="26" TOTAL_2="25" VAR="0.05487179487179487" WEIGHT="6.9890516601371635"/>
<DICH_DATA CI_END="1.9593662286597646" CI_START="0.7471149015436905" EFFECT_SIZE="1.2099056603773586" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="24" LOG_CI_END="0.2921156183433134" LOG_CI_START="-0.12661260130514598" LOG_EFFECT_SIZE="0.08275150851908368" ORDER="524" O_E="0.0" SE="0.24596302895962097" STUDY_ID="STD-Mercer-1992" TOTAL_1="106" TOTAL_2="114" VAR="0.06049781161499135" WEIGHT="6.447108648206399"/>
<DICH_DATA CI_END="0.9929888497185819" CI_START="0.69487390760916" EFFECT_SIZE="0.8306636155606407" ESTIMABLE="YES" EVENTS_1="121" EVENTS_2="152" LOG_CI_END="-0.0030556281741855" LOG_CI_START="-0.1580939956944331" LOG_EFFECT_SIZE="-0.08057481193430932" ORDER="525" O_E="0.0" SE="0.09107030453368997" STUDY_ID="STD-Mercer-1997" TOTAL_1="299" TOTAL_2="312" VAR="0.008293800367859032" WEIGHT="22.985352708478153"/>
<DICH_DATA CI_END="0.8884538786364168" CI_START="0.11169576855163808" EFFECT_SIZE="0.315018315018315" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="-0.05136511234218862" LOG_CI_START="-0.951963279252188" LOG_EFFECT_SIZE="-0.5016641957971884" ORDER="526" O_E="0.0" SE="0.5290158212757581" STUDY_ID="STD-Ovalle_x002d_Salas-1997" TOTAL_1="42" TOTAL_2="43" VAR="0.2798577391600648" WEIGHT="1.6024140973268068"/>
<DICH_DATA CI_END="5.673803374664507" CI_START="0.26809373019576216" EFFECT_SIZE="1.2333333333333334" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7538742812698723" LOG_CI_START="-0.5717133425752071" LOG_EFFECT_SIZE="0.09108046934733258" ORDER="527" O_E="0.0" SE="0.7786567320111645" STUDY_ID="STD-Svare-1997a" TOTAL_1="30" TOTAL_2="37" VAR="0.6063063063063063" WEIGHT="0.7564617889230555"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9570308562702048" CI_START="0.7172362903459559" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8285030241935484" ESTIMABLE="YES" EVENTS_1="526" EVENTS_2="217" I2="0.0" I2_Q="0.0" ID="CMP-001.23" LOG_CI_END="-0.019074059619343317" LOG_CI_START="-0.1443377443493102" LOG_EFFECT_SIZE="-0.08170590198432677" METHOD="MH" MODIFIED="2013-12-18 12:00:54 +0000" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="1.0" P_Q="1.0" P_Z="0.010562281862539057" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3584" TOTAL_2="1225" WEIGHT="99.99999999999999" Z="2.556856371563045">
<NAME>Treatment with surfactant</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9570308562702048" CI_START="0.7172362903459559" EFFECT_SIZE="0.8285030241935484" ESTIMABLE="YES" EVENTS_1="526" EVENTS_2="217" LOG_CI_END="-0.019074059619343317" LOG_CI_START="-0.1443377443493102" LOG_EFFECT_SIZE="-0.08170590198432677" ORDER="528" O_E="0.0" SE="0.07358050847562227" STUDY_ID="STD-Kenyon-2001" TOTAL_1="3584" TOTAL_2="1225" VAR="0.00541409122753112" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.0215697398003618E-7" CI_END="1.01921612318684" CI_START="0.8028942390943453" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9046119354169424" ESTIMABLE="YES" EVENTS_1="757" EVENTS_2="292" I2="0.0" I2_Q="0.0" ID="CMP-001.24" LOG_CI_END="0.008266285238224091" LOG_CI_START="-0.09534165821165505" LOG_EFFECT_SIZE="-0.04353768648671548" METHOD="MH" MODIFIED="2013-12-18 12:01:28 +0000" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="0.9997449801127811" P_Q="1.0" P_Z="0.099513789541377" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3641" TOTAL_2="1283" WEIGHT="100.0" Z="1.6472153513101717">
<NAME>Number of babies requiring ventilation</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.020353490253657" CI_START="0.8020035402771604" EFFECT_SIZE="0.9046143440812721" ESTIMABLE="YES" EVENTS_1="749" EVENTS_2="283" LOG_CI_END="0.008750654380580602" LOG_CI_START="-0.09582371460930082" LOG_EFFECT_SIZE="-0.043536530114360095" ORDER="529" O_E="0.0" SE="0.06142750199613144" STUDY_ID="STD-Kenyon-2001" TOTAL_1="3584" TOTAL_2="1225" VAR="0.003773338001484732" WEIGHT="98.16023767294494"/>
<DICH_DATA CI_END="2.1793612741726296" CI_START="0.3753807531983915" EFFECT_SIZE="0.9044834307992202" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.338329229500157" LOG_CI_START="-0.42552799861402785" LOG_EFFECT_SIZE="-0.043599384556935426" ORDER="530" O_E="0.0" SE="0.448693516948533" STUDY_ID="STD-Kurki--1992" TOTAL_1="57" TOTAL_2="58" VAR="0.20132587215164346" WEIGHT="1.8397623270550567"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9645423341127632" CI_START="0.8063933692601943" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8819300100344036" ESTIMABLE="YES" EVENTS_1="1125" EVENTS_2="436" I2="0.0" I2_Q="0.0" ID="CMP-001.25" LOG_CI_END="-0.015678706259504734" LOG_CI_START="-0.09345305196197744" LOG_EFFECT_SIZE="-0.054565879110741074" METHOD="MH" MODIFIED="2013-12-18 12:01:56 +0000" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="1.0" P_Q="1.0" P_Z="0.005956051280175306" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3584" TOTAL_2="1225" WEIGHT="100.0" Z="2.750191129886132">
<NAME>Number of babies requiring oxygen therapy</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9645423341127632" CI_START="0.8063933692601943" EFFECT_SIZE="0.8819300100344036" ESTIMABLE="YES" EVENTS_1="1125" EVENTS_2="436" LOG_CI_END="-0.015678706259504734" LOG_CI_START="-0.09345305196197744" LOG_EFFECT_SIZE="-0.054565879110741074" ORDER="531" O_E="0.0" SE="0.045685035654852706" STUDY_ID="STD-Kenyon-2001" TOTAL_1="3584" TOTAL_2="1225" VAR="0.002087122482785163" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.768194470309477" CI_END="1.0299925879609073" CI_START="0.606786736338875" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.790560459991537" ESTIMABLE="YES" EVENTS_1="338" EVENTS_2="179" I2="27.75074072825508" I2_Q="0.0" ID="CMP-001.26" LOG_CI_END="0.012834099443754828" LOG_CI_START="-0.21696392096011446" LOG_EFFECT_SIZE="-0.10206491075817983" METHOD="MH" MODIFIED="2013-12-18 12:02:26 +0000" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="0.2505501384286507" P_Q="1.0" P_Z="0.08167690831427642" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.017320247549578623" TOTALS="YES" TOTAL_1="3913" TOTAL_2="1574" WEIGHT="99.99999999999999" Z="1.7410380543727157">
<NAME>Neonatal oxygenation &gt; 28 days</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1012721174874944" CI_START="0.729750171460352" EFFECT_SIZE="0.8964672423245614" ESTIMABLE="YES" EVENTS_1="299" EVENTS_2="114" LOG_CI_END="0.041894643695986555" LOG_CI_START="-0.13682579429914501" LOG_EFFECT_SIZE="-0.04746557530157925" ORDER="533" O_E="0.0" SE="0.10498126995877632" STUDY_ID="STD-Kenyon-2001" TOTAL_1="3584" TOTAL_2="1225" VAR="0.011021067042157471" WEIGHT="64.2906444987121"/>
<DICH_DATA CI_END="0.9161504917978304" CI_START="0.4413359023322765" EFFECT_SIZE="0.6358695652173914" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="64" LOG_CI_END="-0.03803318092923756" LOG_CI_START="-0.355230741597512" LOG_EFFECT_SIZE="-0.1966319612633748" ORDER="534" O_E="0.0" SE="0.18632341728979282" STUDY_ID="STD-Mercer-1997" TOTAL_1="299" TOTAL_2="312" VAR="0.034716415830546264" WEIGHT="35.0153384688266"/>
<DICH_DATA CI_END="9.681804404318333" CI_START="0.017244277042976947" EFFECT_SIZE="0.40860215053763443" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9859563046028171" LOG_CI_START="-1.7633550084770668" LOG_EFFECT_SIZE="-0.38869935193712496" ORDER="535" O_E="0.0" SE="1.6149590746136118" STUDY_ID="STD-Svare-1997a" TOTAL_1="30" TOTAL_2="37" VAR="2.6080928126768534" WEIGHT="0.6940170324612916"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.27" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-12-18 12:02:54 +0000" MODIFIED_BY="[Empty name]" NO="27" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Neonatal encephalopathy</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="537" O_E="0.0" SE="0.0" STUDY_ID="STD-Garcia_x002d_Burguillo-1995" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1171972611914136" CI_START="0.9146479048664722" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0108620748011508" ESTIMABLE="YES" EVENTS_1="938" EVENTS_2="311" I2="0.0" I2_Q="0.0" ID="CMP-001.28" LOG_CI_END="0.048129862357544226" LOG_CI_START="-0.038746056099522995" LOG_EFFECT_SIZE="0.004691903129010606" METHOD="MH" MODIFIED="2013-12-18 12:03:24 +0000" MODIFIED_BY="[Empty name]" NO="28" P_CHI2="1.0" P_Q="1.0" P_Z="0.8323384805566058" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2375" TOTAL_2="796" WEIGHT="99.99999999999999" Z="0.21170334231012675">
<NAME>Serious childhood disability at 7 years</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1171972611914136" CI_START="0.9146479048664722" EFFECT_SIZE="1.0108620748011508" ESTIMABLE="YES" EVENTS_1="938" EVENTS_2="311" LOG_CI_END="0.048129862357544226" LOG_CI_START="-0.038746056099522995" LOG_EFFECT_SIZE="0.004691903129010606" MODIFIED="2009-05-15 09:31:18 +0100" MODIFIED_BY="[Empty name]" ORDER="314" O_E="0.0" SE="0.051031344544413264" STUDY_ID="STD-Kenyon-2001" TOTAL_1="2375" TOTAL_2="796" VAR="0.002604198126010617" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2013-12-05 10:16:04 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Erythromycin versus co-amoxiclav</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-12-05 10:14:30 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Maternal death</NAME>
<GROUP_LABEL_1>Erythromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Co-amoxiclav</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours erythromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours co-amoxiclav</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-12-05 10:14:30 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Serious maternal morbidity</NAME>
<GROUP_LABEL_1>Erythromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Co-amoxiclav</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours erythromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours co-amoxiclav</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-12-05 10:14:30 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="1190" TOTAL_2="1205" WEIGHT="0.0" Z="0.0">
<NAME>Major adverse drug reaction</NAME>
<GROUP_LABEL_1>Erythromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Co-amoxiclav</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours erythromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours co-amoxiclav</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="682" O_E="0.0" SE="0.0" STUDY_ID="STD-Kenyon-2001" TOTAL_1="1190" TOTAL_2="1205" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1982344886116718" CI_START="0.8701149660471861" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.02107872437678" ESTIMABLE="YES" EVENTS_1="241" EVENTS_2="239" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.07854181567011786" LOG_CI_START="-0.06042336137994364" LOG_EFFECT_SIZE="0.009059227145087147" METHOD="MH" MODIFIED="2013-12-05 10:14:30 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.7983040722920903" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1190" TOTAL_2="1205" WEIGHT="99.99999999999999" Z="0.25554256554132265">
<NAME>Maternal infection after delivery prior to discharge</NAME>
<GROUP_LABEL_1>Erythromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Co-amoxiclav</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours erythromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours co-amoxiclav</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1982344886116718" CI_START="0.8701149660471861" EFFECT_SIZE="1.02107872437678" ESTIMABLE="YES" EVENTS_1="241" EVENTS_2="239" LOG_CI_END="0.07854181567011786" LOG_CI_START="-0.06042336137994364" LOG_EFFECT_SIZE="0.009059227145087147" ORDER="683" O_E="0.0" SE="0.08162883288792666" STUDY_ID="STD-Kenyon-2001" TOTAL_1="1190" TOTAL_2="1205" VAR="0.0066632663586450565" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-12-05 10:14:30 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Chorioamnionitis</NAME>
<GROUP_LABEL_1>Erythromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Co-amoxiclav</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours erythromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours co-amoxiclav</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1623534721244488" CI_START="0.8981634967561013" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0217550875771995" ESTIMABLE="YES" EVENTS_1="335" EVENTS_2="332" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="0.06533821725346271" LOG_CI_START="-0.046644599551132065" LOG_EFFECT_SIZE="0.009346808851165334" METHOD="MH" MODIFIED="2013-12-05 10:14:30 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.7435298601803605" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1190" TOTAL_2="1205" WEIGHT="100.0" Z="0.3271824953399921">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Erythromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Co-amoxiclav</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours erythromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours co-amoxiclav</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1623534721244488" CI_START="0.8981634967561013" EFFECT_SIZE="1.0217550875771995" ESTIMABLE="YES" EVENTS_1="335" EVENTS_2="332" LOG_CI_END="0.06533821725346271" LOG_CI_START="-0.046644599551132065" LOG_EFFECT_SIZE="0.009346808851165334" ORDER="684" O_E="0.0" SE="0.06577926091490216" STUDY_ID="STD-Kenyon-2001" TOTAL_1="1190" TOTAL_2="1205" VAR="0.004326911166510776" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.07" MODIFIED="2013-12-05 10:15:32 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Days from randomisation to birth</NAME>
<GROUP_LABEL_1>Erythromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Co-amoxiclav</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours co-amoxiclav</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours erythromycin</GRAPH_LABEL_2>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.08" MODIFIED="2013-12-05 10:14:30 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Days from birth till discharge of mother</NAME>
<GROUP_LABEL_1>Erythromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Co-amoxiclav</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours erythromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours co-amoxiclav</GRAPH_LABEL_2>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2820830291096095" CI_START="1.017729992332355" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1422847067982507" ESTIMABLE="YES" EVENTS_1="414" EVENTS_2="367" I2="0.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="0.10791615148272257" LOG_CI_START="0.0076325732916094945" LOG_EFFECT_SIZE="0.05777436238716605" METHOD="MH" MODIFIED="2013-12-05 10:14:30 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.023926381800684286" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1190" TOTAL_2="1205" WEIGHT="100.0" Z="2.2583093174600304">
<NAME>Birth within 48 hours of randomisation</NAME>
<GROUP_LABEL_1>Erythromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Co-amoxiclav</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours erythromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours co-amoxiclav</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2820830291096095" CI_START="1.017729992332355" EFFECT_SIZE="1.1422847067982507" ESTIMABLE="YES" EVENTS_1="414" EVENTS_2="367" LOG_CI_END="0.10791615148272257" LOG_CI_START="0.0076325732916094945" LOG_EFFECT_SIZE="0.05777436238716605" ORDER="685" O_E="0.0" SE="0.05890707024117786" STUDY_ID="STD-Kenyon-2001" TOTAL_1="1190" TOTAL_2="1205" VAR="0.0034700429243990625" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.128842018641463" CI_START="0.9884470470358327" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0563146121758056" ESTIMABLE="YES" EVENTS_1="725" EVENTS_2="695" I2="0.0" I2_Q="0.0" ID="CMP-002.10" LOG_CI_END="0.052633166696407385" LOG_CI_START="-0.005046591697934913" LOG_EFFECT_SIZE="0.023793287499236242" METHOD="MH" MODIFIED="2013-12-05 10:14:30 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.10587901507793783" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1190" TOTAL_2="1205" WEIGHT="100.0" Z="1.6169965988236294">
<NAME>Birth within 7 days of randomisation</NAME>
<GROUP_LABEL_1>Erythromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Co-amoxiclav</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours erythromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours co-amoxiclav</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.128842018641463" CI_START="0.9884470470358327" EFFECT_SIZE="1.0563146121758056" ESTIMABLE="YES" EVENTS_1="725" EVENTS_2="695" LOG_CI_END="0.052633166696407385" LOG_CI_START="-0.005046591697934913" LOG_EFFECT_SIZE="0.023793287499236242" ORDER="686" O_E="0.0" SE="0.033881375600245546" STUDY_ID="STD-Kenyon-2001" TOTAL_1="1190" TOTAL_2="1205" VAR="0.0011479476125649144" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0281193356984337" CI_START="0.9606935496645452" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9938348022135683" ESTIMABLE="YES" EVENTS_1="1006" EVENTS_2="1025" I2="0.0" I2_Q="0.0" ID="CMP-002.11" LOG_CI_END="0.012043526942709751" LOG_CI_START="-0.017415125249725934" LOG_EFFECT_SIZE="-0.0026857991535080856" METHOD="MH" MODIFIED="2013-12-05 10:14:30 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.7208021110109197" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1190" TOTAL_2="1205" WEIGHT="100.0" Z="0.3573869962683291">
<NAME>Birth before 37 weeks' gestation</NAME>
<GROUP_LABEL_1>Erythromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Co-amoxiclav</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours erythromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours co-amoxiclav</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0281193356984337" CI_START="0.9606935496645452" EFFECT_SIZE="0.9938348022135683" ESTIMABLE="YES" EVENTS_1="1006" EVENTS_2="1025" LOG_CI_END="0.012043526942709751" LOG_CI_START="-0.017415125249725934" LOG_EFFECT_SIZE="-0.0026857991535080856" ORDER="687" O_E="0.0" SE="0.01730415812051688" STUDY_ID="STD-Kenyon-2001" TOTAL_1="1190" TOTAL_2="1205" VAR="2.994338882598503E-4" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="79.9205885951607" CI_START="-41.92058859516069" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="19.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.12" MODIFIED="2013-12-05 10:16:04 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.5410166411943331" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1190" TOTAL_2="1205" UNITS="" WEIGHT="100.0" Z="0.6112763609972605">
<NAME>Birthweight</NAME>
<GROUP_LABEL_1>Erythromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Co-amoxiclav</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours co-amoxiclav</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours erythromycin</GRAPH_LABEL_2>
<CONT_DATA CI_END="79.9205885951607" CI_START="-41.920588595160694" EFFECT_SIZE="19.0" ESTIMABLE="YES" MEAN_1="2102.0" MEAN_2="2083.0" ORDER="688" SD_1="766.0" SD_2="755.0" SE="31.08250410502158" STUDY_ID="STD-Kenyon-2001" TOTAL_1="1190" TOTAL_2="1205" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0466361042648638" CI_START="0.948651862822252" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9964403093050219" ESTIMABLE="YES" EVENTS_1="863" EVENTS_2="877" I2="0.0" I2_Q="0.0" ID="CMP-002.13" LOG_CI_END="0.01979571187943229" LOG_CI_START="-0.022893136144381255" LOG_EFFECT_SIZE="-0.0015487121324744846" METHOD="MH" MODIFIED="2013-12-05 10:14:30 +0000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.886913042949512" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1190" TOTAL_2="1205" WEIGHT="100.0" Z="0.1422113803762959">
<NAME>Birthweight &lt; 2500 g</NAME>
<GROUP_LABEL_1>Erythromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Co-amoxiclav</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours erythromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours co-amoxiclav</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0466361042648638" CI_START="0.948651862822252" EFFECT_SIZE="0.9964403093050219" ESTIMABLE="YES" EVENTS_1="863" EVENTS_2="877" LOG_CI_END="0.01979571187943229" LOG_CI_START="-0.022893136144381255" LOG_EFFECT_SIZE="-0.0015487121324744846" ORDER="689" O_E="0.0" SE="0.02507564064239379" STUDY_ID="STD-Kenyon-2001" TOTAL_1="1190" TOTAL_2="1205" VAR="6.287877536264712E-4" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.051610162476591" CI_START="0.9476462471083431" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9982757253844934" ESTIMABLE="YES" EVENTS_1="836" EVENTS_2="848" I2="0.0" I2_Q="0.0" ID="CMP-002.14" LOG_CI_END="0.02185477435918286" LOG_CI_START="-0.023353752957864918" LOG_EFFECT_SIZE="-7.494892993410197E-4" METHOD="MH" MODIFIED="2013-12-05 10:14:30 +0000" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.948184747094972" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1190" TOTAL_2="1205" WEIGHT="100.0" Z="0.06498650235627644">
<NAME>Neonatal intensive care</NAME>
<GROUP_LABEL_1>Erythromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Co-amoxiclav</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours erythromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours co-amoxiclav</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.051610162476591" CI_START="0.9476462471083431" EFFECT_SIZE="0.9982757253844934" ESTIMABLE="YES" EVENTS_1="836" EVENTS_2="848" LOG_CI_END="0.02185477435918286" LOG_CI_START="-0.023353752957864918" LOG_EFFECT_SIZE="-7.494892993410197E-4" ORDER="690" O_E="0.0" SE="0.02655571273185329" STUDY_ID="STD-Kenyon-2001" TOTAL_1="1190" TOTAL_2="1205" VAR="7.052058786967149E-4" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.15" MODIFIED="2013-12-05 10:14:30 +0000" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Days in neonatal intensive care unit</NAME>
<GROUP_LABEL_1>Erythromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Co-amoxiclav</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours erythromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours co-amoxiclav</GRAPH_LABEL_2>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.16" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-12-05 10:14:30 +0000" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Neonatal infection including pneumonia</NAME>
<GROUP_LABEL_1>Erythromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Co-amoxiclav</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours erythromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours co-amoxiclav</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.885281177867722E-31" CI_END="1.1464146643096669" CI_START="0.6150756850627122" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8397212543554007" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="82" I2="100.0" I2_Q="0.0" ID="CMP-002.17" LOG_CI_END="0.05934173268241181" LOG_CI_START="-0.2110714410006597" LOG_EFFECT_SIZE="-0.07586485415912395" METHOD="MH" MODIFIED="2013-12-05 10:14:30 +0000" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.0" P_Q="1.0" P_Z="0.2714445036521306" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1190" TOTAL_2="1205" WEIGHT="100.0" Z="1.0997421450963514">
<NAME>Positive neonatal blood culture</NAME>
<GROUP_LABEL_1>Erythromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Co-amoxiclav</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours erythromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours co-amoxiclav</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1464146643096669" CI_START="0.6150756850627122" EFFECT_SIZE="0.8397212543554007" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="82" LOG_CI_END="0.05934173268241181" LOG_CI_START="-0.2110714410006597" LOG_EFFECT_SIZE="-0.07586485415912395" ORDER="691" O_E="0.0" SE="0.15884203678823408" STUDY_ID="STD-Kenyon-2001" TOTAL_1="1190" TOTAL_2="1205" VAR="0.025230792651034707" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9431780065629435" CI_START="0.22837543773761174" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4641106442577031" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-002.18" LOG_CI_END="-0.025406334863471297" LOG_CI_START="-0.6413506072065778" LOG_EFFECT_SIZE="-0.33337847103502455" METHOD="MH" MODIFIED="2013-12-05 10:14:30 +0000" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="1.0" P_Q="1.0" P_Z="0.03386694553157583" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1190" TOTAL_2="1205" WEIGHT="100.0" Z="2.121652317551551">
<NAME>Neonatal necrotising enterocolitis</NAME>
<GROUP_LABEL_1>Erythromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Co-amoxiclav</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours erythromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours co-amoxiclav</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9431780065629435" CI_START="0.22837543773761174" EFFECT_SIZE="0.4641106442577031" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="24" LOG_CI_END="-0.025406334863471297" LOG_CI_START="-0.6413506072065778" LOG_EFFECT_SIZE="-0.33337847103502455" ORDER="692" O_E="0.0" SE="0.36180871454766206" STUDY_ID="STD-Kenyon-2001" TOTAL_1="1190" TOTAL_2="1205" VAR="0.1309055459226316" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1643790858668268" CI_START="0.8444534136069752" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9915966386554622" ESTIMABLE="YES" EVENTS_1="236" EVENTS_2="241" I2="0.0" I2_Q="0.0" ID="CMP-002.19" LOG_CI_END="0.06609439620493691" LOG_CI_START="-0.07342430437774766" LOG_EFFECT_SIZE="-0.0036649540864053605" METHOD="MH" MODIFIED="2013-12-05 10:14:30 +0000" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="1.0" P_Q="1.0" P_Z="0.9179861242694863" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1190" TOTAL_2="1205" WEIGHT="100.0" Z="0.10297082734210754">
<NAME>Neonatal respiratory distress syndrome</NAME>
<GROUP_LABEL_1>Erythromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Co-amoxiclav</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours erythromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours co-amoxiclav</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1643790858668268" CI_START="0.8444534136069752" EFFECT_SIZE="0.9915966386554622" ESTIMABLE="YES" EVENTS_1="236" EVENTS_2="241" LOG_CI_END="0.06609439620493691" LOG_CI_START="-0.07342430437774766" LOG_EFFECT_SIZE="-0.0036649540864053605" ORDER="693" O_E="0.0" SE="0.08195397535097511" STUDY_ID="STD-Kenyon-2001" TOTAL_1="1190" TOTAL_2="1205" VAR="0.006716454075828235" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.185421810468046" CI_START="0.8088906532706517" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9792224582140548" ESTIMABLE="YES" EVENTS_1="176" EVENTS_2="182" I2="0.0" I2_Q="0.0" ID="CMP-002.20" LOG_CI_END="0.07387291352117112" LOG_CI_START="-0.0921101828263082" LOG_EFFECT_SIZE="-0.009118634652568547" METHOD="MH" MODIFIED="2013-12-05 10:14:30 +0000" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="1.0" P_Q="1.0" P_Z="0.82949477282098" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1190" TOTAL_2="1205" WEIGHT="100.0" Z="0.21534958559633685">
<NAME>Treatment with surfactant</NAME>
<GROUP_LABEL_1>Erythromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Co-amoxiclav</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours erythromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours co-amoxiclav</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.185421810468046" CI_START="0.8088906532706517" EFFECT_SIZE="0.9792224582140548" ESTIMABLE="YES" EVENTS_1="176" EVENTS_2="182" LOG_CI_END="0.07387291352117112" LOG_CI_START="-0.0921101828263082" LOG_EFFECT_SIZE="-0.009118634652568547" ORDER="694" O_E="0.0" SE="0.09749929242408734" STUDY_ID="STD-Kenyon-2001" TOTAL_1="1190" TOTAL_2="1205" VAR="0.009506112023197694" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1683638481162875" CI_START="0.8570024634974628" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0006451399457421" ESTIMABLE="YES" EVENTS_1="251" EVENTS_2="254" I2="0.0" I2_Q="0.0" ID="CMP-002.21" LOG_CI_END="0.06757811043219498" LOG_CI_START="-0.06701792967328193" LOG_EFFECT_SIZE="2.800903794565252E-4" METHOD="MH" MODIFIED="2013-12-05 10:14:30 +0000" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="1.0" P_Q="1.0" P_Z="0.99349152500135" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1190" TOTAL_2="1205" WEIGHT="100.0" Z="0.008157254191441976">
<NAME>Number of babies requiring ventilation</NAME>
<GROUP_LABEL_1>Erythromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Co-amoxiclav</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours erythromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours co-amoxiclav</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1683638481162875" CI_START="0.8570024634974629" EFFECT_SIZE="1.0006451399457421" ESTIMABLE="YES" EVENTS_1="251" EVENTS_2="254" LOG_CI_END="0.06757811043219498" LOG_CI_START="-0.06701792967328188" LOG_EFFECT_SIZE="2.800903794565252E-4" ORDER="695" O_E="0.0" SE="0.07906238021910096" STUDY_ID="STD-Kenyon-2001" TOTAL_1="1190" TOTAL_2="1205" VAR="0.006250859965909687" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1010890907775663" CI_START="0.8690877158548975" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9782346358909099" ESTIMABLE="YES" EVENTS_1="370" EVENTS_2="383" I2="0.0" I2_Q="0.0" ID="CMP-002.22" LOG_CI_END="0.04182245981438951" LOG_CI_START="-0.06093638858093214" LOG_EFFECT_SIZE="-0.009556964383271324" METHOD="MH" MODIFIED="2013-12-05 10:14:30 +0000" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="1.0" P_Q="1.0" P_Z="0.7154337307349747" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1190" TOTAL_2="1205" WEIGHT="100.0" Z="0.36456823495496943">
<NAME>Number of babies requiring oxygen therapy</NAME>
<GROUP_LABEL_1>Erythromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Co-amoxiclav</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours erythromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours co-amoxiclav</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1010890907775663" CI_START="0.8690877158548975" EFFECT_SIZE="0.9782346358909099" ESTIMABLE="YES" EVENTS_1="370" EVENTS_2="383" LOG_CI_END="0.04182245981438951" LOG_CI_START="-0.06093638858093214" LOG_EFFECT_SIZE="-0.009556964383271324" ORDER="696" O_E="0.0" SE="0.060361056211915114" STUDY_ID="STD-Kenyon-2001" TOTAL_1="1190" TOTAL_2="1205" VAR="0.0036434571070179758" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.856475691760796E-31" CI_END="1.1152518402683533" CI_START="0.6593514599095545" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8575213869331516" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="111" I2="100.0" I2_Q="0.0" ID="CMP-002.23" LOG_CI_END="0.04737294854017897" LOG_CI_START="-0.18088302787738364" LOG_EFFECT_SIZE="-0.06675503966860236" METHOD="MH" MODIFIED="2013-12-05 10:14:30 +0000" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="0.0" P_Q="1.0" P_Z="0.2516255424743863" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1190" TOTAL_2="1205" WEIGHT="100.0" Z="1.1464100576070286">
<NAME>Neonatal oxygenation &gt; 28 days</NAME>
<GROUP_LABEL_1>Erythromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Co-amoxiclav</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours erythromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours co-amoxiclav</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1152518402683533" CI_START="0.6593514599095545" EFFECT_SIZE="0.8575213869331516" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="111" LOG_CI_END="0.04737294854017897" LOG_CI_START="-0.18088302787738364" LOG_EFFECT_SIZE="-0.06675503966860236" ORDER="697" O_E="0.0" SE="0.13407869043298212" STUDY_ID="STD-Kenyon-2001" TOTAL_1="1190" TOTAL_2="1205" VAR="0.017977095228223453" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3443185509699909" CI_START="0.6978589760951268" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9685787358421629" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="69" I2="0.0" I2_Q="0.0" ID="CMP-002.24" LOG_CI_END="0.12850219173566796" LOG_CI_START="-0.15623233108972842" LOG_EFFECT_SIZE="-0.013865069677030228" METHOD="MH" MODIFIED="2013-12-05 10:14:30 +0000" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="1.0" P_Q="1.0" P_Z="0.848619751004474" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1190" TOTAL_2="1205" WEIGHT="100.0" Z="0.1908798198438466">
<NAME>Oxygen treatment &gt; 36 weeks' postconceptual age</NAME>
<GROUP_LABEL_1>Erythromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Co-amoxiclav</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours erythromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours co-amoxiclav</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3443185509699909" CI_START="0.6978589760951268" EFFECT_SIZE="0.9685787358421629" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="69" LOG_CI_END="0.12850219173566796" LOG_CI_START="-0.15623233108972842" LOG_EFFECT_SIZE="-0.013865069677030228" ORDER="698" O_E="0.0" SE="0.1672544681662573" STUDY_ID="STD-Kenyon-2001" TOTAL_1="1190" TOTAL_2="1205" VAR="0.027974057121577578" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.25" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-12-05 10:14:30 +0000" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Neonatal encephalopathy</NAME>
<GROUP_LABEL_1>Erythromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Co-amoxiclav</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours erythromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours co-amoxiclav</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6294429633829066" CI_START="0.7434732600885715" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1006576543660942" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="46" I2="0.0" I2_Q="0.0" ID="CMP-002.26" LOG_CI_END="0.2120391631309583" LOG_CI_START="-0.12873464678535607" LOG_EFFECT_SIZE="0.04165225817280113" METHOD="MH" MODIFIED="2013-12-05 10:14:30 +0000" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="1.0" P_Q="1.0" P_Z="0.6318484544739638" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1190" TOTAL_2="1205" WEIGHT="99.99999999999999" Z="0.4791267610236969">
<NAME>Major cerebral abnormality on ultrasound before discharge</NAME>
<GROUP_LABEL_1>Erythromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Co-amoxiclav</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours erythromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours co-amoxiclav</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6294429633829066" CI_START="0.7434732600885716" EFFECT_SIZE="1.1006576543660942" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="46" LOG_CI_END="0.2120391631309583" LOG_CI_START="-0.12873464678535598" LOG_EFFECT_SIZE="0.04165225817280113" ORDER="699" O_E="0.0" SE="0.20017222280240743" STUDY_ID="STD-Kenyon-2001" TOTAL_1="1190" TOTAL_2="1205" VAR="0.04006891878165664" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2252723118776387" CI_START="0.6570364281104311" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8972449739389426" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="79" I2="0.0" I2_Q="0.0" ID="CMP-002.27" LOG_CI_END="0.08823261964180938" LOG_CI_START="-0.18241055115746574" LOG_EFFECT_SIZE="-0.04708896575782818" METHOD="MH" MODIFIED="2013-12-05 10:14:30 +0000" MODIFIED_BY="[Empty name]" NO="27" P_CHI2="1.0" P_Q="1.0" P_Z="0.4952232751675125" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1190" TOTAL_2="1205" WEIGHT="100.0" Z="0.6820247980543559">
<NAME>Perinatal death/death before discharge</NAME>
<GROUP_LABEL_1>Erythromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Co-amoxiclav</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours erythromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours co-amoxiclav</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2252723118776387" CI_START="0.6570364281104311" EFFECT_SIZE="0.8972449739389426" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="79" LOG_CI_END="0.08823261964180938" LOG_CI_START="-0.18241055115746574" LOG_EFFECT_SIZE="-0.04708896575782818" ORDER="700" O_E="0.0" SE="0.15897713823279613" STUDY_ID="STD-Kenyon-2001" TOTAL_1="1190" TOTAL_2="1205" VAR="0.02527373048068957" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.065347590848481E-30" CI_END="1.0056312966414929" CI_START="0.7888266294842649" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8906563569826467" ESTIMABLE="YES" EVENTS_1="293" EVENTS_2="344" I2="100.0" I2_Q="0.0" ID="CMP-002.28" LOG_CI_END="0.002438780735180523" LOG_CI_START="-0.1030184367549009" LOG_EFFECT_SIZE="-0.050289828009860184" METHOD="MH" MODIFIED="2013-12-05 10:14:30 +0000" MODIFIED_BY="[Empty name]" NO="28" P_CHI2="0.0" P_Q="1.0" P_Z="0.061579338836796525" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="788" TOTAL_2="824" WEIGHT="100.0" Z="1.8693125806644777">
<NAME>Serious childhood disability at 7 years</NAME>
<GROUP_LABEL_1>Erythromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Co-amoxiclav</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours erythromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours co-amoxiclav</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0056312966414929" CI_START="0.7888266294842649" EFFECT_SIZE="0.8906563569826467" ESTIMABLE="YES" EVENTS_1="293" EVENTS_2="344" LOG_CI_END="0.002438780735180523" LOG_CI_START="-0.1030184367549009" LOG_EFFECT_SIZE="-0.050289828009860184" MODIFIED="2009-05-15 09:34:31 +0100" MODIFIED_BY="[Empty name]" ORDER="317" O_E="0.0" SE="0.06194609157531946" STUDY_ID="STD-Kenyon-2001" TOTAL_1="788" TOTAL_2="824" VAR="0.0038373182614578646" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2010-06-10 08:10:24 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>All penicillins (except co-amoxiclav) versus erythromycin</NAME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2013-12-05 10:18:04 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Antibiotics versus no antibiotic</NAME>
<DICH_OUTCOME CHI2="16.716138235276848" CI_END="1.032772348182563" CI_START="0.7219428042087019" CI_STUDY="95" CI_TOTAL="95" DF="23" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8634828111526746" ESTIMABLE="YES" EVENTS_1="322" EVENTS_2="206" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.014004601457731535" LOG_CI_START="-0.14149720797120285" LOG_EFFECT_SIZE="-0.06374630325673566" METHOD="MH" MODIFIED="2013-12-05 10:18:04 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8229447230255292" P_Q="0.34585290901675014" P_Z="0.10806916806458587" Q="0.8886153931073414" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="18" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="4893" TOTAL_2="2550" WEIGHT="200.0" Z="1.6069325365357767">
<NAME>Perinatal death/death before discharge</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>No antibiotic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no antibiotic</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="12.866740453685042" CI_END="1.0794623432545056" CI_START="0.7365835070302802" DF="17" EFFECT_SIZE="0.8916917396171885" ESTIMABLE="YES" EVENTS_1="299" EVENTS_2="172" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="0.03320749669153191" LOG_CI_START="-0.13277800973569548" LOG_EFFECT_SIZE="-0.04978525652208178" MODIFIED="2013-10-17 15:01:33 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7450602775451585" P_Z="0.2397016511644312" STUDIES="18" TAU2="0.0" TOTAL_1="4604" TOTAL_2="2268" WEIGHT="99.99999999999997" Z="1.1757328919214851">
<NAME>Antibiotics versus no antibiotics (all studies)</NAME>
<DICH_DATA CI_END="1.410928927021109" CI_START="0.06478055372995288" EFFECT_SIZE="0.3023255813953488" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.14950513751058012" LOG_CI_START="-1.1885553440560794" LOG_EFFECT_SIZE="-0.5195251032727498" ORDER="702" O_E="0.0" SE="0.7859833503784622" STUDY_ID="STD-Amon-1988a" TOTAL_1="43" TOTAL_2="39" VAR="0.6177698270721526" WEIGHT="1.5388236308567889"/>
<DICH_DATA CI_END="2.9973039350987856" CI_START="0.21352522595574108" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4767307838677607" LOG_CI_START="-0.6705508098838734" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="703" O_E="0.0" SE="0.6739188873051909" STUDY_ID="STD-Camli-1997" TOTAL_1="15" TOTAL_2="16" VAR="0.4541666666666666" WEIGHT="2.093149669715098"/>
<DICH_DATA CI_END="2.961143952340347" CI_START="0.03446126048879469" EFFECT_SIZE="0.3194444444444444" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.47145952059005386" LOG_CI_START="-1.462668841417405" LOG_EFFECT_SIZE="-0.4956046604136756" ORDER="704" O_E="0.0" SE="1.1361165739329822" STUDY_ID="STD-Christmas-1992" TOTAL_1="48" TOTAL_2="46" VAR="1.2907608695652173" WEIGHT="0.7364949083474738"/>
<DICH_DATA CI_END="1.6145911815529068" CI_START="0.024774073125760646" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.20806257615844104" LOG_CI_START="-1.6060025848304786" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="705" O_E="0.0" SE="1.0655908553322622" STUDY_ID="STD-Cox-1995" TOTAL_1="31" TOTAL_2="31" VAR="1.135483870967742" WEIGHT="0.837210314153328"/>
<DICH_DATA CI_END="1.9031160339754112" CI_START="0.08407264567351506" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.27946526825494583" LOG_CI_START="-1.075345285599021" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="706" O_E="0.0" SE="0.7958224257542215" STUDY_ID="STD-Garcia_x002d_Burguillo-1995" TOTAL_1="30" TOTAL_2="30" VAR="0.6333333333333333" WEIGHT="1.5010086447299058"/>
<DICH_DATA CI_END="3.7481195757668" CI_START="0.009379703419095869" EFFECT_SIZE="0.1875" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5738134376766014" LOG_CI_START="-2.027810893549126" LOG_EFFECT_SIZE="-0.7269987279362623" ORDER="707" O_E="0.0" SE="1.5282070104101297" STUDY_ID="STD-Grable-1996" TOTAL_1="31" TOTAL_2="29" VAR="2.3354166666666667" WEIGHT="0.4070531917911609"/>
<DICH_DATA CI_END="3.5437267409652202" CI_START="0.20089417569089793" EFFECT_SIZE="0.84375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.549460225780937" LOG_CI_START="-0.6970326541027743" LOG_EFFECT_SIZE="-0.07378621416091867" ORDER="708" O_E="0.0" SE="0.7321960878829598" STUDY_ID="STD-Johnston-1990" TOTAL_1="40" TOTAL_2="45" VAR="0.536111111111111" WEIGHT="1.7732122849658993"/>
<DICH_DATA CI_END="1.2025975776944275" CI_START="0.7379127667429695" EFFECT_SIZE="0.9420255335365854" ESTIMABLE="YES" EVENTS_1="226" EVENTS_2="82" LOG_CI_END="0.08012032474230664" LOG_CI_START="-0.13199497579401087" LOG_EFFECT_SIZE="-0.02593732552585209" ORDER="709" O_E="0.0" SE="0.1245975775227045" STUDY_ID="STD-Kenyon-2001" TOTAL_1="3584" TOTAL_2="1225" VAR="0.015524556324526359" WEIGHT="61.23452345153854"/>
<DICH_DATA CI_END="15.87886789416035" CI_START="0.06520587696874873" EFFECT_SIZE="1.0175438596491229" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2008195355693063" LOG_CI_START="-1.1857132597884146" LOG_EFFECT_SIZE="0.007553137890445907" ORDER="710" O_E="0.0" SE="1.4018611775209884" STUDY_ID="STD-Kurki--1992" TOTAL_1="57" TOTAL_2="58" VAR="1.9652147610405324" WEIGHT="0.48373278441364886"/>
<DICH_DATA CI_END="4.377819176530504" CI_START="0.2043971430909409" EFFECT_SIZE="0.9459459459459459" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6412578193020794" LOG_CI_START="-0.6895251787355181" LOG_EFFECT_SIZE="-0.024133679716719363" ORDER="711" O_E="0.0" SE="0.7817085205293665" STUDY_ID="STD-Lockwood-1993a" TOTAL_1="37" TOTAL_2="35" VAR="0.611068211068211" WEIGHT="1.5556999875138726"/>
<DICH_DATA CI_END="1.8007080745159152" CI_START="0.3230877481547732" EFFECT_SIZE="0.7627494456762749" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.25544331198497394" LOG_CI_START="-0.4906795105978349" LOG_EFFECT_SIZE="-0.11761809930643045" ORDER="712" O_E="0.0" SE="0.4382762393526795" STUDY_ID="STD-Magwali-1999" TOTAL_1="82" TOTAL_2="86" VAR="0.1920860619811272" WEIGHT="4.949025444763099"/>
<DICH_DATA CI_END="212.52014022610007" CI_START="0.7413216397613307" EFFECT_SIZE="12.551724137931034" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.3274000937961477" LOG_CI_START="-0.1299933222959482" LOG_EFFECT_SIZE="1.0987033857500998" ORDER="713" O_E="0.0" SE="1.4434850569060902" STUDY_ID="STD-McGregor-1991" TOTAL_1="28" TOTAL_2="27" VAR="2.0836491095111787" WEIGHT="0.4562374749134027"/>
<DICH_DATA CI_END="1.7141104165113343" CI_START="0.24291910861073102" EFFECT_SIZE="0.6452830188679245" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.23403879409655265" LOG_CI_START="-0.6145383211858607" LOG_EFFECT_SIZE="-0.19024976354465403" ORDER="714" O_E="0.0" SE="0.49845839804135544" STUDY_ID="STD-Mercer-1992" TOTAL_1="106" TOTAL_2="114" VAR="0.24846077457795432" WEIGHT="3.82611223016484"/>
<DICH_DATA CI_END="2.0574676079868497" CI_START="0.5896522994999839" EFFECT_SIZE="1.1014492753623188" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" LOG_CI_END="0.31333300656556795" LOG_CI_START="-0.22940400347849588" LOG_EFFECT_SIZE="0.04196450154353604" ORDER="715" O_E="0.0" SE="0.3188064062914116" STUDY_ID="STD-Mercer-1997" TOTAL_1="299" TOTAL_2="312" VAR="0.1016375246924446" WEIGHT="9.353226686753498"/>
<DICH_DATA CI_END="5.728787327573674" CI_START="0.3763047207071941" EFFECT_SIZE="1.4682539682539681" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7580627000335901" LOG_CI_START="-0.4244603334626884" LOG_EFFECT_SIZE="0.16680118328545088" ORDER="716" O_E="0.0" SE="0.6946198834591352" STUDY_ID="STD-Morales-1989" TOTAL_1="42" TOTAL_2="37" VAR="0.48249678249678246" WEIGHT="1.9702490105937227"/>
<DICH_DATA CI_END="3.2601867025518723" CI_START="0.4376122170388178" EFFECT_SIZE="1.1944444444444444" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.5132424717140303" LOG_CI_START="-0.35891056208943173" LOG_EFFECT_SIZE="0.07716595481229925" ORDER="717" O_E="0.0" SE="0.5123070092832982" STUDY_ID="STD-Ovalle_x002d_Salas-1997" TOTAL_1="42" TOTAL_2="43" VAR="0.26245847176079734" WEIGHT="3.622054193759633"/>
<DICH_DATA CI_END="1.816821090646348" CI_START="0.17368555618201909" EFFECT_SIZE="0.5617433414043583" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.2593121627672512" LOG_CI_START="-0.760236296298254" LOG_EFFECT_SIZE="-0.25046206676550137" ORDER="718" O_E="0.0" SE="0.5988878117013445" STUDY_ID="STD-Owen-1993a" TOTAL_1="59" TOTAL_2="58" VAR="0.35866661100442515" WEIGHT="2.650480360206185"/>
<DICH_DATA CI_END="8.24504025965545" CI_START="0.18448801500147877" EFFECT_SIZE="1.2333333333333334" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.9161927805995209" LOG_CI_START="-0.7340318419048558" LOG_EFFECT_SIZE="0.09108046934733258" ORDER="719" O_E="0.0" SE="0.9693501120026962" STUDY_ID="STD-Svare-1997a" TOTAL_1="30" TOTAL_2="37" VAR="0.9396396396396396" WEIGHT="1.0117057308198694"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.9726195587852033" CI_END="1.1439009338601895" CI_START="0.41095236186396444" DF="5" EFFECT_SIZE="0.6856302141156263" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="34" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="0.058388414543697274" LOG_CI_START="-0.38620851919134896" LOG_EFFECT_SIZE="-0.1639100523238258" MODIFIED="2010-04-16 13:34:37 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.704207451650241" P_Z="0.1484117528012862" STUDIES="6" TAU2="0.0" TOTAL_1="289" TOTAL_2="282" WEIGHT="100.00000000000001" Z="1.4451642595008325">
<NAME>Antibiotics versus no treatment (no placebo)</NAME>
<DICH_DATA CI_END="1.410928927021109" CI_START="0.06478055372995288" EFFECT_SIZE="0.3023255813953488" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.14950513751058012" LOG_CI_START="-1.1885553440560794" LOG_EFFECT_SIZE="-0.5195251032727498" MODIFIED="2010-04-16 13:34:37 +0100" MODIFIED_BY="[Empty name]" ORDER="373" O_E="0.0" SE="0.7859833503784622" STUDY_ID="STD-Amon-1988a" TOTAL_1="43" TOTAL_2="39" VAR="0.6177698270721526" WEIGHT="11.040314308028066"/>
<DICH_DATA CI_END="2.9973039350987856" CI_START="0.21352522595574108" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4767307838677607" LOG_CI_START="-0.6705508098838734" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2010-04-16 13:34:12 +0100" MODIFIED_BY="[Empty name]" ORDER="374" O_E="0.0" SE="0.6739188873051909" STUDY_ID="STD-Camli-1997" TOTAL_1="15" TOTAL_2="16" VAR="0.4541666666666666" WEIGHT="15.017335179947251"/>
<DICH_DATA CI_END="2.961143952340347" CI_START="0.03446126048879469" EFFECT_SIZE="0.3194444444444444" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.47145952059005386" LOG_CI_START="-1.462668841417405" LOG_EFFECT_SIZE="-0.4956046604136756" MODIFIED="2010-04-16 13:34:09 +0100" MODIFIED_BY="[Empty name]" ORDER="375" O_E="0.0" SE="1.1361165739329822" STUDY_ID="STD-Christmas-1992" TOTAL_1="48" TOTAL_2="46" VAR="1.2907608695652173" WEIGHT="5.283994287175825"/>
<DICH_DATA CI_END="1.8007080745159152" CI_START="0.3230877481547732" EFFECT_SIZE="0.7627494456762749" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.25544331198497394" LOG_CI_START="-0.4906795105978349" LOG_EFFECT_SIZE="-0.11761809930643045" MODIFIED="2010-04-16 13:34:05 +0100" MODIFIED_BY="[Empty name]" ORDER="376" O_E="0.0" SE="0.4382762393526795" STUDY_ID="STD-Magwali-1999" TOTAL_1="82" TOTAL_2="86" VAR="0.1920860619811272" WEIGHT="35.50686078182405"/>
<DICH_DATA CI_END="5.728787327573674" CI_START="0.3763047207071941" EFFECT_SIZE="1.4682539682539681" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7580627000335901" LOG_CI_START="-0.4244603334626884" LOG_EFFECT_SIZE="0.16680118328545088" MODIFIED="2010-04-16 13:34:01 +0100" MODIFIED_BY="[Empty name]" ORDER="377" O_E="0.0" SE="0.6946198834591352" STUDY_ID="STD-Morales-1989" TOTAL_1="42" TOTAL_2="37" VAR="0.48249678249678246" WEIGHT="14.135582470828583"/>
<DICH_DATA CI_END="1.816821090646348" CI_START="0.17368555618201909" EFFECT_SIZE="0.5617433414043583" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.2593121627672512" LOG_CI_START="-0.760236296298254" LOG_EFFECT_SIZE="-0.25046206676550137" MODIFIED="2010-04-16 13:33:58 +0100" MODIFIED_BY="[Empty name]" ORDER="378" O_E="0.0" SE="0.5988878117013445" STUDY_ID="STD-Owen-1993a" TOTAL_1="59" TOTAL_2="58" VAR="0.35866661100442515" WEIGHT="19.015912972196237"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2013-12-05 10:19:52 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>3 versus 7 day ampicillin regimens</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-12-05 10:18:53 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Maternal death</NAME>
<GROUP_LABEL_1>3 day</GROUP_LABEL_1>
<GROUP_LABEL_2>7 day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3 day</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7 day</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-12-05 10:18:53 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Serious maternal morbidity</NAME>
<GROUP_LABEL_1>3 day</GROUP_LABEL_1>
<GROUP_LABEL_2>7 day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3 day</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7 day</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-12-05 10:18:53 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Major adverse drug reaction</NAME>
<GROUP_LABEL_1>3 day</GROUP_LABEL_1>
<GROUP_LABEL_2>7 day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3 day</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7 day</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.333681442199326" CI_START="0.3605479592443318" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="0.6368569842842896" LOG_CI_START="-0.4430369582681768" LOG_EFFECT_SIZE="0.09691001300805642" METHOD="MH" MODIFIED="2013-12-05 10:18:53 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.7250066074652759" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="42" TOTAL_2="42" WEIGHT="100.0" Z="0.3517755360089364">
<NAME>Maternal infection after delivery prior to discharge</NAME>
<GROUP_LABEL_1>3 day</GROUP_LABEL_1>
<GROUP_LABEL_2>7 day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3 day</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7 day</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.333681442199326" CI_START="0.3605479592443318" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6368569842842896" LOG_CI_START="-0.4430369582681768" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="726" O_E="0.0" SE="0.6343350474165466" STUDY_ID="STD-Lewis-2003" TOTAL_1="42" TOTAL_2="42" VAR="0.4023809523809524" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6251264297844346" CI_START="0.32546736680965205" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-005.05" LOG_CI_END="0.21088715338987554" LOG_CI_START="-0.4874925497224384" LOG_EFFECT_SIZE="-0.13830269816628143" METHOD="MH" MODIFIED="2013-12-05 10:18:53 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.43758502247360753" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="42" TOTAL_2="42" WEIGHT="99.99999999999999" Z="0.776277735915335">
<NAME>Chorioamnionitis</NAME>
<GROUP_LABEL_1>3 day</GROUP_LABEL_1>
<GROUP_LABEL_2>7 day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3 day</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7 day</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6251264297844346" CI_START="0.32546736680965205" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.21088715338987554" LOG_CI_START="-0.4874925497224384" LOG_EFFECT_SIZE="-0.13830269816628143" ORDER="727" O_E="0.0" SE="0.41023169464345793" STUDY_ID="STD-Lewis-2003" TOTAL_1="42" TOTAL_2="42" VAR="0.1682900432900433" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9105764349472232" CI_START="0.7244321764184913" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1764705882352942" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-005.06" LOG_CI_END="0.28116441685394133" LOG_CI_START="-0.1400022682825268" LOG_EFFECT_SIZE="0.07058107428570728" METHOD="MH" MODIFIED="2013-12-05 10:18:53 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.5112325015350847" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="42" TOTAL_2="42" WEIGHT="100.00000000000001" Z="0.6569197824624143">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>3 day</GROUP_LABEL_1>
<GROUP_LABEL_2>7 day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3 day</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7 day</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.910576434947223" CI_START="0.7244321764184913" EFFECT_SIZE="1.1764705882352942" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="17" LOG_CI_END="0.2811644168539413" LOG_CI_START="-0.1400022682825268" LOG_EFFECT_SIZE="0.07058107428570728" ORDER="728" O_E="0.0" SE="0.24739539565787616" STUDY_ID="STD-Lewis-2003" TOTAL_1="42" TOTAL_2="42" VAR="0.06120448179271709" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.07" MODIFIED="2013-12-05 10:19:30 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Days from randomisation to birth</NAME>
<GROUP_LABEL_1>3 day</GROUP_LABEL_1>
<GROUP_LABEL_2>7 day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 7 day</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 3 day</GRAPH_LABEL_2>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.08" MODIFIED="2013-12-05 10:18:53 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Days from birth till discharge of mother</NAME>
<GROUP_LABEL_1>3 day</GROUP_LABEL_1>
<GROUP_LABEL_2>7 day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3 day</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7 day</GRAPH_LABEL_2>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.867192458354287" CI_START="0.4555405568167827" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-005.09" LOG_CI_END="0.4574568456482473" LOG_CI_START="-0.3414729516928738" LOG_EFFECT_SIZE="0.05799194697768673" METHOD="MH" MODIFIED="2013-12-05 10:18:53 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.775999682422003" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="42" TOTAL_2="42" WEIGHT="100.0" Z="0.28453595759701483">
<NAME>Birth within 48 hours of randomisation</NAME>
<GROUP_LABEL_1>3 day</GROUP_LABEL_1>
<GROUP_LABEL_2>7 day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3 day</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7 day</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.8671924583542863" CI_START="0.4555405568167827" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.4574568456482472" LOG_CI_START="-0.3414729516928738" LOG_EFFECT_SIZE="0.05799194697768673" ORDER="729" O_E="0.0" SE="0.46929531772445293" STUDY_ID="STD-Lewis-2003" TOTAL_1="42" TOTAL_2="42" VAR="0.22023809523809523" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4228896948317593" CI_START="0.7027951665067325" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-005.10" LOG_CI_END="0.15317123403882704" LOG_CI_START="-0.15317123403882701" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2013-12-05 10:18:53 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="42" TOTAL_2="42" WEIGHT="100.0" Z="0.0">
<NAME>Birth within 7 days of randomisation</NAME>
<GROUP_LABEL_1>3 day</GROUP_LABEL_1>
<GROUP_LABEL_2>7 day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3 day</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7 day</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4228896948317593" CI_START="0.7027951665067325" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="25" LOG_CI_END="0.15317123403882704" LOG_CI_START="-0.15317123403882701" LOG_EFFECT_SIZE="0.0" ORDER="730" O_E="0.0" SE="0.17994708216848748" STUDY_ID="STD-Lewis-2003" TOTAL_1="42" TOTAL_2="42" VAR="0.032380952380952385" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-12-05 10:18:53 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Birth before 37 weeks' gestation</NAME>
<GROUP_LABEL_1>3 day</GROUP_LABEL_1>
<GROUP_LABEL_2>7 day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3 day</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7 day</GRAPH_LABEL_2>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.12" MODIFIED="2013-12-05 10:19:52 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Birthweight</NAME>
<GROUP_LABEL_1>3 day</GROUP_LABEL_1>
<GROUP_LABEL_2>7 day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 7 day</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 3 day</GRAPH_LABEL_2>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.13" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-12-05 10:18:53 +0000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Birthweight &lt; 2500 g</NAME>
<GROUP_LABEL_1>3 day</GROUP_LABEL_1>
<GROUP_LABEL_2>7 day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3 day</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7 day</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1907787079454208" CI_START="0.8397865979023156" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-005.14" LOG_CI_END="0.07583106051912483" LOG_CI_START="-0.07583106051912483" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2013-12-05 10:18:53 +0000" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="42" TOTAL_2="42" WEIGHT="100.0" Z="0.0">
<NAME>Neonatal intensive care</NAME>
<GROUP_LABEL_1>3 day</GROUP_LABEL_1>
<GROUP_LABEL_2>7 day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3 day</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7 day</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1907787079454208" CI_START="0.8397865979023156" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="36" LOG_CI_END="0.07583106051912483" LOG_CI_START="-0.07583106051912483" LOG_EFFECT_SIZE="0.0" ORDER="731" O_E="0.0" SE="0.0890870806374748" STUDY_ID="STD-Lewis-2003" TOTAL_1="42" TOTAL_2="42" VAR="0.007936507936507936" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.15" MODIFIED="2013-12-05 10:18:53 +0000" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Days in neonatal intensive care unit</NAME>
<GROUP_LABEL_1>3 day</GROUP_LABEL_1>
<GROUP_LABEL_2>7 day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3 day</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7 day</GRAPH_LABEL_2>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.16" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-12-05 10:18:53 +0000" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Neonatal infection including pneumonia</NAME>
<GROUP_LABEL_1>3 day</GROUP_LABEL_1>
<GROUP_LABEL_2>7 day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3 day</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7 day</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.17" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-12-05 10:18:53 +0000" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Positive neonatal blood culture</NAME>
<GROUP_LABEL_1>3 day</GROUP_LABEL_1>
<GROUP_LABEL_2>7 day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3 day</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7 day</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.04080964147321538" CI_END="2.8597787463301696" CI_START="0.06529251889702008" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4321135936719174" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-005.18" LOG_CI_END="0.45633243419026664" LOG_CI_START="-1.1851365765789552" LOG_EFFECT_SIZE="-0.36440207119434437" METHOD="MH" MODIFIED="2013-12-05 10:18:53 +0000" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.8399059105798614" P_Q="1.0" P_Z="0.38418329016509956" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="65" TOTAL_2="65" WEIGHT="99.99999999999999" Z="0.8702143394081155">
<NAME>Neonatal necrotising enterocolitis</NAME>
<GROUP_LABEL_1>3 day</GROUP_LABEL_1>
<GROUP_LABEL_2>7 day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3 day</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7 day</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.306321714020261" CI_START="0.047113615320280106" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.724793577042504" LOG_CI_START="-1.3268535683704665" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="732" O_E="0.0" SE="1.2051476890327395" STUDY_ID="STD-Lewis-2003" TOTAL_1="42" TOTAL_2="42" VAR="1.4523809523809526" WEIGHT="64.01179941002948"/>
<DICH_DATA CI_END="7.780254682310321" CI_START="0.014281166317568032" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8909938136107249" LOG_CI_START="-1.8452363230500497" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="733" O_E="0.0" SE="1.6072751268321592" STUDY_ID="STD-Segel-2003" TOTAL_1="23" TOTAL_2="23" VAR="2.5833333333333335" WEIGHT="35.9882005899705"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.023512892209575843" CI_END="1.4933962421844802" CI_START="0.6202106922045424" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9624034066340885" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-005.19" LOG_CI_END="0.17417505418347995" LOG_CI_START="-0.20746075095679428" LOG_EFFECT_SIZE="-0.01664284838665719" METHOD="MH" MODIFIED="2013-12-05 10:18:53 +0000" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.8781308504749803" P_Q="1.0" P_Z="0.8642669421899491" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="65" TOTAL_2="65" WEIGHT="100.00000000000001" Z="0.17094508952596307">
<NAME>Neonatal respiratory distress syndrome</NAME>
<GROUP_LABEL_1>3 day</GROUP_LABEL_1>
<GROUP_LABEL_2>7 day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3 day</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7 day</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6829526805760078" CI_START="0.5176087962336318" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="0.2260719051299337" LOG_CI_START="-0.2859983518848201" LOG_EFFECT_SIZE="-0.02996322337744321" ORDER="734" O_E="0.0" SE="0.3007926037591192" STUDY_ID="STD-Lewis-2003" TOTAL_1="42" TOTAL_2="42" VAR="0.09047619047619049" WEIGHT="55.5442522889115"/>
<DICH_DATA CI_END="1.932815784639387" CI_START="0.5173798806628506" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.286190463688654" LOG_CI_START="-0.28619046368865403" LOG_EFFECT_SIZE="0.0" ORDER="735" O_E="0.0" SE="0.3362193900727166" STUDY_ID="STD-Segel-2003" TOTAL_1="23" TOTAL_2="23" VAR="0.11304347826086958" WEIGHT="44.45574771108851"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.20" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-12-05 10:18:53 +0000" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Treatment with surfactant</NAME>
<GROUP_LABEL_1>3 day</GROUP_LABEL_1>
<GROUP_LABEL_2>7 day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3 day</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7 day</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.21" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-12-05 10:18:53 +0000" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Number of babies requiring ventilation</NAME>
<GROUP_LABEL_1>3 day</GROUP_LABEL_1>
<GROUP_LABEL_2>7 day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3 day</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7 day</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.22" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-12-05 10:18:53 +0000" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Number of babies requiring oxygen therapy</NAME>
<GROUP_LABEL_1>3 day</GROUP_LABEL_1>
<GROUP_LABEL_2>7 day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3 day</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7 day</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.23" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-12-05 10:18:53 +0000" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Neonatal oxygenation &gt; 28 days</NAME>
<GROUP_LABEL_1>3 day</GROUP_LABEL_1>
<GROUP_LABEL_2>7 day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3 day</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7 day</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.24" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-12-05 10:18:53 +0000" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Oxygen treatment &gt; 36 weeks' postconceptual age</NAME>
<GROUP_LABEL_1>3 day</GROUP_LABEL_1>
<GROUP_LABEL_2>7 day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3 day</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7 day</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.25" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-12-05 10:18:53 +0000" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Neonatal encephalopathy</NAME>
<GROUP_LABEL_1>3 day</GROUP_LABEL_1>
<GROUP_LABEL_2>7 day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3 day</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7 day</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.1167286722195486" CI_START="0.03564991463693386" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-005.26" LOG_CI_END="0.49369899628170993" LOG_CI_START="-1.4479415057210347" LOG_EFFECT_SIZE="-0.47712125471966244" METHOD="MH" MODIFIED="2013-12-05 10:18:53 +0000" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="1.0" P_Q="1.0" P_Z="0.3354231921437295" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="65" TOTAL_2="65" WEIGHT="100.0" Z="0.9632478046729352">
<NAME>Neonatal intraventricular haemorrhage</NAME>
<GROUP_LABEL_1>3 day</GROUP_LABEL_1>
<GROUP_LABEL_2>7 day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3 day</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7 day</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.956271095255056" CI_START="0.013965224384746686" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9007095724875305" LOG_CI_START="-1.8549520819268552" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="736" O_E="0.0" SE="1.6186892965481947" STUDY_ID="STD-Lewis-2003" TOTAL_1="42" TOTAL_2="42" VAR="2.6201550387596897" WEIGHT="49.64618249534451"/>
<DICH_DATA CI_END="7.780254682310321" CI_START="0.014281166317568032" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8909938136107249" LOG_CI_START="-1.8452363230500497" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="737" O_E="0.0" SE="1.6072751268321592" STUDY_ID="STD-Segel-2003" TOTAL_1="23" TOTAL_2="23" VAR="2.5833333333333335" WEIGHT="50.353817504655495"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9441649798707068" CI_END="2.9431786946180964" CI_START="0.054567806993968564" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.40075280031046645" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-005.27" LOG_CI_END="0.4688166310192905" LOG_CI_START="-1.2630634995713714" LOG_EFFECT_SIZE="-0.3971234342760405" METHOD="MH" MODIFIED="2013-12-05 10:18:53 +0000" MODIFIED_BY="[Empty name]" NO="27" P_CHI2="0.33120918110670716" P_Q="1.0" P_Z="0.3687341723948878" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="65" TOTAL_2="65" WEIGHT="100.0" Z="0.8988469985303674">
<NAME>Perinatal death/death before discharge</NAME>
<GROUP_LABEL_1>3 day</GROUP_LABEL_1>
<GROUP_LABEL_2>7 day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3 day</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7 day</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.465490926561218" CI_START="0.06466008772360077" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1893637105217114" LOG_CI_START="-1.1893637105217114" LOG_EFFECT_SIZE="0.0" ORDER="738" O_E="0.0" SE="1.3972762620115438" STUDY_ID="STD-Lewis-2003" TOTAL_1="42" TOTAL_2="42" VAR="1.9523809523809526" WEIGHT="53.00859598853869"/>
<DICH_DATA CI_END="2.6189118760956447" CI_START="0.007792611676468944" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4181208850730818" LOG_CI_START="-2.108316965101596" LOG_EFFECT_SIZE="-0.8450980400142568" ORDER="739" O_E="0.0" SE="1.4840420992616592" STUDY_ID="STD-Segel-2003" TOTAL_1="23" TOTAL_2="23" VAR="2.2023809523809526" WEIGHT="46.99140401146131"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.28" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-12-05 10:18:53 +0000" MODIFIED_BY="[Empty name]" NO="28" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Serious childhood disability at 7 years</NAME>
<GROUP_LABEL_1>3 day</GROUP_LABEL_1>
<GROUP_LABEL_2>7 day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3 day</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7 day</GRAPH_LABEL_2>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-12-18 11:49:10 +0000" MODIFIED_BY="Denise Atherton">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-11-22 11:15:22 +0000" MODIFIED_BY="Denise Atherton" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAADnCAMAAAD7EqYIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-12-18 11:45:24 +0000" MODIFIED_BY="[Empty name]" NO="2" REF_ID="CMP-001.03" SETTINGS="SHOW_EFFECT_ESTIMATE:YES;SHOW_STUDY_NAMES:NO;DISTINGUISH_SUBGROUPS:YES;SHOW_CI_LINES:YES;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Any antibiotic versus placebo, outcome: 1.3 Perinatal death/death before discharge.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2013-12-18 11:46:08 +0000" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-001.04" SETTINGS="SHOW_EFFECT_ESTIMATE:YES;SHOW_STUDY_NAMES:NO;DISTINGUISH_SUBGROUPS:YES;SHOW_CI_LINES:YES;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Any antibiotic versus placebo, outcome: 1.4 Neonatal infection including pneumonia.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2013-12-18 11:46:44 +0000" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.05" SETTINGS="SHOW_EFFECT_ESTIMATE:YES;SHOW_STUDY_NAMES:NO;DISTINGUISH_SUBGROUPS:YES;SHOW_CI_LINES:YES;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Any antibiotic versus placebo, outcome: 1.5 Neonatal necrotising enterocolitis.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2013-12-18 11:49:10 +0000" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.07" SETTINGS="SHOW_EFFECT_ESTIMATE:YES;SHOW_STUDY_NAMES:NO;DISTINGUISH_SUBGROUPS:YES;SHOW_CI_LINES:YES;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Any antibiotic versus placebo, outcome: 1.7 Major cerebral abnormality on ultrasound before discharge.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2009-09-23 10:48:28 +0100" MODIFIED_BY="[Empty name]">
<FEEDBACK_ITEM ID="FBK-01" NO="1">
<TITLE>Shapiro, March 2003</TITLE>
<DATE_SUBMITTED>
<DATE DAY="" MONTH="" YEAR=""/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY>
<P>The ORACLE study accounts for the vast majority of women included in this review, 4826 out of around 6000 women. ORACLE did not have a stopping rule, so that one cannot gauge why the study was stopped when it was. Were repeated statistical tests done? The impression, unfortunately, is that the study may have been stopped when a significant result was obtained. If so, this makes the "significant" conclusions untenable.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY>
<P>Thank you for your comments. The Medical Research Council (UK) ORACLE Trial had both a Steering Group and a Data Monitoring Committee. The Data Monitoring Committee agreed terms of reference before the start of the Study. These were documented in the trial protocol, as follows:<BR/>"The independent Data Monitoring Committee (chairman: Professor Adrian Grant, Aberdeen; members: Professor Forrester Cockburn, Glasgow; Mr Richard Gray, Oxford; Professor Charles Rodeck, London) will conduct interim analyses of morbidity and mortality among all trial participants. The Trial Director and Steering Group will be informed if at any time the randomised comparisons in this study have provided both (i) proof beyond reasonable doubt of a difference in a major endpoint between the study and control groups, and (ii) evidence that would be expected to alter substantially the choice of treatment for patients whose doctors are, in the light of the evidence from the other randomised trials, substantially uncertain whether to recommend antibiotics. Exact criteria of "proof beyond reasonable doubt" are not specified, but members of the committee have expressed sympathy with the view that it should generally involve a difference of at least three standard deviations in a major endpoint. Using this criterion has the practical advantage that the exact number of interim analyses is of little importance, and so no fixed schedule is proposed."</P>
<P>The Committee met annually throughout trial recruitment, and for the last time in June 1999. At that time the conditions for discontinuation had not been met so it was decided to carry on until funding ceased. Recruitment closed on 31st May 2000, as this allowed time for the last women to deliver, data to be chased and cleaned, analysis to be undertaken and reports prepared for publication.</P>
<P>[Summary of response from Sara Kenyon, May 2003]</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS>
<P>Summary of comment from Mervyn Shapiro, March 2003.</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
<FEEDBACK_ITEM ID="FBK-02" MODIFIED="2009-09-23 10:48:28 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2008-02-20 11:35:57 +0000" MODIFIED_BY="Sonja Henderson">Stones, February 2008</TITLE>
<DATE_SUBMITTED>
<DATE DAY="20" MONTH="2" YEAR="2008"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2009-09-23 10:48:28 +0100" MODIFIED_BY="[Empty name]">
<P>In 'Characteristics of included studies' for <LINK REF="STD-Almeida-1996" TYPE="STUDY">Almeida 1996</LINK>a the dose of amoxycillin is given as 75 g where it should be 0.75 g or perhaps 750 mg for clarity.</P>
<P>[Summary of feedback from William Stones, February 2008]</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2008-02-20 11:42:27 +0000" MODIFIED_BY="Sonja Henderson">
<P>Thank you for bringing this to our attention. We have corrected the error.</P>
<P>[Reply from Sara Kenyon, February 2008]</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2008-02-20 11:42:50 +0000" MODIFIED_BY="Sonja Henderson">
<P>Feedback: William Stones</P>
<P>Reply: Sara Kenyon</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2013-11-23 17:09:18 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2013-11-23 17:09:18 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-11-23 17:09:10 +0000" MODIFIED_BY="[Empty name]">Methods used to assess trials included in a previous version of this review (published 2003, Issue 2).</TITLE>
<APPENDIX_BODY MODIFIED="2013-11-23 17:09:18 +0000" MODIFIED_BY="[Empty name]">
<P>The following methods were used to assess <LINK REF="STD-Almeida-1996" TYPE="STUDY">Almeida 1996</LINK>; <LINK REF="STD-Amon-1988a" TYPE="STUDY">Amon 1988a</LINK>; <LINK REF="STD-Camli-1997" TYPE="STUDY">Camli 1997</LINK>; <LINK REF="STD-Christmas-1992" TYPE="STUDY">Christmas 1992</LINK>; <LINK REF="STD-Cox-1995" TYPE="STUDY">Cox 1995</LINK>; <LINK REF="STD-Ernest-1994" TYPE="STUDY">Ernest 1994</LINK>; <LINK REF="STD-Garcia_x002d_Burguillo-1995" TYPE="STUDY">Garcia-Burguillo 1995</LINK>; <LINK REF="STD-Grable-1996" TYPE="STUDY">Grable 1996</LINK>; <LINK REF="STD-Johnston-1990" TYPE="STUDY">Johnston 1990</LINK>; <LINK REF="STD-Kenyon-2001" TYPE="STUDY">Kenyon 2001</LINK>; <LINK REF="STD-Kurki--1992" TYPE="STUDY">Kurki 1992</LINK>; <LINK REF="STD-Lewis-2003" TYPE="STUDY">Lewis 2003</LINK>; <LINK REF="STD-Lockwood-1993a" TYPE="STUDY">Lockwood 1993a</LINK>; <LINK REF="STD-Magwali-1999" TYPE="STUDY">Magwali 1999</LINK>; <LINK REF="STD-McGregor-1991" TYPE="STUDY">McGregor 1991</LINK>; <LINK REF="STD-Mercer-1992" TYPE="STUDY">Mercer 1992</LINK>; <LINK REF="STD-Mercer-1997" TYPE="STUDY">Mercer 1997</LINK>; <LINK REF="STD-Morales-1989" TYPE="STUDY">Morales 1989</LINK>; <LINK REF="STD-Ovalle_x002d_Salas-1997" TYPE="STUDY">Ovalle-Salas 1997</LINK>; <LINK REF="STD-Owen-1993a" TYPE="STUDY">Owen 1993a</LINK>; <LINK REF="STD-Segel-2003" TYPE="STUDY">Segel 2003</LINK>; <LINK REF="STD-Svare-1997a" TYPE="STUDY">Svare 1997a</LINK>.</P>
<P>All trials identified by the methods described in the search strategy were scrutinised by the reviewers. We processed included trial data as described in <LINK REF="REF-Alderson-2004" TYPE="REFERENCE">Alderson 2004</LINK>. We evaluated trials under consideration for inclusion and methodological quality. There was no blinding of authorship. We assigned quality scores for concealment of allocation to each trial, using the criteria described in section six of the Cochrane Reviewers' Handbook (<LINK REF="REF-Alderson-2004" TYPE="REFERENCE">Alderson 2004</LINK>): A = adequate; B = unclear; C = inadequate; D = not used.</P>
<P>We excluded trials that proved on closer examination not to be true randomised trials. We analysed outcomes on an intention-to-treat basis.</P>
<P>We extracted and double entered data. Wherever possible, we sought unpublished data from the investigator. Where outcomes were published in the form of percentages or graphs, the number of events were calculated. Where maternal outcomes were presented, numerators and denominators were calculated based on the number of mothers. Babies from multiple pregnancies have been treated as a single unit, with the worst outcome among the babies included in analyses. Of the 22 trials included, 12 only randomised singletons. Of the seven remaining, two did not state whether multiples were included. Of the five trials that included multiples, two specified how they had analysed the data (<LINK REF="STD-Kenyon-2001" TYPE="STUDY">Kenyon 2001</LINK>; <LINK REF="STD-Mercer-1997" TYPE="STUDY">Mercer 1997</LINK>) and both used the worst outcomes in any baby.</P>
<P>We tested for heterogeneity between trial results using a standard Chi-squared test. For dichotomous data, we calculated the relative risk and for continuous variables, the weighted mean difference; in both cases, we reported 95% confidence intervals.</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>